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Abstract
The development of pathological bone outside the skeleton, termed heterotopic ossification (HO), is a
significant clinical complication that often greatly reduces mobility and diminishes overall quality of life for
affected individuals. Patients with fibrodysplasia ossificans progressiva (FOP; OMIM #135100), a genetic
disorder of HO in which most affected individuals express a recurrent heterozygous gain-of-function
mutation (R206H) in the bone morphogenetic protein (BMP) type I receptor ACVR1/ALK2, develop
episodes of HO formation frequently follow injury. Terminal HO formation in FOP occurs following a series
of lesion development stages, of which the first recognized is an inflammatory stage associated with immune
cell invasion. Of note, an early inflammatory response is a normal response to tissue injury, however in tissues
expressing the FOP mutation, the repair program rapidly diverges from a path leading to tissue repair and
instead forms ectopic cartilage and bone. I hypothesized that Acvr1R206H enhances the early inflammatory
response to injury in FOP and that immune cells promote a permissive microenvironment for the
downstream anabolic events that result in HO. Using a conditional knock-in Acvr1R206H mouse model
(Acvr1cR206H/+) to investigate the cellular and molecular inflammatory events in FOP Acvr1cR206H/+
and wild-type Acvr1+/+ mice following injury, I determined that the response to tissue injury is similar
between cohorts up to 48 hours post-injury, but then diverges toward a prolonged fibroproliferative stage,
then to chondrogenic, and osteogenic events in Acvr1cR206H/+ mice. This coincides with a significantly
elevated and prolonged pro-inflammatory cytokine expression in vivo and in vitro. I further investigated how
modulation of the inflammatory response controls the development of HO in FOP. Induction of the R206H
mutation exclusively in immune cells, by whole bone marrow transplant or LysM-Cre-induced myeloid-
lineage expression, or selective inhibition of the inflammatory response by Interleukin-6 (IL-6) and tumor
necrosis factor-alpha (TNF-α) neutralizing agents were insufficient to prevent HO formation. However,
depletion of mast cells and macrophages from Acvr1cR206H/+ mice dramatically impaired development of
HO, highlighting a direct immune cell contribution to HO formation.
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ABSTRACT 
THE IMMUNOLOGICAL CONTRIBUTIONS TO HETEROTOPIC 
OSSIFICATION DISORDERS – INSIGHTS FROM FIBRODYSPLASIA 
OSSIFICANS PROGRESSIVA 
 
Michael Richard Convente 
Eileen M. Shore 
 
The development of pathological bone outside the skeleton, termed heterotopic 
ossification (HO), is a significant clinical complication that often greatly reduces mobility 
and diminishes overall quality of life for affected individuals. Patients with fibrodysplasia 
ossificans progressiva (FOP; OMIM #135100), a genetic disorder of HO in which most 
affected individuals express a recurrent heterozygous mutation (R206H) in the bone 
morphogenetic protein (BMP) type I receptor ACVR1/ALK2, develop episodes of HO 
formation frequently follow injury. Terminal HO formation in FOP occurs following a 
series of lesion development stages, of which the first recognized is an inflammatory stage 
associated with immune cell invasion. Of note, an early inflammatory response is a normal 
response to tissue injury, however in tissues expressing the FOP mutation, the repair 
program rapidly diverges from a path leading to tissue repair and instead forms ectopic 
cartilage and bone. I hypothesized that Acvr1R206H enhances the early inflammatory 
response to injury in FOP and that immune cells promote a permissive microenvironment 
for the downstream anabolic events that result in HO. Using a conditional knock-in 
 xii 
 
Acvr1R206H mouse model (Acvr1cR206H/+) to investigate the cellular and molecular 
inflammatory events in FOP Acvr1cR206H/+ and wild-type Acvr1+/+ mice following injury, I 
determined that the response to tissue injury is similar between cohorts up to 48 hours post-
injury, but then diverges toward a prolonged fibroproliferative stage, then to chondrogenic, 
and osteogenic events in Acvr1cR206H/+ mice. This coincides with a significantly elevated 
and prolonged pro-inflammatory cytokine expression in vivo and in vitro. I further 
investigated how modulation of the inflammatory response controls the development of 
HO in FOP. Induction of the R206H mutation exclusively in immune cells, by whole bone 
marrow transplant or LysM-Cre-induced myeloid-lineage expression, or selective 
inhibition of the inflammatory response by Interleukin-6 (IL-6) and tumor necrosis factor-
alpha (TNF-α) neutralizing agents were insufficient to prevent HO formation. However, 
depletion of mast cells and macrophages from Acvr1cR206H/+ mice dramatically impaired 
development of HO, highlighting a direct immune cell contribution to HO formation. 
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Introduction 
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1.1 Bone Morphogenetic Protein (BMP) signaling 
1.1.1 TGF-β/BMP superfamily ligands and receptors 
 Bone morphogenetic proteins (BMPs) are a subset of extracellular signaling ligands 
belonging to the transforming growth factor-beta (TGF-β) superfamily [Miyazono et al. 
2010]. The TGF-β/BMP superfamily is composed of more than thirty signaling ligands, 
including TGF-βs, BMPs, activins, inhibins, growth differentiation factors (GDFs), nodal, 
myostatin, and anti-Müllerian hormone [Miyazawa et al. 2002, Derynck et al. 2003]. BMPs 
represent the largest subset of the TGF-β/BMP superfamily, with over twenty ligands 
identified [Bragdon et al. 2011]. BMPs were initially discovered as factors that stimulate 
production of new bone in demineralized bone matrix implants in vivo [Urist 1965]. BMPs 
and other TGF-β/BMP superfamily ligands have substantial roles in numerous biological 
systems, including stem cell renewal and differentiation, embryological development, 
immune cell development, iron homeostasis, skeletal muscle development and 
regeneration, cancer, and others [Elliott et al. 2005, Babitt et al. 2006, Watabe et al. 2009, 
Wu et al. 2009, Wu et al. 2012, Sartori et al. 2013, Hager-Theodorides et al. 2014, Martinez 
et al. 2015]. BMPs have a unique and crucial role during the earliest stages of 
embryological development. BMPs are required for patterning the dorso-ventral axis in 
both invertebrates and vertebrates [Little et al. 2006, Tucker et al. 2008, Ramel et al. 2013]. 
Later in vertebrate development, BMPs are required for all stages of endochondral long 
bone formation - mesenchymal condensation, chondrogenesis, and osteogenesis [Lim et al. 
2015, Salazar et al. 2016]. In the adult, BMPs are involved in skeletal homeostasis and 
normal bone turnover [Wu et al. 2016], as well as in many other biological systems [Babitt 
 3 
 
et al. 2006, Shi et al. 2011, Choi et al. 2012, Wu et al. 2012, Brazil et al. 2015, Sartori et 
al. 2015, Salazar et al. 2016]. 
 The TGF-β/BMP superfamily receptors are grouped into two classes of 
transmembrane serine/threonine kinases, type I and type II [Shi et al. 2003, Miyazono et 
al. 2010] (Figure 1.1). Type I consists of seven receptors (ALK1/ACVR1L, 
ALK2/ACVR1, ALK3/BMPR1A, ALK4/ACVR1B, ALK5/TGFβR1, ALK6/BMPR1B, 
and ALK7/ACVR1C). Type II consists of four receptors (ACTR2A, ACTR2B, BMPR2, 
TGFβR2). The type I and type II receptors that preferentially mediate signaling in response 
to BMP ligands are ALK1, ALK2, ALK3, ALK6, ACTR2A, ACTR2B, and BMPR2; 
ALK4, ALK5, ALK7, and TGFβR2 mediate TGF-β signaling. Type I receptors contain 
several conserved domains – an extracellular ligand binding domain, a transmembrane 
domain, a glycine/serine (GS) rich domain, and a protein kinase domain [Yadin et al. 
2016]. Type II receptor structure is highly similar to type I receptors, except for an absent 
GS domain. BMPs bind as heterodimers to two type I extracellular ligand binding domains 
and facilitate recruitment of two type II receptors to form a tetrameric receptor signaling 
complex [Wrana et al. 1992]. Following BMP dimer binding and receptor complex 
formation, the constitutively active type II receptor kinase domain, now in proximity of the 
adjacent type I receptor via a conformational shift, phosphorylates serine residues within 
GS domain of adjacent type I receptors [Wrana et al. 1992]. This transphosphorylation 
event activates the kinase domain of the type I receptors, allowing for subsequent 
phosphorylation of downstream canonical and non-canonical signaling proteins [Salazar et 
al. 2016]. 
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 BMP signaling is tightly controlled by multiple antagonist proteins that act both 
extracellularly and intracellularly (Figure 1.1). The availability of BMP ligands is 
controlled by extracellular antagonists, including Noggin, Chordin, and Gremlin, that bind 
and sequester free BMPs to prevent their binding to receptors [Brazil et al. 2015]. 
Additionally, the decoy BMP and Activin Membrane Bound Inhibitor (BAMBI) receptor 
can bind BMPs and limit availability of ligand dimers for propagation of faithful BMP 
signaling [Brazil et al. 2015]. Intracellular antagonism of BMP signaling functions through 
an inhibitory mechanism that prevents promiscuous receptor activation in the absence of 
ligand. FKBP12 binds to type I BMP and TGF-β receptors in a leucine/proline motif within 
the GS domain and stabilizes the inactive confirmation of type I receptors. Upon ligand 
binding, FKBP12 dissociates from the receptor complex and allows signaling to advance 
[Wang et al. 1996, Chaikuad et al. 2012, Yadin et al. 2016]. 
 
1.1.2 Canonical and non-canonical signaling pathways 
TGF-β/BMP superfamily ligands can propagate signaling through canonical 
(Smad-dependent) and non-canonical (Smad-independent) mechanisms to regulate gene 
transcription (Figure 1.1). Pathway activation is dependent on available receptors and 
ligands, which have stronger binding affinities for preferred BMP or TGF-β receptor 
partners. 
Canonical TGF-β/BMP signaling is mediated by a consortium of Smad proteins 
that are classified into three groups: regulatory Smads (R-Smads), common Smad (co-
Smad), and inhibitory Smads (I-Smads). Five mammalian R-Smads participate in the 
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canonical signaling pathway. Smad1, Smad5, and Smad8 serve as signaling mediators 
induced primarily by BMPs, whereas Smad2 and Smad3 serve as signaling mediators 
induced primarily by TGF-βs and activins. The TGF-β and BMP signaling branches 
converge with the utilization of the co-Smad Smad4 by all R-Smads. Smad6 and Smad7 
function as I-Smads through Smad-receptor or Smad-Smad interactions that inhibit proper 
signaling [Katagiri et al. 2016]. 
The R-Smads contain three domains: the highly-conserved DNA-binding “Mad-
homology 1” (MH1) and type I receptor-activated MH2 domains, and a variable linker 
domain. The MH2 domain has a conserved C-terminal motif, Ser-X-Ser, that is 
phosphorylated by the activated type I receptor. Phosphorylation of R-Smad by the 
activated type I receptor induces translocation into the nucleus and Smad4 recognition of 
the phosphorylated R-Smad pSer-X-pSer motif. R-Smads bind to a specific 5’-GTCT-3’ 
DNA motif known as the Smad-binding element (SBE) through their MH1 domain [Shi et 
al. 1998]. Many Smad-responsive promoters contain one or more SBEs within their 
promoter sequence. The core R-Smad-Smad4 complex is most commonly a hetero-trimeric 
complex composed of two phosphorylated R-Smads and one Smad4 protein. However, due 
to relatively low DNA binding affinity, incorporation of different DNA-binding co-factors 
to the nuclear R-Smad-Smad4 complex via interactions with the “Smad4 activation 
domain” (SAD) present on Smad4 allows for enhanced DNA binding and gene target 
specificity. Many TGF-β/BMP responsive gene promoters contain SBEs and adjacent 
cognate co-factor binding motifs for targeted gene expression [Massagué et al. 2005]. 
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 Smad6 and Smad7 are I-Smads that function to inhibit TGF-β/BMP signaling. Both 
Smad6 and Smad7 are structurally similar to the R-Smads, however they lack a DNA-
binding MH1 domain and a C-terminal Ser-X-Ser motif. Smad6 targets BMP signaling by 
functioning as a competitive inhibitor preventing phosphorylated Smad1 from binding to 
Smad4 [Hata et al. 1998]. Smad7 interacts stably with activated BMP and TGF-β and 
functions as a competitive inhibitor of R-Smad phosphorylation [Hayashi et al. 1997, 
Nakao et al. 1997]. 
 TGF-β/BMP signaling can also be mediated by multiple non-canonical, Smad-
independent mechanisms. Receptor complex activation can propagate signaling through 
downstream signaling pathways such as extracellular signal-regulated kinase (ERK), p38 
map kinase, C-jun N-terminal kinase (JNK), and nuclear factor kappa beta (NF-κB). All 
are thought to be mediated by TGF-β activated kinase 1 (TAK1). Additional non-canonical 
signaling pathways include phosphoinositide 3-kinase (PI3K) and Protein Kinase A 
(PKA), the latter of which operates through cyclic AMP effector signaling [Taylor et al. 
2004, Bragdon et al. 2011]. 
 
1.2 The immune system and its role in injury repair 
1.2.1 Evolution and overview of the immune system 
 The immune system is a coordinated cellular and molecular system that first 
evolved as a defense against infectious species [Cooper et al. 2006, Dzik 2010, Flajnik et 
al. 2010, Horvath et al. 2010, Buchmann 2014, Rath et al. 2015]. The earliest appearance 
of a primitive immune system in prokaryotes was the evolution of the Clustered Regularly 
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Interspaced Short Palindromic Repeats (CRISPR) DNA region, first observed in 
Escherichia coli. In combination with CRISPR-associated (Cas) genes, the CRISPR/Cas 
system protects prokaryotes from viral genetic elements through a targeted process that 
results in permanent identification and destruction of foreign sequences [Horvath et al. 
2010, Rath et al. 2015]. 
Evolution of a more sophisticated “self vs. non-self” recognition system occurred 
simultaneously with emergence of increasingly complex multicellular eukaryotes during 
the Cambrian explosion starting 542 million years ago [Buchmann 2014]. This mechanism 
depended on evolution of appropriate molecules and cells that perform two functions in 
sequence: detection of non-self pathogens, and phagocytic lysis of identified pathogens. 
Recognition of pathogen-associated molecular patterns (PAMPs), such as 
lipopolysaccharides (LPS) and viral genetic elements, first evolved in multicellular 
sponges with the appearance of LPS-binding receptors. The emergence of intracellular 
receptors that can detect pathogens and foreign DNA, such as the nucleotide-binding 
oligomerization domain-like receptors (NOD-like receptors, or “NLRs”), further enhanced 
the ability of organisms to detect pathogens, including viruses, fungi, parasites, and their 
associated PAMP molecules [Takeuchi et al. 2010, Buchmann 2014]. Evolution of cells 
with phagocytic function occurred concurrent with the appearance of recognition receptors, 
with early multi-cellular species in the Porifera and Cnidaria phyla containing phagocytic 
amebocytes [Dzik 2010]. Cells with equivalent function are found throughout the 
invertebrates, with more sophisticated and diverse cell types, such as macrophages and 
granulocytes, first appearing in sea stars, sea urchins, tunicates, and others [Rhodes et al. 
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1982, Crivellato et al. 2010]. This system, classified today as innate immunity, relies on 
early detection of conserved PAMPs to trigger a first-wave inflammatory response to limit 
pathogen invasion [Akira et al. 2006]. 
A more targeted immune response, dependent on diversification of evolved 
antigen-receptor genes to initially and permanently recognize unique non-self molecules, 
defines the adaptive immune system. The primordial adaptive immune system was first 
observed in jawless invertebrates belonging to the Agnatha superclass of the Chordata 
phylum, which includes lampreys and hagfish among its members [Cooper et al. 2006]. 
Jawless fish possess a primitive mechanism for generating genetic diversity required for 
mounting antigen-specific immune responses. This mechanism depends upon use of 
variant leucine-rich repeats (LRRs) to form variable lymphocyte receptors (VLRs), 
generating clonal specificity through somatic recombination [Litman et al. 2010]. The 
appearance of an adaptive immune system most closely resembling its modern composition 
in mammals was first observed in jawed vertebrates, specifically jawed fish [Cooper et al. 
2006]. Detection of unique antigens required concurrent evolution of several genes and 
gene loci – the variable-diversity-joining rearrangement (VDJ) locus, the major 
histocompatibility complex (MHC) locus, and the set of recombination-activating genes 
(RAGs) [Flajnik et al. 2010]. In combination, all three components provided the parts and 
machinery for functional and lasting defense against unique antigens. A new diverse class 
of immune cells termed lymphocytes evolved in parallel and utilized the above genetic 
components to mount robust and efficient attacks against pathogens [Flajnik et al. 2010]. 
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The classic antigen recognition and clonal expansion of lymphocytes described above 
remains the foundation of adaptive immunity in modern vertebrates. 
 Hematopoietic stem cells (HSCs) are a multipotent, self-renewing cell population 
that resides in the bone marrow niche [Zon 2008]. HSCs are able to generate all transient 
and terminally differentiated immune cells [Benveniste et al. 2003], which are classified 
into two main groups: myeloid lineage and lymphoid lineage (Figure 1.2). HSCs are 
defined by a triple-labeling identification by the Lineage (Lin), stem cells antigen-1 (Sca-
1), and c-Kit proteins; HSCs are Lin-, Sca-1+, c-Kit+. HSCs are subdivided into two 
populations: a long-term (LT-HSC) population that can self-renew or asymmetrically 
divide to produce the other, a short-term (ST-HSC) population that retains multipotency 
while undergoing robust proliferation and differentiation toward the numerous transient 
and terminal immune cell lineages. ST-HSCs can differentiate into common myeloid 
progenitors (CMPs) or common lymphoid progenitors (CLPs), which serve as multipotent 
progenitor populations for all myeloid and lymphoid lineages, respectively [Challen et al. 
2009]. Cells derived from CMPs compose the innate immune system, and cells derived 
from CLPs compose the adaptive immune system. 
 
1.2.2 Innate immunity 
 The innate immune system functions as a first line of defense against infectious 
species, utilizing several families of pattern recognition receptors such as toll-like receptors 
(TLRs) or NLRs to provide a short-term barrier against pathogen invasion [Mogensen 
2009]. Cells of the innate immune system, such as neutrophils and macrophages, possess 
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the ability to attach to and digest pathogens, assisting with clearance of active infection. In 
species with a functional antigen-mediated immune system, innate immune cells also play 
a major role in presentation of digested pathogenic particles, activating and inducing clonal 
expansion of adaptive immune cells. 
 
Receptors and molecular pathways of innate immunity 
 Cells of the innate immune system, also known as leukocytes, express several 
families of receptors and signaling molecules that perform two functions in sequence: 
recognition of non-self pathogens, and presentation of antigens to cells of the adaptive 
immune system. Both of these functions use the complement system, which is composed 
of receptors and soluble proteins that function as a surveillance system against pathogens. 
Complement proteins include pattern recognition proteins like C1q, proteases that regulate 
the complement signaling cascade, opsonization proteins that increase detection of foreign 
species by host immune cells, and receptors that bind to opsonized pathogens to induce 
phagocytic destruction. The complement system is often the first to recognize pathogens 
and also functions to alert other immune cells to an ongoing infection [Ricklin et al. 2010]. 
Cells of the innate immune system also express a comprehensive panel of pattern 
recognition receptors that recognize conserved pathogen moieties, including 
lipopolysaccharides, peptidoglycans, flagellin, and others [Buchmann 2014]. Receptor 
families like the TLRs and NLRs alert the host of an active infection and induce 
inflammatory factor expression that amplifies the host immune response. 
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 The TLR family of pattern recognition receptors was initially discovered in 
Drosophila melanogaster and soon after confirmed to be expressed in vertebrates [Hansson 
et al. 2005]. TLRs recognize conserved moieties and genetic elements from pathogens, 
including LPS, double-stranded RNA, and bacterial flagella, among others [Kawai et al. 
2010]. TLRs are classified into two branches: cell-surface receptors and intracellular 
receptors. TLR1, TLR2, TLR4, TLR5, and TLR6 reside on the cell surface and detect 
PAMPs that primarily compose bacterial and fungi membrane moieties, such as lipids and 
lipoproteins. TLR3, TLR7, TLR8, TLR9, and TLR10 reside intracellularly within 
endosomes and detect microbial nucleic acids. All TLRs signal through the intracellular 
effector protein MyD88, except for TLR3, which signals downstream through the TIR-
domain-containing adapter-inducing interferon-β (TRIF) protein. Upon moiety binding, 
receptor activation, and signal propagation, the TLR family upregulates inflammatory 
signaling proteins, such as NF-κB, that potentiate a host inflammatory response [Kawai et 
al. 2010]. 
 The NLR and TLR families of pattern recognition receptors identify similar 
conserved pathogen moieties; however, NLRs propagate signaling through a TLR-
independent mechanism. NLRs primarily reside in the cytosol, although low cell-surface 
expression has been detected. NOD1 and NOD2 are the two major NLRs and both 
recognize peptidoglycan motifs present in bacterial cell walls [Shaw et al. 2008]. In 
addition to their pattern recognition function, NLRs can form inflammasomes, protein 
complexes composed of NLRs and other scaffold proteins, that activate caspase-1, a key 
step for processing pro-inflammatory cytokines [Martinon et al. 2002]. 
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Origin of innate immune cells 
 All myeloid lineage cells of the innate immune system are derived from a 
clonogenic common myeloid progenitor (CMP) [Akashi et al. 2000]. CMPs can 
differentiate into two distinct transient progenitor populations: megakaryocyte/erythrocyte 
progenitors (MEPs) and granulocyte/macrophage progenitors (GMPs). The MEP branch 
differentiates into all cells of the erythropoietic lineage, including erythrocytes, 
megakaryocytes, and platelets, and is not considered to have substantial inflammatory 
function. The GMP branch differentiates into granulocytes, which includes neutrophils and 
mast cells, as well as monocyte/macrophage lineages [Kolaczkowska et al. 2013, Dahlin 
et al. 2014]. 
 
Neutrophils 
 Neutrophils are the most abundant leukocyte in the blood and are the first 
responding cells during active pathogen infection [Witko-Sarsat et al. 2000]. Neutrophils 
defend against pathogen infection through several mechanisms, including phagocytosis, 
oxidative bursts, and neutrophil extracellular traps (NETs) [Brinkmann et al. 2004, de 
Oliveira et al. 2016]. The lifespan of neutrophils in circulation is relatively short, ranging 
from eight to twelve hours. Neutrophils in circulation migrate to localized sites of infection 
upon detection of cytokines and other inflammatory factors released by tissue-resident 
cells. Neutrophil migration from blood vessels to infection sites, termed extravasation, 
involves a cascade of events including cell rolling, adhesion, and transmigration through 
vessel endothelial cells [Phillipson et al. 2011]. Upon reaching a site of active infection, 
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neutrophils attack foreign species and secrete numerous pro-inflammatory cytokines and 
chemokines, including TNF-α, IL-1β, IL-6, among others, amplifying the local immune 
response [Witko-Sarsat et al. 2000, Kaplanski et al. 2003]. 
 
Monocytes/macrophages 
 Monocytes are leukocytes that participate in phagocytosis of pathogens. During 
active infection, monocytes are recruited to the site of pathogen invasion and convert into 
macrophages or dendritic cells [Ginhoux et al. 2014]. Monocytes survey the biological 
landscape via passage through the circulatory system, with reserve populations residing in 
the spleen primed for deployment [Swirski et al. 2009]. Macrophages derived from 
monocytes phagocytose pathogens and contribute to acute inflammatory events that defend 
against infection. Tissue resident macrophages, such as Kupffer cells, alveolar 
macrophages, and microglia, reside in numerous organs and provide local protection 
against pathogens and other functions. These cells, however, are derived from the 
embryonic yolk sac and are distinct from monocyte-derived macrophage populations 
[Epelman et al. 2014]. 
Macrophages that respond to infection or injury are broadly grouped into two 
branches: the pro-inflammatory M1 macrophages and the anti-inflammatory M2 
macrophages. M1 macrophages are first-responder macrophages that produce and secrete 
numerous pro-inflammatory cytokines and chemokines to sustain an ongoing acute 
inflammatory reaction. M1 macrophages communicate with adaptive immune cells via 
inflammatory factors including IFN-γ and TNF-α, leading to cytotoxic attacks pathogens 
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and damaged tissue. Following the initial pro-inflammatory response, M1 macrophages 
can class-switch into anti-inflammatory M2 macrophages, which participate in wound 
repair and final pathogen clearance [Italiani et al. 2014]. 
 
Mast cells 
 Mast cells are tissue resident granulocytes distributed throughout the vascularized 
tissues and serosal cavity. Mast cells were originally recognized for their roles in allergy 
response and anaphylaxis [Bischoff 2007]; however, they have recently been appreciated 
for having diverse biological roles, including wound repair, scar formation, fibrosis, pain 
pathophysiology, angiogenesis, and ectopic bone formation [Kalesnikoff et al. 2008, Kan 
et al. 2011, Thevenot et al. 2011, Gri et al. 2012, Frieri et al. 2013, Vincent et al. 2013, 
Douaiher et al. 2014, Convente et al. 2015]. Mast cells are the major inflammatory cell 
involved in allergenic responses, mediated by Immunoglobulin E (IgE) antibody response. 
During active bouts of allergy, IgE class antibodies bind to FcεRIα receptors present on the 
cell surface of mast cells, triggering an intracellular signaling cascade that results in 
degranulation and release of histamine, proteases, cytokines, and chemokines [Kalesnikoff 
et al. 2008, Crivellato et al. 2010]. Non-IgE-mediated stimulation of mast cells, induced by 
neuropeptides like Substance P, can also stimulate mast cell degranulation and release of 
inflammatory factors [Azzolina et al. 2003, O'Connor et al. 2004, Galli et al. 2005]. 
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Dendritic cells 
 Dendritic cells are defined as professional antigen presenting cells (APCs) that help 
direct the adaptive immune response. Classic dendritic cells are derived from CMPs and 
are thought to be appropriately classified as myeloid lineage cells, however some dendritic 
cells have also been identified having a CLP origin. Dendritic cells express MHC Class I 
and Class II receptors, which contribute to antigen presentation, however a subset of 
dendritic cells can also express putative T cell receptors like CD4 and CD8 [Merad et al. 
2013, Mildner et al. 2014]. Given their dual roles as APCs and T cell co-stimulatory cells, 
dendritic cells are considered the interface between innate and adaptive immunity. 
 
1.2.3 Adaptive immunity 
 The adaptive immune system provides long term defense against pathogens and 
other non-self particles, utilizing somatic gene rearrangement mechanisms to generate 
diverse and clonally expressed antigen receptors [Boehm 2011]. Cells of the adaptive 
immune system, such as T cells and B cells, possess the ability to recognize specific 
antigens and mount robust antigen-specific immune responses through use of T cell 
receptors (TCRs) and B cell receptors (BCRs). The adaptive immune system is unique in 
its ability to detect and respond to secondary waves of pathogen invasion derived from a 
set of mechanisms commonly termed as “memory” [Boehm 2011]. 
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The Variable-Diversity-Joining V(D)J locus and assembly of TCRs and immunoglobulins 
 Cells of the adaptive immune system, known as lymphocytes, initiate a functional 
antigen-mediated immune response through mechanisms that generate antigen-specific 
receptors that bind only to a single putative antigen. The variable-diversity-joining – also 
known as V(D)J – locus is a complex region of genes segments that serve as the foundation 
for TCR and immunoglobulin formation. During differentiation of T and B cells, single V, 
(D), and J segments from the V(D)J locus are randomly recombined to form a unique cell-
surface receptor [Schatz et al. 2011]. This process depends on a consortium of enzymes 
that work in tandem to faithfully complete receptor construction. The recombination-
activating genes (RAG1 and RAG2) function as endonucleases and recombinases that carry 
out faithful V(D)J recombination [Oettinger et al. 1990]. RAG1 and RAG2 are required 
for development of mature T and B cells, as mutations in either gene are known to cause 
severe immunodeficiency disorders [Notarangelo et al. 2016]. Additional receptor 
diversity is introduced by the terminal deoxynucleotidyl transferase (TdT) enzyme. TdT is 
a specialized DNA polymerase that adds two-to-five random N-nucleotides to linked V(D)J 
sites during recombination, substantially increasing genetic diversity capacity of formed 
receptors [Yamtich et al. 2010]. 
 
Origin of adaptive immune cells 
 All lymphoid lineage cells of the adaptive immune system are derived from a 
clonogenic common lymphoid progenitor (CLP) [Kondo et al. 1997]. CLPs can 
differentiate into three distinct populations – T cells, B cells, and natural killer cells. Both 
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T cells and B cells differentiate through a series of transient progenitor cells known as pro- 
and pre-stages that are accompanied with generation of their V(D)J-derived cell-surface 
receptors used for antigen-mediated immune function. 
 
T cells 
 T cells are derived from HSCs but mature within the thymus [Zuniga-Pflucker 
2004]. Multiple subpopulations of T cells exist, including helper T cells, cytotoxic (killer) 
T cells, and regulatory T cells, among others, that are defined by varied function and cell-
surface receptor expression [Broere et al. 2011]. The earliest T cell progenitors, also known 
as thymocytes, are double-negative for CD4 and CD8 receptors and migrate from the bone 
marrow to the thymus, where they undergo multiple checkpoints and differentiation stages, 
including two antigen evaluation checkpoints known as positive and negative selection 
[Starr et al. 2003], until they reach their mature state. Positive selection preferentially 
selects for developing thymocytes that can interact with MHC-presented antigens. At this 
stage, developing thymocytes express both CD4 and CD8 receptors. Developing 
thymocytes within an accepted range of peptide binding affinities receive a Wnt-dependent 
survival signal [Ioannidis et al. 2001] and proceed to negative selection, which ensures that 
thymocytes do not bind to self-peptides. Thymocytes that fail this checkpoint are removed 
by apoptosis [Starr et al. 2003]. Upon passing all developmental checkpoints, thymocytes 
are directed down a CD4 or CD8 lineage depending on their TCR binding affinity to MHC 
Class I or Class II peptides, respectively, where they are now defined as mature T cells. 
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 T cells circulate throughout the body in a naïve, unstimulated state until they 
encounter a putative antigen. Upon antigen binding, T cells require an additional co-
stimulatory signal mediated through the CD28 receptor for full activation [Chen et al. 
2013]. Once activated, the antigen-specific T cell clonally expands by several orders of 
magnitude and mediates a cytotoxic mechanism against pathogens expressing the putative 
antigen [Broere et al. 2011]. 
 
B cells 
 B cells are lymphocytes that act in humoral immunity by functioning as antibody-
producing cells. B cells undergo a similar developmental pathway as T cells, including 
V(D)J recombination of the immunoglobulin portion of the BCR and a positive/negative 
selection process [Pieper et al. 2013]. Naïve mature B cells express unique cell-surface 
immunoglobulin receptors mimicking the structure of an antibody. Upon binding of 
putative antigen, the unique B cell is activated, clonally expands, and differentiates into a 
plasma cell that secretes soluble antibodies against the antigen. A residual memory B cell 
subpopulation remains to recognize pathogen secondary responses and secrete antibodies 
accordingly [LeBien et al. 2008]. 
 
Natural killer (NK) cells 
 Natural killer (NK) cells are cytotoxic cells derived from CLPs [Kondo et al. 1997]. 
However, unlike CD8+ cytotoxic T cells, which require antigen-specific binding to initiate 
destruction mechanisms, NK cells are able to identify and destroy pathogens in absence of 
 19 
 
any antigen-mediated process [Vivier et al. 2011]. Notably, NK cells are able to detect and 
destroy unhealthy host “self” cells, hence their eponym. Similar to dendritic cells, NK cells 
function as intermediaries between the innate and adaptive immune systems. 
 
1.2.4 Inflammatory contribution to injury and wound repair 
 A second, yet equally important function of the immune system is the ability to 
respond to tissue injury. The panel of pattern recognition receptors (PRRs) utilized for 
pathogen detection, such as TLRs and NLRs, also can bind to damage-associated molecular 
patterns (DAMPs) that are released from damaged cells following injury [Takeuchi et al. 
2010]. The DAMP family of molecules is extensive, composed of numerous proteoglycan, 
glycosaminoglycan, glycoprotein, nucleic acid, and inorganic phosphate molecules 
[Schaefer 2014]. DAMPs can be released by an injury force in tandem with cellular and 
nuclear membrane rupture, however DAMPs may also be released following early innate 
immunity responses to pathogens, such as neutrophil oxidative bursts that may 
indiscriminately damage host tissue [Brinkmann et al. 2004, Rubartelli et al. 2007, de 
Oliveira et al. 2016]. 
 The inflammatory response during tissue injury and wound repair can be grouped 
into two main phases – a pro-inflammatory phase that coincides with cytokine, chemokine, 
and immune cell propagation that functions to clear damaged tissue and resultant pathogen 
infection; and an anti-inflammatory phase that dampens the pro-inflammatory response and 
recruits progenitors cells to regenerate damaged tissue. 
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The cascade of pro-inflammatory and anti-inflammatory events in skeletal muscle 
injury and regeneration have been well characterized [Chargé et al. 2004, Philippou et al. 
2012]. Neutrophils are the earliest responding cells to skeletal muscle injury, functioning 
to digest damaged tissue and protect against pathogen invasion from open wounds 
[Philippou et al. 2012]. Neutrophils secrete numerous chemokines and cytokines, such as 
CXCL8, IL-8, TNF-α, IL-1β, and IL-6 [Witko-Sarsat et al. 2000, Kaplanski et al. 2003, de 
Oliveira et al. 2016], that recruit additional immune cells to the site of injury. Classically-
activated M1 macrophages, derived from migratory monocytes, are next to respond to 
injury. These cells phagocytose damaged tissue, secrete TNF-α and nitric oxide (NO), and 
perform anti-microbial functions [Murray et al. 2011]. As clearance of damaged tissue 
nears its completion, the pro-inflammatory response is dampened and replaced with an 
anti-inflammatory response that coincides with the transition of M1 to M2 macrophages 
[Arnold et al. 2007, Laskin et al. 2011]. M2 macrophages secrete anti-inflammatory 
proteins and growth factors, including IL-4, IL-10, TGF-β1, and platelet-derived growth 
factor (PDGF) to support myofibroblast differentiation and eventual restoration of 
damaged skeletal muscle [Murray et al. 2011]. 
 
1.3 Regulation of the immune system by BMP pathway signaling 
 Immune cells communicate primarily via inflammatory chemokine and cytokine 
pathway networks. However, the BMP signaling pathway also has significant roles in the 
development, recruitment, stimulation, and cross-talk of progenitor and terminally 
differentiated immune cell populations [Chen et al. 2016]. Adult human HSCs express 
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BMP type I receptors and BMP ligands, and maintain robust repopulation capacity when 
cultured with high BMP4 concentrations, indicating a significant role for BMP signaling 
in HSC self renewal [Bhatia et al. 1999]. Smad4 is required for HSC self-renewal, further 
demonstrating the importance of BMP/TGF-β signaling in HSC biology [Karlsson et al. 
2007]. In addition to its role in HSC self-renewal, BMP signaling also directs cell fate of 
HSCs toward myeloid or lymphoid lineages [Crisan et al. 2015].   
 
1.3.1 BMP signaling in the innate immune system 
 BMP ligands function as chemoattractant factors to recruit several innate immune 
cell populations to sites of infection or injury. Injection of recombinant human BMP-2B 
(later renamed BMP4) was demonstrated to induce monocyte migration in an in vitro assay 
[Cunningham et al. 1992]. Additionally, BMP4 was shown to recruit monocytes in pro-
atherogenic conditions [Simoes Sato et al. 2014], and BMP6 was shown to induce 
neutrophil migration into ovaries [Akiyama et al. 2014]. In human dendritic cells, BMP 
signaling promotes maturation from monocyte precursors, induces IL-8 and TNF-α 
secretion, and enhances T cell stimulatory capacity [Martinez et al. 2011]. BMP signaling 
also potentiates the inflammatory state of other innate immune cells, inducing IL-1β and 
NO production in macrophages and Substance P expression in mast cells [Kwon et al. 
2009, Salisbury et al. 2011]. 
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1.3.2 BMP signaling in the adaptive immune system 
 The BMP signaling pathway is active in multiple adaptive immune cells. BMP2 
and BMP4 are crucial signaling ligands for progression of CD4-/CD8- double-negative T 
cell precursors to CD4+/CD8+ double-positive cells [Hager-Theodorides et al. 2014]. In 
mature CD4 T cells, BMP receptors are upregulated during TCR antigen binding, and BMP 
signaling is required for production of the cell survival and homeostasis signals IL-7, 
CXCR4, and CCR9 [Martinez et al. 2015]. In contrast, BMP signaling was shown to 
decrease TH17 helper T cell and regulatory T cell differentiation, suggesting that not all T 
cell subsets respond identically to the BMP signaling pathway [Yoshioka et al. 2012]. 
BMPs generally have a suppressive effect on B cells, inhibiting IgM, IgG, and IgA 
production in naïve and memory B cells, although the effect was ligand-specific [Huse et 
al. 2011]. 
 
1.4 Fibrodysplasia ossificans progressiva 
1.4.1 Clinical features 
 Fibrodysplasia ossificans progressiva (FOP) is clinically defined by two 
characteristic features: 1) progressive formation of heterotopic ossification (HO), and 2) 
congenital malformations of the great toe (clinically termed “hallux valgus”) (Figure 1.3). 
 At birth, the only observable phenotype of FOP is the presence of hallux valgus, a 
deformity of the great toe that is present in nearly all FOP patients [Kaplan et al. 2009]. As 
the child ages, appearance of HO usually manifests within the first decade of life. HO 
develops progressively within soft connective tissues, including skeletal muscle, tendon, 
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and ligament, in a characteristic pattern that first impacts the cranial, axial, and dorsal 
regions, including the head, neck, shoulders, and back [Pignolo et al. 2016]. HO in FOP is 
often induced by tissue injury events, including intramuscular vaccination, contusion, blunt 
force trauma, and surgical removal of ectopic bone [Lanchoney et al. 1995, Glaser et al. 
1998, Scarlett et al. 2004]; however, HO can also form in the absence of overt injury 
[Cohen et al. 1993]. As HO progresses, patient mobility is increasingly diminished as joints 
ankylose and ectopic bone extends across adjacent tissues [Smith 1998, Kaplan et al. 2004, 
Pignolo et al. 2016]. 
 FOP patients frequently present with abnormalities in addition to the two classical 
features. Over half of patients with FOP have conductive hearing impairment, cervical 
spine fusions of the facet joints between C2 and C7, short, broad femoral necks, and tibial 
osteochondromas [Kaplan et al. 2005, Schaffer et al. 2005, Deirmengian et al. 2008]. 
Craniofacial alterations, including reduced mandible and low-set ears, have also been 
observed [Hammond et al. 2012]. Some FOP patients report multiple neurological 
complications, including recurrent severe headaches, neuropathic pain, and recurrent 
seizures [Kitterman et al. 2012]. Later in life, patients commonly develop thoracic 
insufficiency syndrome (TIS), a life-threatening cardiopulmonary condition that can cause 
pneumonia and right-sided heart failure, and is a common cause of death in FOP [Kaplan 
et al. 2010]. 
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1.4.2 Histopathology of FOP lesions 
 Following a conclusive diagnosis of FOP, biopsies are not recommended, as the 
accompanying tissue injury stimulates new HO formation at site of collection [Pignolo et 
al. 2016]. However, biopsies collected prior to diagnosis of FOP have revealed the 
histological sequence of catabolic and anabolic events throughout lesion development 
[Kaplan et al. 1993, Gannon et al. 1998, Gannon et al. 2001, Glaser et al. 2003, Hegyi et 
al. 2003] (Figure 1.4). The earliest stage of lesion development involves robust invasion of 
neutrophils, monocytes/macrophages, mast cells, and lymphocytes that accompany 
extensive connective tissue destruction [Gannon et al. 1998, Gannon et al. 2001, Kaplan et 
al. 2005]. Subsequently, fibroproliferative cells mark the transition from the catabolic to 
anabolic phase, which occurs with concomitant with angiogenesis [Gannon et al. 1998, 
Glaser et al. 2003]. Lineage tracing studies (Lounev 2009; Medici et al) suggest that the 
fibroproliferative cells transition to endochondral ossification with characteristic cartilage 
morphology and extracellular matrix composition [Kaplan et al. 1993, Gannon et al. 1998, 
Glaser et al. 2003]. A final osteogenesis stage occurs, resulting in mature heterotopic bone 
that may contain an active bone marrow niche [Kaplan et al. 1993]. The origin of cells that 
contribute to HO remains incompletely defined. Tie-2, Mx1, and Scx have been used as 
markers to identify lineages that contribute to HO development in vivo [Lounev et al. 2009, 
Wosczyna et al. 2012, Agarwal et al. 2016, Dey et al. 2016]. Of note, cells of hematopoietic 
or vascular smooth muscle origin were not represented in the fibroproliferative, 
chondrogenic, or osteogenic stages of HO [Kaplan et al. 2007, Lounev et al. 2009]. 
 
 25 
 
1.4.3 Causative mutations in ACVR1 in FOP 
In 2006, ACVR1 was identified as the mutated gene in FOP [Shore et al. 2006]. 
ACVR1 encodes for the BMP type I receptor Activin-like kinase 2 (ALK2). FOP is 
inherited in an autosomal dominant pattern, although most cases of FOP arise from 
sporadic mutations with no associated family history [Shore et al. 2010]. Greater than 95% 
of patients express a specific heterozygous missense mutation, an arginine to histidine 
amino acid residue change at codon 206 (R206H) caused by a single nucleotide substitution 
(c.617G>A) (Figure 1.5) [Shore et al. 2006, Kaplan et al. 2009]. The R206H mutation is 
located within the GS domain of ALK2 and is predicted to impair salt bridge formation 
with a tertiary-adjacent aspartate residue at codon 269 [Groppe et al. 2007], reducing 
binding affinity for FKBP12, an inhibitory protein that stabilizes the inactive conformation 
of the receptor [Huse et al. 1999, Shen et al. 2009, Chaikuad et al. 2012]. 
 Additional causative mutations in ACVR1 have been identified in patients with FOP 
in combination with atypical features and/or more severe or mild FOP characteristics 
[Convente et al. 2017]. All identified classic and variant FOP mutations are single 
nucleotide substitutions within the GS or protein kinase domains of ALK2, except for a 
three-nucleotide deletion spanning two codons that results in replacement of a single amino 
acid residue (P197-F198 del ins L) (Figure 1.5) [Kaplan et al. 2009]. 
 
1.4.4 ACVR1R206H causes enhanced BMP signaling activity 
 In vitro studies using cells derived from human patients and various animal models 
have demonstrated elevated BMP pathway signaling caused by the ACVR1 R206H 
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mutation. Patient-derived lymphoblastoid cell lines (LCLs) exhibited enhanced 
phosphorylated-p38 MAPK levels and BMP target gene expression in the presence of 
BMP4 ligand [Fiori et al. 2006]. Upregulation of canonical BMP signaling by ALK2R206H 
was first observed using FOP patient-derived stem cells from human exfoliated deciduous 
teeth (SHED) [Billings et al. 2008]. Ligand-independent and ligand-dependent activation 
of ALK2R206H was also observed in SHED cells, and confirmed in chick limb bud 
micromass cultures and zebrafish embryonic development assays [Billings et al. 2008, 
Shen et al. 2009]. Increased signaling has also been observed in over-expression C2C12 
(mouse myoblast precursor line), COS-7 (monkey kidney cell line), and MC3T3-E1 
(mouse pre-osteoblast cell line) experiments, indicating the enhanced activity of 
ALK2R206H is not cell specific [Fukuda et al. 2009, Shen et al. 2009]. Notably, increased 
signaling conferred by ALK2R206H is not prevented by addition of extracellular BMP 
antagonists, such as noggin, further suggesting that the enhanced signaling activity is in 
part ligand-independent [Shen et al. 2009]. 
 The observed enhanced signaling activity in ALK2R206H is consistent with 
predictive structural modeling data [Groppe et al. 2007, Chaikuad et al. 2012]. The crystal 
structure of ALK2 [Chaikuad et al. 2012] indicates that FOP mutations may alter 
interactions that stabilize the inactive state of the kinase domain, leading to inappropriate 
activation. Furthermore, the ACVR1 R206H mutation is predicted to reduce binding of 
FKBP12, an intracellular regulatory protein that binds the GS domain of BMP/TGF-β type 
I receptors to prevent leaky receptor activation in absence of ligand binding [Wang et al. 
1996, Groppe et al. 2007]. Co-immunoprecipitation and size exclusion high-performance 
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liquid chromatography (HPLC) experiments have shown reduced FKBP12 binding affinity 
to ALK2R206H compared to wild-type ALK2 [Shen et al. 2009, Song et al. 2010, van Dinther 
et al. 2010, Groppe et al. 2011], matching structural homology predictions. 
  
1.4.5 Conditional-on knock-in mouse model of FOP 
 The need for high fidelity mouse models is essential to studying FOP, especially in 
light of the rarity of biopsy tissue. A knock-in mouse model was generated to carry the 
identical nucleotide substitution as in patients, c.617G>A;R206H in exon 5 at the 
endogenous Acvr1 locus [Chakkalakal et al. 2012]. Chimeric founder mice were viable, 
however germline transmission pups died perinatally. These mice phenocopied all clinical 
features of FOP, including the two characteristic features of disease – progressive HO and 
great toe malformation. An unexpected finding from the chimeric model is the presence of 
wild-type cells in ectopic bone, suggesting that although the ACVR1 R206H mutation is 
necessary to induce the bone formation process, the mutation is not necessary for 
differentiation of progenitor cells into cartilage and bone within maturing lesions. 
Histopathological analysis also demonstrated that lesion development in the knock-in 
mouse model progressed through all catabolic and anabolic stages seen in FOP. This mouse 
model was the first to demonstrate that the ACVR1 R206H mutation is sufficient to cause 
FOP [Chakkalakal et al. 2012]. 
 In order to study FOP etiology throughout neonatal development and adulthood, a 
conditional-on knock-in Acvr1R206H mouse was generated [Hatsell et al. 2015]. This mouse 
contains an engineered gene construct at the endogenous Acvr1 locus with the human wild-
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type exon 5 followed by downstream mouse R206H exon 5 in anti-sense orientation, with 
adjacent intron sequence and engineered LoxP sites in between. Upon Cre-recombinase-
mediated recombination, the human wild-type exon is deleted and the mouse R206H exon 
is flipped into sense orientation, generating a functional Acvr1R206H allele (Figure 1.6). The 
Acvr1R206H allele can be induced globally, or in specific cell populations induced by 
promoter-driven Cre recombinase expression. Several studies have used these mice for in 
vitro and in vivo experiments [Hatsell et al. 2015, Chakkalakal et al. 2016, Dey et al. 2016]. 
 
1.5 Project summary 
 Much has been learned about cellular and molecular mechanisms driving FOP 
pathology since the discovery of the gene mutation in 2006. Clinical evaluation, in 
combination with mouse model data, has vastly expanded the knowledge of disease, 
especially for the later chondrogenesis and osteogenesis stages. Previous work from our 
lab and others has demonstrated accelerated chondrogenesis as a consequence of the 
ACVR1 R206H mutation, and the first clinical trials for FOP are currently evaluating drug 
efficacy at inhibiting this stage of lesion progression. Despite the recent advances in 
understanding of FOP pathology, an area that remains unclear is the contribution of the 
immune system to disease initiation and progression. As outlined in the Introduction, BMP 
signaling is crucial for immune cell development and activation. This suggests that the 
increased activity conferred by Acvr1R206H would enhance the early inflammatory response 
stage of FOP disease progression, which occurs in episodes of HO even without an overt 
injury. In the case of tissue injury, an early inflammatory response is seen in both FOP 
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patients and unaffected individuals, yet the final outcome of the injury repair program is 
strikingly dissimilar, as FOP patients develop ectopic cartilage and bone in place of faithful 
tissue regeneration. Elucidating how the ACVR1 R206H mutation and the inflammatory 
response direct the divergence of repair events has not been determined and is a goal of 
this project. 
 I investigated two primary research questions for this project: 1) to determine the 
effect of Acvr1R206H on the cellular and molecular inflammatory response to tissue injury, 
and 2) to determine whether modulation of the immune system can control HO formation. 
The experimental results presented in this dissertation demonstrate an active role for 
Acvr1R206H in driving an elevated inflammatory response in FOP, and that inhibition of the 
immune system can impair HO development in an FOP genetic background. 
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Figure 1.1: BMP and TGF-β signaling pathways 
BMP and TGF-β signaling pathways (canonical and non-canonical) are shown. Extracellular, membrane-
bound, and intracellular antagonists are included. Abbreviations: EC = extracellular domain; TM = 
transmembrane domain; GS = glycine/serine domain; PK = protein kinase domain 
 
 
 
 31 
 
 
 
Figure 1.2: Hematopoiesis differentiation chart 
Generalized hematopoiesis self-renewal and differentiation chart is shown. LT-HSCs self-renew or 
asymmetrically divide into ST-HSCs, which proliferate and differentiate into two branches – CLPs or CMPs. 
All lymphoid- and myeloid-derived precursor and terminally differentiated cells are derived from either CLPs 
or CMPs, respectively. Abbreviations: HSC = hematopoietic stem cell; LT-HSC = long-term HSC; ST-HSC 
= short-term HSC; CLP = common lymphoid progenitor; CMP = common myeloid progenitor; GMP = 
granulocyte/macrophage progenitor; MEP = megakaryocyte/erythrocyte progenitor 
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Figure 1.3: Clinical diagnostic features of FOP 
(A) Three-dimensional volume rendering demonstrating progressive HO observed in FOP. (B) Radiograph 
of feet showing the great toe malformation (“hallux valgus”) in FOP. 
 
Figure panels (A) and (B) from Shore E.M., Xu, M., Feldman, G.J., Fenstermacher, D.A., Cho, T.J., Choi I.H., Conner, J.M., Delai P., 
Glasser, D.L., LeMerrer, M., Morhart R., Rogers J.G., Smith R., Triffitt J.T., Urtizberea, J.A., Zasloff, M., Brown, M.A., Kaplan, F.S. 
“A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva.”  
Nature Genetics. 2006 May, 38(5):527-527. 
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Figure 1.4: Histopathology of FOP lesion 
(A) Schematic representation of lesion progression in FOP. In response to injury, skeletal muscle destruction 
occurs followed by robust immune cell invasion. As these catabolic events conclude, an anabolic stage begins 
with recruitment of fibroproliferative progenitor cells that condense and differentiate to chondrocytes, 
ultimately resulting in mature bone with an active marrow niche. (B) Histological section from Acvr1cR206H/+ 
mouse containing all sections of lesion. (C) Histological section from FOP patient biopsy containing 
comparable stages of lesion to mouse. Scale bar = 100 μm. Abbreviations: DM = damaged muscle; FP = 
fibroproliferation; C = chondrocytes; B = bone. 
 
Figure panel (C) from Kaplan, F.S., Pignolo, R.J., Shore, E.M. “The FOP metamorphogene encodes a novel type I receptor that 
dysregulates BMP signaling.” Cytokine & Growth Factor Reviews. 2009 20(5-6):399-407. 
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Figure 1.5: ALK2 classical and variant mutations in FOP 
ALK2, the BMP type I receptor mutated in FOP, consists of four domains: an extracellular ligand binding 
domain (EC), a transmembrane domain (TM), a glycine/serine domain (GS), and a protein kinase domain 
(PK). A total of 12 mutations have been identified, all present within the GS or PK domains. Over 95% of 
patients possess the classical R206H mutation. 
 
Based on figure from Convente M, Towler O, Stanley A, Brewer N, Allen R, Kaplan F, Shore E. "Chapter 
30: Fibrodysplasia (Myositis) Ossificans Progressiva." In: Thakker R, Whyte M, Eisman J, Igarashi T, 
editors. Genetics of Bone Biology and Skeletal Disease: 2nd Edition (in press). 2: Elsevier; 2017. 
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Figure 1.6: Conditional-on knock-in Acvr1R206H mouse 
(A) Sequence of Acvr1 exon 5, with the nucleotide substitution c.617G>A shown. (B) Structure of the 
Acvr1[R206H]FIEx allele. The wild-type human exon 5 region is in sense orientation, followed downstream by 
the R206H mouse exon 5 region in antisense orientation; both regions are flanked by two pairs of loxP sites 
arranged so that the wild-type region is deleted and the R206H region is flipped into sense orientation upon 
recombination. (C) Structure of R206H allele post-recombination. 
 
Figure panels (A), (B), and (C) from Hatsell, S. J., Idone, V., Wolken, D. M., Huang, L., Kim, H. J., Wang, L., Wen, X., Nannuru, K. 
C., Jimenez, J., Xie, L., Das, N., Makhoul, G., Chernomorsky, R., D'Ambrosio, D., Corpina, R. A., Schoenherr, C. J., Feeley, K., Yu, 
P. B., Yancopoulos, G. D., Murphy, A. J., Economides, A. N. “ACVR1R206H receptor mutation causes fibrodysplasia ossificans 
progressiva by imparting responsiveness to activin A.” Science Translational Medicine. 2015 October, 7(303):303ra137. 
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Chapter Two 
Materials and Methods 
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2.1 Study Animals 
 All procedures were reviewed and approved by the Institutional Animal Care and 
Use Committee at University of Pennsylvania. 
 
2.1.1 Knock-in Acvr1R206H/+ mouse colony 
 A conditional knock-in Acvr1R206H/+ mouse was previously generated [Hatsell et al. 
2015]. Mice were crossed into two different induction systems – ERT2-Cre tamoxifen 
induction, and R26-rtTA; TetO-Cre doxycycline induction. 
Our lab obtained B6.129-Gt(ROSA)26Sortm(cre/ERT2)Tyj/J mice from the Jackson 
Laboratory (Stock #008463; hereafter referred to as “ERT2-Cre”). These mice express Cre 
recombinase under the presence of tamoxifen. ERT2-Cre mice were mated with 
Acvr1cR206H/+ mice to generate ERT2-Cre; Acvr1cR206H/+ mice that express the mutant 
Acvr1cR206H after administration of tamoxifen (200 μL of 10 mg/mL concentration 
dissolved in corn oil). This FOP mouse is referred to as ERT2-Cre; Acvr1cR206H/+ and was 
only used for our bone marrow transplant experiment. 
 Acvr1[R206H]FlEx/+ mice with mice double transgenic for R26-rtTA and tetO-Cre 
(heterozygous Gt(ROSA)26Sortm1(rtTA_M2)Jae and hemizygous Tg(tetO-Cre)1Jaw; (Jackson 
Laboratory) were mated to generate doxycycline-inducible global allele expression 
Acvr1[R206H]FlEx/+; Gt(ROSA)26Sortm1(rtTA_M2)Jae; Tg(tetO-Cre)1Jaw mice. This FOP mouse 
is hereafter referred to as Acvr1cR206H/+ and was used for all experiments unless otherwise 
noted. 
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2.1.2 c-KitW-sh/W-sh mast cell-deficient mouse colony 
 Our lab obtained heterozygous B6.Cg-KitW-sh/HNihrJaeBsmGlliJ from the Jackson 
Laboratory (Stock #012861, “White Sash”). To generate mast cell-deficient Acvr1cR206H/+ 
mice, I mated Acvr1cR206H/+ mice with heterozygous White Sash B6.Cg-KitW-
sh/HNihrJaeBsmGlliJ) to generate compound heterozygous Acvr1cR206H/+; B6.Cg-KitW-
sh/HNihrJaeBsmGlliJ mice. Offspring from this parental generation cross were mated to 
generate homozygous mast cell-deficient Acvr1cR206H/+; B6.Cg-KitW-sh/W-
sh/HNihrJaeBsmGlliJ mice (hereafter referred to as Acvr1cR206H/+; c-KitW-Sh/W-sh). 
 
2.1.3 B6.SJL CD45.1 mice for allogenic bone marrow transplant 
 B6.SJL CD45.1 mice were obtained from the National Cancer Institute and used as 
recipients for allogenic bone marrow transplant from CD45.2 donor bone marrow (ERT2-
Cre; Acvr1cR206H/+ or Acvr1+/+ mice). Donors and recipients expressed different isoforms 
of CD45 to quantify engraftment and reconstitution of donor bone marrow into recipients. 
 
2.1.4 LysM-Cre mouse colony 
 LysM (also known as Lyz2) encodes the sequence for the Lysozyme M protein, a 
glycoside hydrolase enzyme that is expressed in myeloid lineage cells, including 
monocytes and macrophages [Cross et al. 1988, Faust et al. 2000]. Our lab obtained 
B6.129P2-Lyz2tm1(cre)Ifo/J mice from the Jackson Laboratory (Stock #004781; hereafter 
referred to as LysM-Cre) To induce expression of Acvr1cR206H exclusively in myeloid 
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lineage cells, I mated heterozygous Acvr1cR206H/+ with heterozygous LysM-Cre/+ mice to 
generate LysM-Cre/+; Acvr1cR206H/+ mice. 
 
2.2 PCR Genotyping 
2.2.1 Extraction of genomic DNA 
 Tail snips were collected from 3 week mice and processed using the KAPA Express 
Extract Kit (KAPA Biosystems). Tissue was placed in 100 μL digestion buffer (88 μL PCR 
grade water 10 μL KAPA Express Extract Buffer, 2 μL KAPA Express Extract Enzyme (1 
U/μL) and lysed at 75°C for 10 minutes, and inactivated at 95°C for 5 minutes. 
 
2.2.2 Preparation of PCR reaction 
 A master-mix containing 12.5 μL KAPA2X Robust HotStart ReadyMix, 1.0 μL of 
forward and reverse primer solution (200 μM final concentration), 1.0 μL genomic DNA, 
and 10.5 μL PCR grade water (total volume of 25 μL) was made for each reaction. 
 
2.2.3 PCR protocol for genotyping doxycycline-inducible Acvr1cR206H/+ mice 
 Acvr1cR206H/+ mice require expression of three transgenes for doxycycline-inducible 
expression of the Acvr1cR206H allele - R26-rtTA, tetO-Cre, and Acvr1[R206H]FlEx. Expression 
of all three amplicons for a single mouse indicates a positive Acvr1cR206H/+ animal. Primer 
pair sequences targeting each transgene, thermocycler method, and agarose gel 
composition are listed in Table 2.1. 
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2.2.4 PCR protocol for genotyping tamoxifen-inducible ERT2-Cre; Acvr1cR206H/+ mice 
 Acvr1cR206H/+ mice require expression of two transgenes for tamoxifen-inducible 
expression of the Acvr1cR206H allele – ERT2-Cre and Acvr1[R206H]FlEx. Expression of both 
amplicons for a single mouse indicates a positive ERT2-Cre; Acvr1cR206H/+ animal. Primer 
pair sequences targeting each transgene, thermocycler method, and agarose gel 
composition are listed in Table 2.2. 
 
2.2.5 PCR protocol to confirm Acvr1cR206H recombination and expression 
 Expression of the Acvr1cR206H allele is confirmed by detecting presence of amplicon 
32 bp greater in length compared to unrecombined allele from genomic DNA sample post-
induction. Primer pair sequences, thermocycler method, and agarose gel composition are 
listed in Table 2.3. 
 
2.2.6 PCR protocol for genotyping mast cell-deficient c-KitW-Sh/W-sh mice 
 c-KitW-Sh/W-sh mice require homozygous expression of the mutant c-KitW-Sh allele for 
full mast cell deficiency. Primer pair sequences, thermocycler method, and agarose gel 
composition are listed in Table 2.4. For additional genotype confirmation, in a C57BL/6J 
background, c-KitW-Sh/+ mice have a patch of white fur around the abdomen and back; c-
KitW-Sh/W-sh mice have entirely white fur [Grimbaldeston et al. 2005]. 
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2.2.7 PCR protocol for genotyping LysM-Cre mice 
 Heterzygous and hemizygous expression of LysM-Cre and Acvr1cR206H/+, 
respectively, will activate the Acvr1cR206H allele exclusively in myeloid lineage populations. 
Primer pair sequences, thermocycler method, and agarose gel composition are listed in 
Table 2.5. 
 
2.3 Cross-sectional injury experimental design 
 Skeletal muscles of Acvr1cR206H/+ and Acvr1+/+ mice (4 weeks of age) were injured 
by injecting 50 μL of 20 μM cardiotoxin from Naja mossambica mossambica (Sigma-
Aldrich) into hamstring muscles of the hind limbs. Mice were euthanized by CO2 
asphyxiation and whole hind limbs were collected at days 0, 1, 2, 3, 4, 5, 6, 7, 10, and 14 
post-injection. Day 0 samples were collected without cardiotoxin injection. Acvr1cR206H/+ 
mice were placed on a doxycycline chow diet (625 mg/kg doxycycline chow) for 5 days 
prior to cardiotoxin injection to induce mutant gene expression. 
 
2.4 Isolation and culture of primary murine immune cells 
2.4.1 Isolation of murine bone marrow 
 Whole bone marrow was collected from femurs and tibias of Acvr1cR206H/+ and 
Acvr1+/+ mice. Skeletal muscle was removed from femurs and tibias, and the bones were 
cut at the diaphyseal midshaft, with approximately 0.5 mm of each epiphysis removed. 10 
mL D-MEM was aspirated through each hollow cortical bone piece using a 27G needle 
into a 15 mL conical tube. Cells were spun and plated fresh in appropriate 
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maturation/growth medium, or resuspended in 95% : 5% ratio; FBS : DMSO freeze 
medium and kept for long term storage in liquid nitrogen. 
 
2.4.2 Maturation of primary murine mast cells from whole bone marrow 
 Whole bone marrow was cultured in suspension for 6 weeks in mast cell maturation 
medium (RPMI 1640, 10% FBS, 1X Penicillin/Streptomycin, 25 mM HEPES, 1X MEM 
Non-Essential Amino Acids, 1X GlutaMAX, 100 mM Sodium pyruvate, 50 μM β-
mercaptoethanol) with added recombinant murine Stem Cell Factor (Peprotech; 15 ng/mL 
final concentration) and recombinant murine Interleukin (IL)-3 (Peprotech; 12 ng/mL final 
concentration) [Jamur et al. 2011]. Mast cell purity was determined via flow cytometry and 
gating for c-kit receptor/CD117 and FcεRIα receptor double-positive cells [Weller et al. 
2005]. 
 
2.4.3 Isolation of primary murine macrophages by thioglycollate elicitation 
 To obtain primary murine macrophages, 1.5 mL aged 4.0% thioglycolate solution 
(Sigma-Aldrich) was injected intraperitoneally into Acvr1cR206H/+ and Acvr1+/+ mice 
[Zhang et al. 2008]. After 5 days, mice were euthanized by CO2 asphyxiation and peritoneal 
exudate was collected using 10 mL PBS. Cells were centrifuged at 300 x G for 5 minutes 
and plated in 100 cm plates in macrophage growth medium (RPMI 1640, 5% FBS, 10 mM 
HEPES, 1X Penicillin/Streptomycin, 1X GlutaMAX, 23.3 mM Sodium bicarbonate, 50 
μM β-mercaptoethanol). 
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2.5 BMP ligand and inflammatory stimulation of immune cells 
2.5.1 BMP ligand stimulation of immune cells 
 1 X 106 mast cells or 5 X 105 macrophages were plated in Tyrode’s solution for 
overnight or 2 hours, respectively, and then treated with increasing concentrations of 
recombinant human BMP4 for 1 hour.  
 
2.5.2 Mast cell inflammatory stimulation with Substance P 
1 X 106 cells were plated in 1 mL Tyrode’s solution overnight, and then stimulated 
with 100 μM Substance P (Sigma-Aldrich) plus 15 ng/mL of recombinant human BMP4 
for 1 hour. 
 
2.5.2 Mast cell degranulation assay 
Mast cell degranulation was assayed using a Mast Cell Degranulation Assay Kit 
(EMD Millipore). 1.5 X 106 cells were plated in 1 mL Tyrode’s solution overnight, and 
then stimulated with 100 μM Substance P, plus 15 ng/mL of recombinant human BMP4 
for 1 hour. Cells were spun and 180 μL of conditioned medium was added to 20 μL tryptase 
substrate in a 96 well plate for 2 hours in an incubator at 37°C and 5% CO2. The assay 
detects the chromophore p-nitroanaline (pNA) after tryptase-mediated cleavage of the 
labeled substrate tosyl-gly-pro-lys-pNA. The free pNA is quantified using a microplate 
reader at a wavelength of 405 nm. 
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2.5.2 Macrophage inflammatory stimulation with lipopolysaccharides 
For macrophage inflammatory stimulation, 5 X 105 cells were plated in 1 mL 
Tyrode’s solution for 2 hours, and then stimulated with 1 ng/mL lipopolysaccharides 
(Sigma-Aldrich) plus 15 ng/mL of recombinant human BMP4 for 1 hour. 
 
2.6 Gene and protein expression analysis 
2.6.1 Gene expression analysis 
RNA was isolated from mast cells and macrophages using TRIzol (Thermo Fisher 
Scientific) and quantified using a Nanodrop instrument. 1.0 μg cDNA was synthesized 
using High Capacity RNA-to-cDNA reagents (Applied Biosystems). Real-time 
quantitative PCR reactions contained forward/reverse primers (0.37 μM), cDNA (1:5 
dilution), and 1X Fast SYBR Green PCR Master Mix (Applied Biosystems) for a final 
volume of 13 μL; each sample was analyzed in triplicate. Target gene mRNAs were 
quantified from standard curves and normalized to Gapdh. Forward and reverse primers 
are listed in Table 2.6. 
 
2.6.2 Protein expression analysis 
Total cell protein was recovered using RIPA lysis and extraction buffer (Thermo 
Fisher Scientific) containing Halt Protease and Halt Phosphatase Inhibitor Cocktails 
(Thermo Fisher Scientific) and quantified using Pierce BCA Protein Assay Kit (Thermo 
Fisher Scientific). 30 μg protein were electrophoresed through 4-12% Bolt Bis-Tris 
polyacrylamide gels (Thermo Fisher Scientific) and transferred to nitrocellulose 
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membranes using a Bio-Rad Trans Blot Turbo instrument (Bio-Rad). Membranes were 
blocked in 5% Bovine Serum Albumin and incubated with primary antibody against 
Phosphorylated Smad 1/5/8 (Cell Signaling Technology, 1:750 dilution) at 4°C overnight. 
Membranes were then incubated with primary antibody against GAPDH (Cell Signaling 
Technology, 1:5000 dilution) at room temperature for 1 hour. Bound primary antibodies 
were detected with anti-rabbit horseradish peroxidase-conjugated secondary antibody (Cell 
Signaling Technology, 1:10,000 dilution) at room temperature for 1 hour. Detected 
proteins were imaged with WesternSure PREMIUM Chemiluminescent Substrate (LI-
COR) using a LI-COR C-DiGit Blot Scanner, and quantified using LI-COR Image Studio 
software. 
 
2.7 In vivo heterotopic ossification experiments 
2.7.1 Injury-induced heterotopic ossification assay 
 Skeletal muscles of Acvr1cR206H/+ and Acvr1+/+ mice (4 weeks of age) were injured 
by injecting 50 μL of 20 μM cardiotoxin from Naja mossambica mossambica (Sigma-
Aldrich) into hamstring muscles of the hind limbs. Heterotopic ossification develops by 14 
days post-injection with 100% consistency. 
 
2.7.2 Targeted depletion of mast cells and macrophages in vivo 
 Three immunodeficient Acvr1cR206H/+ transgenic mice were generated: mast cell-
deficient Acvr1cR206H/+; c-KitW-Sh/W-sh mice, a macrophage-depleted Acvr1cR206H/+; Clo. 
mice, and combined mast cell-deficient and macrophage-depleted Acvr1cR206H/+; c-KitW-
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Sh/W-sh; Clo. mice. Heterotopic ossification was initiated by injury as in 2.7.1, except that 
duration of experiment was 17 days post-injury. 
 
2.7.3 Clodronate-liposome mediated macrophage depletion 
 To deplete macrophages from mouse cohorts [van Rooijen et al. 1984, Van Rooijen 
1989], clodronate-liposomes (100 μL / 10 g bodyweight) were injected intraperitoneally 
using a 27G needle into appropriate mouse cohorts. Clodronate-liposomes were obtained 
from the lab of Dr. Nico van Rooijen (http://www.clodronateliposomes.com, The 
Netherlands). 
 
2.7.4 Bone marrow transplant of Acvr1cR206H/+ bone marrow into recipient mice 
 Whole bone marrow from donor mice was collected from femurs and tibias. 
Recipient mice were irradiated with 1000 rads, allowed to recover, and then injected with 
5 X 106 bone marrow cells by tail vein injection. Engraftment of donor bone marrow and 
immune cell reconstitution occurred for 8 weeks. Donor mice expressed the CD45.2 
isoform, recipient mice expressed the CD45.1 isoform; this allows for detection of 
engraftment and reconstitution by flow cytometry. 
  
2.7.5 Injection of neutralizing agents as a method for inhibiting heterotopic 
ossification development 
 To neutralize the pro-inflammatory cytokines TNF-α and IL-6, I injected etanercept 
(targets TNF-α), mouse-anti-IL-6 antibody, or etanercept and mouse-anti-IL-6-antibody 
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via retro-orbital delivery into Acvr1cR206H/+ mice. The first experiment utilized the 
following dosing regimens: etanercept (4.0 mg/kg, 3X week; targets TNF-α), mouse-anti-
IL-6 antibody (150 mg per mouse, 3X week) or etanercept and mouse-anti-IL-6-antibody 
(previous concentrations). The second experiment utilized the following dosing regimens: 
etanercept (4 mg/kg, 2X week; 2 mg/kg, 2X week; 4 mg/kg, 3X week). 
 
2.7.6 Retro-orbital blood collection for detection of serum cytokines 
 Mice were anesthetized by 3% isoflurane gas. Blood (no more than 150 μL) was 
collected by retro-orbital bleeding using heparinized micro-hematocrit capillary tubes 
(Fisher Scientific). After conclusion of blood collection, mice were blotted with gauze to 
stop bleeding, returned to their cage and monitored for several minutes to ensure return to 
normal activity. Blood was collected at Day 0, Day 7, and Day 14 during course of two-
week experiment; if blood collection and antibody injection days overlapped, blood was 
collected before antibody injection. Collected blood was centrifuged in Microvette 
Capillary Blood EDTA collection tubes (Kent Scientific) at 14 X G for 20 minutes at 4° C. 
Serum was collected and stored in separate tubes at -80°C before analysis. 
 
2.7.7 Micro Computed Tomography (μCT) analysis 
High-resolution, cross-sectional images of hind limbs were obtained using a 
VivaCT 40 (Scanco Medical AG) at a source voltage of 55 kV, a source current of 145 μA, 
and an isotropic voxel size of 19.0 μm. A three-dimensional (3D) rendering was 
reconstructed using Scanco microCT V6.1 software. Thresholding values for heterotopic 
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ossification detection ranged from 240 – 1,000 Hounsfield units. Detected heterotopic 
ossification was quantified using Scanco microCT V6.1 software. 
 
2.8 Flow Cytometry 
2.8.1 Confirming primary murine mast cell purity 
 Mast cells were incubated with c-Kit-APC (BioLegend, 1:150 dilution) and FcεRIα-
PE (BioLegend, 1:150 dilution) antibodies for 30 minutes and then run on a BD 
FACSCalibur instrument (BD Biosciences). Double-positive cells expressing c-Kit and 
FcεRIα receptors were gated as mast cells. 
 
2.8.2 Confirming clodronate-liposome-mediated macrophage depletion 
 Whole bone marrow was collected at sacrifice from clodronate-liposome-injected 
cohorts and stained with F4/80-PE (BD Pharmingen), CD11b-PerCP/Cy5.5 (BD 
Pharmingen), and MHC Class II-APC antibodies (BD Pharmingen). Cells were run on a 
BD FACSCanto instrument (BD Biosciences). Triple-positive cells expressing F4/80, 
CD11b, and MHC Class II receptors were gated as macrophages. 
 
2.8.3 Confirming allogenic hematopoetic engraftment and immune cell reconstitution 
 Whole bone marrow and spleens were collected from bone marrow transplant 
recipient mice and analyzed by flow cytometry to determine engraftment of donor CD45.1 
bone marrow and reconstitution of five immune cell populations: B cells, CD4 T cells, 
CD8 T Cells, neutrophils, and natural killer cells. Cell expressing the following receptors 
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were used to detect listed immune cell populations and gated as indicated: CD45.1+, 
CD45.2+, CD19+ (B cells), CD3e+ / CD4+ (CD4 T cells), CD3e+ / CD8a+ (CD8 T cells), 
CD11b+ / Gr-1+ (neutrophils), CD3e- / CD49b+ / NK1.1+ (natural killer cells). 
 
2.9 Histological analysis 
2.9.1 Sample preparation 
 Hind limb samples were collected at sacrifice and fixed in 4% paraformaldehyde 
for 24 hours. Samples were decalcified in Immunocal (Decal Chemical Corporation) for 3 
days, embedded in paraffin blocks, and sectioned serially at 5 μm. 
 
2.9.2 Gross morphology histological stain 
 Deparaffinized sections were stained with combined Alcian Blue / Orange G / 
Hematoxylin / Eosin stain to detect glycosaminoglycans (GAG), bone, nucleated cells, and 
skeletal muscle, respectively. 
 
2.9.3 Mast cell detection via combined eosinophil and mast cell (C.E.M.) stain 
 Deparaffinized sections were stained with C.E.M. stain (American Master Tech) to 
identify mast cells. 
 
2.9.4 Immunohistochemstry 
Deparaffinized sections were treated for antigen retrieval with 10 mM Sodium-
Citrate buffer (pH 6.0) at 95°C for 20 minutes (for cytokine and chemokine detection) or 
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Digest-All 2 Trypsin (Thermo Fisher Scientific) at 37°C for 10 minutes (for immune cell 
detection). Endogenous peroxidase activity was quenched with 3% hydrogen peroxide 
solution. Sections were blocked using Background Buster (Innovex Biosciences) and 
incubated with primary antibodies overnight at 4°C. Sections were then incubated with 
appropriate host secondary antibody and developed using SuperPicture Polymer DAB 
Detection Kit (Thermo Fisher Scientific) and counterstained with haematoxylin. Primary 
antibodies used were: Phosphorylated Smad 1/5/8 (Cell Signaling, 1:50 dilution), 
Myeloperoxidase (Abcam, 1:200 dilution), F4/80 (Abcam, 1:500 dilution), CD3 (Abcam, 
1:50 dilution), TNF-α (Abcam, 1:100 dilution), IL-6 (Abcam, 1:400 dilution), IL-1β 
(Abcam, 1:400 dilution), MCP-1 (Abcam, 1:200 dilution), IL-13 (Abcam, 1:400 dilution), 
Activin A (LS Bio, 1:400 dilution). 
 
2.10 Statistical analysis 
Data obtained were analyzed statistically using GraphPad Prism 7 software 
(unpaired, two-sided, equal variance Student’s t test; two-way ANOVA with Sidak’s 
multiple comparisons test; two-way repeated measures ANOVA with Holm-Sidak’s 
multiple comparisons test; one-way ANOVA with Tukey’s multiple comparisons test); 
values are expressed as the mean ± SEM. Statistical significance was p < 0.05. 
 51 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.1: PCR protocol for genotyping doxycycline-inducible Acvr1cR206H/+ mice 
 
 Acvr1[R206H]FlEx 
Forward 
primer 
5'-AACCAACATTGCCTGCTGCCCA-3' 
(ES3350) 
5'-GCGCGTTAGCTTAGCTCTGT-3' 
(ES3748) 
Reverse 
primer 
5'-GCAGCCTCGTGGATTCACGCT-3' 
(ES3351) 
5'-ACTCACATGAAGGGCAGCAA-3' 
(ES3750) 
  
Denature 94°C; 30 seconds 
Anneal 65°C; 45 seconds 
Extension 72°C; 35 seconds 
Cycles 35 
Agarose Gel 2.0% 
Amplicon 
length 
650 bp (ES3350/3351) 
or 
280 bp (ES3748/3750) 
PCR protocol for genotyping doxycycline-inducible Acvr1cR206H/+ mice 
 R26-rtTA TetO-Cre 
Forward 
primer 
5'-GCGAAGAGTTTGTCCTCAACC-3' 
(ES3356) 
5'-ATTCTCCCACCGTCAGTACG-3' 
(ES2856) 
Reverse 
primer 
5'-AAAGTCGCTCTGAGTTGTTAT-3' 
(ES3357) 
5'-CGTTTTCTGAGCATACCTGGA-3' 
(ES2857) 
   
Denature 95°C; 15 seconds 95°C; 15 seconds 
Anneal 60°C; 15 seconds 60°C; 15 seconds 
Extension 72°C; 15 seconds 72°C; 15 seconds 
Cycles 35 35 
Agarose Gel 2.0% 2.0% 
Amplicon 
length 
350 bp 500 bp 
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Table 2.2: PCR protocol for genotyping tamoxifen-inducible ERT2-Cre;Acvr1cR206H/+ mice 
 
 
 
 Acvr1[R206H]FlEx 
Forward 
primer 
5'-AACCAACATTGCCTGCTGCCCA-3' 
(ES3350) 
Reverse 
primer 
5'-GCAGCCTCGTGGATTCACGCT-3' 
(ES3351) 
  
Denature 94°C; 30 seconds 
Anneal 65°C; 45 seconds 
Extension 72°C; 35 seconds 
Cycles 35 
Agarose Gel 2.0% 
Amplicon 
length 
650 bp 
PCR protocol for genotyping tamoxifen-inducible ERT2-Cre;Acvr1cR206H/+ mice 
 ERT2-Cre mutant ERT2-Cre wild-type 
Forward 
primer 
5'-AAAGTCGCTCTGAGTTGTTAT-3' 
(ES3718) 
5'-AAAGTCGCTCTGAGTTGTTAT-3' 
(ES3718) 
Reverse 
primer 
5'-CCTGATCCTGGCAATTTCG-3' 
(ES3720) 
5'-GGAGCGGGAGAAATGGATATG-3' 
(ES3719) 
   
Denature 95°C; 60 seconds 95°C; 60 seconds 
Anneal 58°C; 60 seconds 58°C; 60 seconds 
Extension 72°C; 60 seconds 72°C; 60 seconds 
Cycles 35 35 
Agarose 
Gel 
2.0% 2.0% 
Amplicon 
length 
825 bp 650 bp 
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Table 2.3: PCR protocol for detecting recombination of Acvr1cR206H allele 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCR protocol for detecting recombination of Acvr1cR206H allele 
 Acvr1cR206H recombination 
Forward 
primer 
5'-TGTATTGCAGGACGCTGAAG-3' 
 (ES2935) 
Reverse 
primer 
5'-CCCCTGAAGTGGAATAACCA-3' 
(ES2936) 
  
Denature 94°C; 30 seconds 
Anneal 55°C; 45 seconds 
Extension 72°C; 35 seconds 
Cycles 35 
Agarose 
Gel 
4.0% 
Amplicon 
length 
Recombination = 370 bp and 336 bp 
No recombination = 336 bp 
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Table 2.4: PCR protocol for genotyping mast cell-deficient c-KitW-Sh/W-sh mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCR protocol for genotyping mast cell-deficient c-KitW-Sh/W-sh mice 
 c-KitW-Sh mutant c-Kit wild-type 
Forward 
primer 
5'-AGGCTTGCAGCGCATTAT-3' 
(ES3755) 
5'-TTTGCACGTGCTAGTTACAC-3' 
(ES3753) 
Reverse 
primer 
5'-GAGGATTCATAGTTGTTCAATGTCC-3' 
(ES3756) 
5'-TTAAGATGGCACCCTGCTG-3' 
(ES3754) 
   
Denature 95°C; 30 seconds 94°C; 60 seconds 
Anneal 57°C; 60 seconds 57°C; 60 seconds 
Extension 72°C; 60 seconds 72°C; 60 seconds 
Cycles 35 35 
Agarose 
Gel 
2.0% 2.0% 
Amplicon 
length 
165 bp 650 bp 
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Table 2.5: PCR protocol for genotyping LysM-Cre mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCR protocol for genotyping LysM-Cre mice 
 LysM-Cre 
Forward 
primer 
5'-CCCAGAAATGCCAGATTACG-3' 
 (ES4018) 
Reverse 
primer 
5'-CTTGGGCTGCCAGAATTTCTC-3' 
(ES4019) 
  
Denature 95°C; 15 seconds 
Anneal 60°C; 15 seconds 
Extension 72°C; 15 seconds 
Cycles 35 
Agarose 
Gel 
2.0% 
Amplicon 
length 
700 bp 
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Target Full Transcript 
Name 
Forward Primer Reverse Primer Stock  
Number 
Actr2a Activin receptor type 
2a 
GAACATGATGGAGGCGGCAGCAG 
 
GACCCCGTCCAATCAGCTCCA 
 
ES3318/ 
3319 
Actr2b Activin receptor type 
2b 
CCTACTCAAGACCCAGGACCACC 
 
GAGCAACTGGGCTTTCCAGACAC 
 
ES3320/ 
3321 
Acvr1 Activin A receptor 
type 1 
TGGTACAGAGAACGGTGGCT 
 
ACTTCTCCATACCGGCCCTTC 
 
ES3213/ 
3217 
Acvrl1 Activin A receptor 
Like type 1 
ACACCCACCATCCCTAACC 
 
ACCAGCACTCTCTCATCATCTG 
 
ES3306/ 
3307 
Acvr1b Activin A receptor 
type 1B 
GCGGCGGTTACTATGGCGGA 
 
CGCACACAGCAGAGCCTGGAT 
 
ES3310/ 
3311 
Acvr1c Activin A receptor 
type 1C 
GCTCTGGGACCCCGAAGCCTTG 
 
ACACACACACTTCAGTCCTGCCGCA 
 
ES3316/ 
3317 
Bmpr1a Bone morphogenetic 
protein receptor type 
1A 
AGCGATGAATGTCTTCGAGCAGTT 
 
TCAAAGCTGTGAGTCTGGAGGCT 
 
ES3308/ 
3309 
Bmpr1b Bone morphogenetic 
protein receptor type 
1B 
CCTCCCTCTGCTGGTCCAAAGGA CCTCGCCATAGCGGCCTTTTCC 
 
ES3314/ 
3315 
Bmpr2 Bone morphogenetic 
protein receptor type 
2 
GAACATGATGGAGGCGGCAGCAG 
 
GACCCCGTCCAATCAGCTCCA 
 
ES3322/ 
3323 
Il1b Interleukin 1 Beta GCCAAGCTTCCTTGTGCAAGTGT 
 
GCCCTTCATCTTTTGGGGTCCG 
 
ES3443/ 
3444 
Il6 Interleukin 6 TCGGAGGCTTAATTACACATGTT 
 
TGCCATTGCACAACTCTTTTCT 
 
ES3479/ 
3480 
Gapdh Glyceraldehyde 3-
phosphate 
dehydrogenase 
CAAGGTCATCCATGACAACTTT 
 
GGCCATCCACAGTCTTCTGG 
 
ES2452/ 
2453 
Tgfb1 Transforming growth 
factor beta 1 
GGACACACAGTACAGCAAGGTCC 
 
CTCCACCTTGGGCTTGCGAC 
 
ES3439/ 
3440 
Tgfbr1 Transforming growth 
factor beta 2 
GGCAGAGCTGTGAGGCCTTGAGA 
 
ATGCCTTCCTGTTGGCTGAGTTGTG 
 
ES3312/ 
3313 
Tgfbr2 Transforming growth 
factor beta receptor 2 
CGCACGTTCCCAAGTCGGATGT 
 
TCGCTGGCCATGACATCACTGT 
 
ES3465/ 
3466 
Tnf Tumor Necrosis 
Factor 
CCCACGTCGTAGCAAACCAC 
 
AGGTACAACCCATCGGCTGGC 
 
ES3449/ 
3450 
 
Table 2.6: Quantitative real-time RT-PCR primers 
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Figure 2.1: Genotyping of Acvr1cR206H/+ mice by PCR 
DNA isolated from mouse tail snips was amplified with primers specific to Acvr1[R206H]FlEx, R26-rtTA, and 
TetO-Cre. Lower bands <100 bp in Acvr1[R206H]FlEx gel are non-specific primer dimer amplicons and do not 
reflect genotype. Lanes marked with an asterisk indicate Acvr1cR206H/+ mice. 
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Figure 2.2: Genotyping of ERT2-Cre mice by PCR 
DNA isolated from mouse tail snips was amplified with primers specific to ERT2-Cre. Lanes marked with 
an asterisk indicate ERT2-Cre mice. 
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Figure 2.3: Detection of recombined and expressed Acvr1cR206H allele in mice by PCR 
DNA isolated from mouse tail snips was amplified with primers specific to recombination of Acvr1[R206H]FlEx 
amplicon (370 bp) and Acvr1+/+ control amplicon (336 bp), indicating active Acvr1cR206H allele expression. 
Lanes marked with an asterisk indicate recombined DNA and active Acvr1cR206H allele expression. 
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Figure 2.4: Genotyping of c-KitW-sh/W-sh mice by PCR 
DNA isolated from mouse tail snips was amplified with primers specific to c-KitW-sh and c-Kit+ alleles. Lanes 
are marked with mouse genotypes. Non-specific bands for the c-Kit+ PCR do not reflect genotype. 
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Figure 2.5: Genotyping of LysM-Cre;Acvr1[R206H]FlEx mice by PCR 
DNA isolated from mouse tail snips was amplified with primers specific to LysM-Cre and Acvr1[R206H]FlEx 
alleles. Lanes marked with an asterisk indicate LysM-Cre;Acvr1[R206H]FlEx mice. 
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Chapter Three 
 
Acvr1R206H amplifies and prolongs the cellular and molecular 
inflammatory response to injury 
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3.1 Summary 
 An early inflammatory response is observed in all HO episodes occuring in FOP, 
whether induced by tissue trauma or without overt injury. In either scenario, patients often 
report swellings, tissue stiffness, sensations of warmth, and pain – termed “flare-ups” – 
that indicate the onset of localized disease. Although some flare-ups resolve without 
progression to HO, many continue through the characterized catabolic and anabolic events 
of lesion formation. The presence of immune cells has been noted in biopsies from human 
patients, however the limited availability of samples has hindered further in vivo 
investigation. Given the role of BMP signaling in hematopoietic development and immune 
cell activation, I hypothesized that the ACVR1 R206H mutation amplifies the 
inflammatory response to tissue injury, establishing a supportive microenvironment for the 
subsequent fibroliferative, chondrogenic, and osteogenic stages that result in terminal HO 
and mature bone tissue. 
 I used a recently available conditional-on knock-in Acvr1R206H mouse (hereafter 
referred to as Acvr1cR206H/+) to investigate the cellular and molecular inflammatory 
response to injury by examining levels of secreted inflammatory factors. I show that 
Acvr1cR206H causes early divergence from the normal skeletal muscle repair program, 
however, surprisingly, the earliest events are histologically indistinguishable between 
Acvr1cR206H/+ and control Acvr1+/+ mice during the first 48-hours post-injury. As lesions 
progress, the cellular and molecular inflammatory responses are not only amplified in 
Acvr1cR206H/+ mice, but also persist over time. At the cellular level, Acvr1cR206H/+ expression 
in primary mast cells potentiated their inflammatory activation. These results suggest that 
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the ACVR1 R206H mutation produces an inflammatory response to tissue injury that 
mimics chronic inflammation. 
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3.2 Introduction 
3.2.1 The inflammatory response to tissue injury in FOP 
 Patient biopsies show tissue destruction and an influx of immune cells at the earliest 
stage of lesion progression in FOP [Kaplan et al. 1993]. Histological analysis revealed the 
presence of neutrophils, macrophages, mast cells, and lymphocytes [Kaplan et al. 1993, 
Gannon et al. 2001, Kaplan et al. 2005]. Mast cell involvement in FOP patient lesions was 
particularly remarkable, with mast cell density reaching peak levels unseen in any other 
inflammatory myopathy [Gannon et al. 2001]. The same early inflammatory response 
(Figure 1.4) has been shown in chimeric Alk2R206H/+ mice, the first FOP mouse model 
expressing the Acvr1 R206H mutation [Chakkalakal et al. 2012]. It is important to note, 
however, that immune cell invasion is a characteristic feature of the normal tissue injury 
program, and the early response is qualitatively similar to what occurs in FOP [Chargé et 
al. 2004, Bentzinger et al. 2013]. 
Following normal tissue injury by cardiotoxin (CTX), a snake venom commonly 
used to study skeletal muscle damage and repair [Couteaux et al. 1988], a cascade of early 
inflammatory events activates a localized immune response. In response to tissue damage, 
tissue resident macrophages and mast cells detect DAMPs and release pro-inflammatory 
cytokines, including TNF-α, IL-1β, IL-6, and Activin A, that recruit neutrophils to the 
localized site of injury [Galli et al. 2011, Hedger et al. 2011]. Neutrophils are the first 
migratory responding cell to tissue damage and further potentiate the ongoing 
inflammatory response [Phillipson et al. 2011, Kolaczkowska et al. 2013] via secretion of 
their own TNF-α, IL-1β, and IL-8 [Witko-Sarsat et al. 2000]. Monocytes and mast cell 
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progenitors then migrate to the injury site and differentiate into macrophages and mature 
mast cells. These mature immune cells clear damaged debris and secrete chemokines 
necessary for recruitment of fibroproliferative cells that act as scaffold intermediaries while 
the skeletal muscle regeneration program augments [Murray et al. 2011, Duchesne et al. 
2013, Wynn et al. 2013]. Within 1-2 weeks, skeletal muscle is fully restored through a 
well-characterized regeneration program initiated by muscle stem cell activation [Karalaki 
et al. 2009, Bentzinger et al. 2013]. 
The normal skeletal muscle injury and repair program establishes a baseline cellular 
and molecular response that can be used to compare to injured Acvr1 R206H tissue. 
Despite ongoing interest in the early inflammatory events during FOP lesion formation, 
few studies have directly quantified any immune cell populations in lesion tissue [Gannon 
et al. 2001, Chakkalakal et al. 2016], and none have investigated the molecular 
inflammatory response. Our conditionl-on knock-in Acvr1cR206H/+ mouse model 
recapitulates features of FOP [Hatsell et al. 2015, Chakkalakal et al. 2016] and is a key tool 
that can be used to investigate the inflammatory response to injury. These mice 
reproducibly develop HO two weeks following CTX injection, establishing a reliable and 
genetically high fidelity model to study the inflammatory response in FOP. 
 
3.2.2 BMP pathway control of inflammatory activation 
 The BMP signaling pathway has well-defined roles in hematopoesis and 
inflammatory activation of numerous immune cell populations [Starr et al. 2003, Karlsson 
et al. 2007, Huse et al. 2011, Yoshioka et al. 2012] (also see Chapter 1.3). In the clinic, use 
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of recombinant BMPs as treatment for fractures is commonly associated with 
inflammation, soft tissue edema, and radiculitis [MacDonald et al. 2010, Lee et al. 2012, 
Villavicencio et al. 2016]. Notably, edema is a common feature of flare-ups as reported by 
FOP patients, and often precedes the catabolic lesion events [Pignolo et al. 2016]. Soft 
tissue swelling has also been observed in chimeric Alk2R206H/+ mice [Chakkalakal et al. 
2012]. Current therapies for FOP, while palliative, predominantly target edema, pain, and 
other inflammatory symptoms [Kaplan et al. 2016, Pignolo et al. 2016], although the 
pursuit for therapeutics that pause or even reverse symptoms is ongoing. Previous 
observations suggest that BMP signaling has distinct cellular and molecular functions 
within the immune system, and given the R206H mutation present in FOP, the dysregulated 
BMP signaling may be an appealing therapeutic target. 
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3.3 Results 
3.3.1 The Acvr1 R206H mutation causes early divergence from the normal skeletal 
muscle repair program 
 I conducted a cross-sectional injury study to investigate the histological events 
throughout lesion development in Acvr1cR206H/+ and Acvr1+/+ mice, specifically focusing 
on the cellular and molecular inflammatory response. To induce conditional expression of 
the Acvr1cR206H allele, I administered doxycycline to Acvr1cR206H/+ mice for five days prior 
to injury; this amount of time is sufficient to induce Cre-recombinase-mediated 
recombination of the Acvr1cR206H allele (Figure 2.3). Hamstring muscles of Acvr1cR206H/+ 
and Acvr1+/+ mice were injured by CTX injection, and sacrificed at various time points 
over two-weeks; day 0 samples (without injury) were collected (Figure 3.1). 
Uninjured Acvr1cR206H/+ skeletal muscle has normal skeletal muscle morphology 
(Figure 3.2A). The early tissue destruction and immune cell influx events are 
indistinguishable between Acvr1cR206H/+ and Acvr1+/+ lesion through 2 days post-injury 
(days 1-2; Figure 3.2B, C). As the lesions progress, mutant tissue exhibits robust immune 
cell invasion (days 3-4; Figure 3.3A, B) and progressive accumulation of 
glycosaminoglycan (GAG), an extracellular matrix component associated with 
chondrogenesis [San Antonio et al. 1987] (days 5-6; Figure 3.3C, D). In contrast, the 
immune cell invasion in control tissue peaks at day four, but then clears from the injury 
site. 
By day 7 post-injury, Acvr1+/+ lesions exhibited further immune cell clearance and 
presence of regenerating muscle (Figure 3.4A), however Acvr1cR206H/+ lesions showed a 
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persistence of fibroproliferative cells together with ectopic pre-hypertrophic chondrocytes 
(Figure 3.4A). By day 10, immune cells were absent from Acvr1+/+ tissue, with skeletal 
muscle repair reaching near completion at day 14 (Figure 3.4B, C). Myocentric nuclei, 
which denote ongoing skeletal muscle repair, were observed in late-stage Acvr1+/+ tissue 
(Figure 3.5). By contrast, heterotopic endochondral ossification had significantly 
progressed from day 6 to day 7 (Figure 3.4A) in Acvr1cR206H/+ tissue, with abundant 
hypertrophic chondrocytes and bone matrix present at day 10 (Figure 3.4C) and more 
mature heterotopic bone at day 14 (Figure 3.4C). These results suggest that the ACVR1 
R206H mutation disrupts the normal skeletal muscle repair program, driving heterotopic 
endochondral ossification in place of normal skeletal muscle regeneration. 
 
3.3.2 BMP signaling is upregulated in Acvr1cR206H/+ post-traumatic lesions 
 Upregulated BMP signaling has been observed in late-stage lesions from our 
previous chimeric Alk2R206H/+ mouse model, as detected by enhanced levels of nuclear 
phosphorylated-Smad 1/5/8 (p-Smad 1/5/8) protein in tissue [Chakkalakal et al. 2012]. I 
investigated the levels of p-Smad 1/5/8 by immunohistochemistry (IHC) throughout lesion 
progression in our Acvr1cR206H/+ mouse model. Levels of p-Smad 1/5/8 were higher in 
Acvr1cR206H/+ mice compared with controls at all stages examined - the early tissue 
destruction stage, intermediate fibroproliferative stage, and late ectopic cartilage and bone 
stage (Figure 3.6). p-Smad 1/5/8 was detected within the cell nuclei, consistent with the 
expected localization of p-Smad 1/5/8 protein following BMP pathway activation (Figure 
1.1). Elevated p-Smad1/5/8 protein was most prominent in the nuclei of fibroproliferative 
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cells and pre-hypertrophic chondrocytes, consistent with accelerated chondrogenesis 
resulting from the ACVR1 R206H mutation [Culbert et al. 2014]. 
Because the Acvr1cR206H/+ mouse model globally expresses the R206H mutant 
allele, I examined BMP signaling levels at other tissue sites. I investigated the levels of p-
Smad 1/5/8 protein at the endogenous knee joint growth plate and femoral bone marrow 
niche and detected higher p-Smad1/5/8 expression at both sites in Acvr1cR206H/+ mice 
(Figure 3.7AB), confirming that activation of the conditional Acvr1cR206H allele occurs 
widely and is active in cell types known to be responsive to BMP signaling. Enhanced 
BMP pathway signaling in the bone marrow is of particular interest since bone marrow is 
the primary adult hematopoietic tissue and source of hematopoietic stem cells from which 
mature immune cell populations are derived [Zhao et al. 2012] (Figure 1.2). 
 
3.3.3 The cellular and molecular pro-inflammatory response is amplified and 
prolonged in Acvr1cR206H/+ mice following tissue injury 
 Previous studies using patient biopsies and FOP mouse models observed that 
multiple immune cell types are present in developing HO lesions, with most attention given 
to cells of the innate immune system such as neutrophils, macrophages, and mast cells 
[Gannon et al. 1998, Gannon et al. 2001, Kaplan et al. 2005, Chakkalakal et al. 2012, 
Chakkalakal et al. 2016]. However, these studies were limited to the earliest stages of lesion 
progression and most did not quantify immune cells nor investigate cytokine and 
chemokine contributions. To examine the immunological contributions to HO 
development in FOP in detail, I investigated the cellular and molecular inflammatory 
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response to skeletal muscle injury through lesion progression to HO formation. I first 
quantified cell density of four immune cells known to reside within lesion tissue – 
neutrophils, macrophages, mast cells, and T cells [Chakkalakal et al. 2012]. 
 Neutrophils are recruited within hours after tissue injury in response to damage-
associated molecular pattern (DAMP) pathway activation [Phillipson et al. 2011] and then 
release proteases that degrade damaged tissue in preparation for clearance by macrophages 
[Tidball 2005]. Neutrophil numbers were significantly elevated in early Acvr1cR206H/+ 
lesions compared to Acvr1+/+ (Figure 3.8A), reaching peak density at day 2 and persisting 
at higher levels at day 4. 
 Macrophages rapidly respond to neutrophils, phagocytosing damaged tissue and 
debris generated by neutrophils and secreting cytokines and chemokines that recruit 
progenitor cells to facilitate wound healing [Laskin et al. 2011]. Macrophages were 
significantly increased in early- and intermediate-stage (days 2-6) Acvr1cR206H/+ lesions 
compared to Acvr1+/+ (Figure 3.8B). While numbers of macrophages in control tissue 
returned to pre-injury levels by day 6, these cells persisted in Acvr1cR206H/+ lesions. 
Mast cells contribute to diverse biological processes, including wound repair, 
fibrosis, pain pathophysiology, and allergy [Bischoff 2007, Thevenot et al. 2011, Heron et 
al. 2013, Douaiher et al. 2014], and have been previously reported in biopsy samples from 
FOP patients [Gannon et al. 2001] and in FOP mouse models [Chakkalakal et al. 2012, 
Chakkalakal et al. 2016]. Consistent with previous studies, I determined that mast cell 
density was significantly greater in Acvr1cR206H/+ lesions, and that elevated levels of mast 
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cells became evident by day 4 following injury and persisted at high levels through day 14 
and heterotopic bone formation (Figure 3.8C). 
In addition to cells of the innate immune system, T cells have also been reported in 
FOP lesions [Gannon et al. 1998, Chakkalakal et al. 2012], and a BMP4 over-expression 
mouse model that lacked mature lymphocytes formed reduced HO [Kan et al. 2009]. At 
day 3 post-injury, T cell density was more than 2-fold higher in Acvr1cR206H/+ lesions 
compared to Acvr1+/+, similarly to myeloid lineage cells, and higher numbers of T cells 
persisted through the progression to heterotopic bone (Figure 3.8D). 
A maximal inflammatory response depends on the synthesis and secretion of pro-
inflammatory cytokines and chemokines that amplify and sustain an ongoing immune 
response and act as chemoattractant molecules for progenitor cells that participate in tissue 
repair [Ishida et al. 2007, Fong et al. 2011, Halova et al. 2012, Turner et al. 2014]. To 
determine whether the elevated and prolonged immune cell response in Acvr1cR206H/+ 
lesions (Figure 3.8) is accompanied by general or specific differences in pro-inflammatory 
cytokines and chemokines, I examined expression in early-, intermediate-, and late-stage 
Acvr1cR206H/+ and Acvr1+/+ lesions. The pro-inflammatory cytokines TNFα, IL-1β, and IL-
6 were detected at higher levels in Acvr1cR206H/+ lesions compared to Acvr1+/+ throughout 
lesion progression (Figure 3.9 and 3.10). TNFα and IL-6 were robustly present and detected 
as early as day 2 post-injury in Acvr1cR206H/+ lesions (Figure 3.9AB), while IL-1β more 
slightly increased (Figure 3.10). These cytokines were detected throughout the injured 
tissues. 
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Monocyte chemoattractant protein-1 (MCP-1) is a chemokine abundantly produced 
by white adipose tissue [Fasshauer et al. 2015] that functions to recruit monocytes and 
other immune cells [Deshmane et al. 2009], and was previously proposed as a predictive 
biomarker for blast injury patients who developed HO [Evans et al. 2012]. In both 
Acvr1cR206H/+ and Acvr1+/+ lesions, MCP-1 was mainly localized to white adipose adjacent 
to skeletal muscle, with generally low detection in the lesions throughout their progression 
(Figure 3.11A). 
IL-13 is a pro-inflammatory cytokine that is expressed in many fibrosis pathologies 
[Wynn et al. 2012, Borthwick et al. 2013] and, like MCP-1, was suggested as a predictive 
biomarker for blast injury patients who developed HO [Forsberg et al. 2014]. IL-13 
expression was relatively low and equivalent in Acvr1cR206H/+ and Acvr1+/+ lesions (Figure 
3.11B). 
Activin A is a TGF-β superfamily ligand involved in inflammatory stimulation and 
regulation of several immune cell populations [Aleman-Muench et al. 2012]. Recently, 
Activin A was reported to aberrantly activate BMP pathway signaling through Acvr1R206H 
and contribute to HO progression in FOP [Hatsell et al. 2015]. I detected higher Activin A 
expression in intermediate- and late-stage Acvr1cR206H/+ lesions relative to controls (Figure 
3.12A), with Activin A expression in fibroproliferative regions as well as in ectopic 
chondrocytes (Figure 3.12B). 
These results suggest that although the inflammatory response is substantially 
upregulated in Acvr1cR206H/+ mice, the response is not a total upregulation of all 
inflammatory mediators. 
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3.3.4 Increased BMP signaling conferred by Acvr1cR206H/+ in mast cells enhances 
inflammatory activation 
The ACVR1 R206H mutation confers increased BMP pathway signaling in 
numerous cell types, including fibroblastic cells such as patient-derived SHED cells and 
mouse-derived MEFs [Culbert et al. 2014, Wang et al. 2016]. Expression of Acvr1R206H 
potentiates cell-autonomous differentiation programs of these tri-potent mesenchymal 
cells, accelerating their differentiation toward chondrogenic and osteogenic fates. 
However, despite the cell-autonomous effects of the ACVR1 R206H mutation in these 
mesenchymal cells, the mutation alone does not appear to be sufficient to promote 
spontaneous cell differentiation [Culbert et al. 2014], as is supported by the episodic nature 
of HO formation in FOP patients. Rather, an additional stimulus appears to trigger onset 
of bone formation. I considered that immune cells could play such a role and investigated 
whether increased BMP signaling conferred by Acvr1cR206H  in immune cells could 
upregulate their inflammatory activation. 
To examine the effect of enhanced BMP signaling conferred by the ACVR1 R206H 
mutation on the inflammatory potential of immune cells, I examined primary murine mast 
cells and macrophages in vitro. I collected primary mast cells by harvesting whole bone 
marrow from Acvr1cR206H/+ and Acvr1+/+ mice and culturing cells in suspension for 6 weeks 
in mast cell maturation medium. Mast cell purity was verified by flow cytometry, gating 
for c-kit receptor/CD117 and FcεRIα receptor double-positive cells [Weller et al. 2005] 
(Figure 3.13). Macrophages were collected by intraperitoneal injection of 1.5 mL aged 
4.0% thioglycolate solution into Acvr1cR206H/+ and Acvr1+/+ mice [Zhang et al. 2008]. After 
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5 days, peritoneal exudate was collected from euthanized mice and plated in macrophage 
growth medium. 
 I examined BMP pathway signaling competency in mast cells and macrophages, 
detecting expression of a broad panel of BMP/TGF-β type I and II receptor mRNAs, 
including Acvr1, the type I receptor mutated in FOP [Shore et al. 2006], in both cell types 
(Figure 3.14A). BMP pathway activity, quantified by p-Smad1/5/8 protein levels, was 
increased in both mast cells and macrophages expressing the Acvr1cR206H allele compared 
with Acvr1+/+ (Figure 3.14B, C, D) with relative levels of p-Smad1/5/8 between 
Acvr1cR206H/+ and Acvr1+/+ similar to that reported previously [Culbert et al. 2014]. 
BMP pathway activation has been previously reported to enhance the inflammatory 
state of multiple immune cell populations [Hong et al. 2009, Lee et al. 2011, Martinez et 
al. 2011, Martinez et al. 2015]. To investigate whether expression of the Acvr1cR206H allele 
in mast cells and macrophages confers enhanced inflammatory signaling, I examined pro-
inflammatory cytokine expression. Acvr1cR206H/+ mast cells exhibited significantly elevated 
mRNA expression of TNFα and IL-6 and a trend toward elevated IL-1β compared with 
Acvr1+/+ mast cells (Figure 3.15A). No significant differences in cytokine expression 
between Acvr1cR206H/+ and Acvr1+/+ macrophages were detected (Figure 3.15B). 
Degranulation is a directed response to inflammatory stimulation in granulocytes, 
including mast cells [Kulka et al. 2008], releasing numerous inflammatory mediators, 
including TNFα and other cytokines [Moon et al. 2014]. Quantification of degranulation 
showed elevated activity in Acvr1cR206H/+ mast cells compared to controls (Figure 3.15C). 
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These data reveal an elevated and prolonged pro-inflammatory response in 
Acvr1cR206H/+ tissues in response to injury, as well as in Acvr1cR206H/+ mast cells, with higher 
expression of multiple, but not all, pro-inflammatory cytokines and chemokines 
investigated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 77 
 
3.4 Discussion 
3.4.1 Acvr1R206H disrupts the normal skeletal muscle regeneration program, favoring 
heterotopic endochondral ossification 
 Skeletal muscle regeneration is a well-characterized process that faithfully restores 
tissue to its pre-injury state. Shortly after tissue injury and immune cell influx, a skeletal 
muscle-resident stem cell population known as muscle stem cells (or satellite cells) is 
activated from its quiescent state and begins the muscle regeneration process [Wang et al. 
2012]. Muscle stem cells are identified through their expression of Pax-7, and are 
indispensible for adult skeletal muscle regeneration [Sambasivan et al. 2011]. Following 
muscle stem cell activation, clonal expansion and migration to the injury site occurs, after 
which a self-renewing pool of quiescent muscle stem cells is restored, with the remaining 
daughter cells cells continuing the regeneration process assisted by myogenic regulatory 
factors (MRFs) [Schultz et al. 1985]. The pool of proliferated muscle stem cells is now 
referred to as myogenic precursor cells (MPCs) that are characterized by upregulation of 
two MRFs, Myf5 and MyoD [Cooper et al. 1999]. Expansion of MPCs is followed by their 
upregulation of MRF4 and myogenin, the later of which is associated with terminal 
differentiation of myoblasts into myocytes and fusion of these cells to new or existing 
fibers [Karalaki et al. 2009]. The final result is regenerated skeletal muscle that is 
indistinguishable from its pre-injury state [Bentzinger et al. 2013]. 
 As observed in Figures 3.3, and 3.4, the normal skeletal muscle regenerative 
program in the Acvr1cR206H/+ group is disrupted, instead replaced by the metamorphosis of 
damaged tissue with fibroproliferative cells and eventual ectopic cartilage and bone. In 
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contrast, the repair mechanism is fully functional in the Acvr1+/+ group, with the cellular 
events matching the previously established regeneration timeline (Figures 3.2, 3.3, 3.4, 3.5) 
[Bentzinger et al. 2013]. It is known that elevated BMP signaling prevents myogenic 
differentiation of satellite cells [Ono et al. 2011], suggesting a negative feedback 
mechanism that limits skeletal muscle regenerative capacity may exist in FOP. 
Additionally, MEF cells expressing Acvr1R206H were shown to be primed toward 
chondrogenic differentiation in vitro, [Culbert et al. 2014], which may suggest a similar 
mechanism in vivo that may compensate for any regenerative deficiency existing in muscle 
stem cells or their subsequent myogenic populations. Strikingly, despite the progressive 
divergence in response to injury between Acvr1cR206H/+ and Acvr1+/+ cohorts, the tissue 
morphology is equivalent up to 48 hours post-injury (Figure 3.2). This suggests that the 
early repair stages of damaged tissue turnover, mediated in part by active caspase-3 
[Chakkalakal et al. 2012], may be unaffected by the ACVR1 R206H mutation. However, 
an alternative possibility is that inflammatory gene expression changes as a consequence 
of the R206H shortly after tissue injury, but histological changes in tissue composition are 
not observable until 2-3 days post-injury. This can be addressed using the same cross-
sectional injury protocol as indicated in Figure 3.1. Injured skeletal muscle could be 
collected and digested, and immune cells could be quantified and collected using 
fluorescence-activated cell sorting (FACS). Collected immune cell populations could then 
be investigated for inflammatory gene expression by qRT-PCR or microarray, as well as 
inflammatory factor secretory potential by ELISA. 
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3.4.2 The inflammatory response following skeletal muscle injury in an Acvr1R206H 
background mimics chronic inflammation 
 An important question addressed in our experiments is how does Acvr1R206H affect 
the cellular and molecular inflammatory response to tissue injury. An inflammatory phase 
is part of the normal tissue injury response, with influx of immune cells and upregulation 
of pro-inflammatory cytokines and chemokines observed [Tidball 2005, Philippou et al. 
2012]. Neutrophils, macrophages, and mast cells all release pro-inflammatory cytokines 
that promote clearance of damaged muscle and upregulate growth factors that promote 
regenerative events. Neutrophils release nitric oxide (NO), which aids in digesting injured 
tissue for subsequent phagocytosis by macrophages [Nguyen et al. 2003]. Neutrophils, 
macrophages, mast cells, and damaged muscle fibers all release TNFα, IL-1β, and IL-6 
[Smith et al. 2008], pro-inflammatory factors that are involved in the destruction of skeletal 
muscle following injury. Many of these factors are linked in inflammatory networks that 
cyclically upregulate each other and potentiate the pro-inflammatory response [Panzer et 
al. 1993, Gallucci et al. 1998]. However, eventually the pro-inflammatory response is 
dampened and is replaced by anti-inflammatory cytokines, including IL-4, IL-10, and 
TGF-β, factors that promote tissue regeneration [Philippou et al. 2012]. 
 The key cellular event that initiates the anti-inflammatory response during tissue 
injury is the transition from classically-activated M1 macrophages, which are involved in 
pathogen and damaged tissue phagocytosis, to anti-inflammatory M2 macrophages, which 
promote tissue healing [Laskin et al. 2011, Murray et al. 2011]. M2 macrophages secrete 
known anti-inflammatory factors, including IL-4, IL-10, IL-13, and TGF-β, as well as 
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respond to these same factors [Gordon 2003, Arnold et al. 2007, Barron et al. 2011]. In 
concert with IL-4 and IL-10 activity that promotes myoblast fusion and muscle 
regeneration [Horsley et al. 2003, Arnold et al. 2007], M2 macrophages also secrete a 
consortium of growth factors, including platelet-derived growth factor (PDGF) [Murray et 
al. 2011], that facilitate tissue repair. Failing to transition to an M2 macrophage state 
impairs wound healing via a TNFα mechanism [Sindrilaru et al. 2011]. Overall, proper 
skeletal muscle regeneration depends on appropriate balance and timing of the M1 and M2 
macrophage response [Arnold et al. 2007]. 
 The density of neutrophils, macrophages, mast cells, and T cells was significantly 
increased in the Acvr1cR206H/+ cohort following injury, compared to Acvr1+/+, and 
macrophage and mast cell density remained elevated as the lesion progressed (Figure 3.8). 
These data were the first to quantify the density of multiple immune cells throughout lesion 
progression, an important finding that supports the hypothesis of an elevated immune 
response in FOP. However, there are some limitations with this experiment, as well as 
additional approaches that could further improve the dataset. Quantification of immune 
cells was performed via IHC of paraffin-embedded histological sections and manual cell 
counting. This approach is not easily conducive to multiple cell labeling, which is 
important for identifying immune cell subtypes, such as CD4 vs. CD8 T cells. Using 
cryosections to avoid paraffin auto-fluorescence image artifacts, allows for multiple cell 
marker labeling by different fluoro-tagged antibodies. For even greater immune cell 
subtype identification and quantification, injured skeletal muscle can be collected and 
digested, after which immune cells can be quantified using multi-laser flow cytometry and 
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multiple cell labeling that is required to indentify certain immune cell populations (such as 
double-positive c-Kit and FcεRIα for mast cells [Weller et al. 2005]). 
 Although neutrophil density was robustly increased in early Acvr1cR206H/+ lesions 
compared to Acvr1+/+ lesions, the first time point investigated for injured mice was two 
days post-injury. Neutrophils are known to respond rapidly to injury, with first populations 
appearing as early as one hour post-injury [Tidball 2005]. Additional experiments 
examining neutrophil density at earlier time points following injury, such as 3, 6, 12, and 
24 hours post-injury, will provide further clarification of the neutrophil response in early 
FOP lesions. 
 Mast cell density was equivalent between cohorts up to 3 days post-injury, after 
which the numbers of these cells were significantly elevated in Acvr1cR206H/+ lesions 
(Figure 3.8). This trend matches mast cell quantification of early- and intermediate-stage 
human biopsy samples [Gannon et al. 2001]; however, mast cell density was observed to 
decrease in late-stage human samples, while we found mast cells remained elevated in 
mouse samples through day 4-14 time points (Figure 3.8C). TNFα is a known mast cell 
chemoattractant factor [Halova et al. 2012], suggesting that elevated TNFα present in 
Acvr1cR206H/+ lesions may enhance mast cell recruitment to the site of injury. 
 Given the role of BMP signaling in hematopoietic development and immune cell 
activation, I hypothesized that the ACVR1 R206H mutation amplifies the inflammatory 
response to tissue injury, establishing an appropriate microenvironment for the subsequent 
fibroliferative, chondrogenic, and osteogenic stages that result in terminal HO. The robust 
increase in TNFα, IL-1β, and IL-6 levels in vivo and in vitro in an Acvr1cR206H/+ background 
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suggests a setting that mimics chronic inflammation, maintaining a microenvironment 
conducive to continued tissue destruction at the expense of skeletal muscle regeneration. 
These cytokines are involved in the normal tissue injury response, which is replicated in 
our Acvr1+/+ cohort (Figures 3.10 and 3.11); however, they are amplified in the 
Acvr1cR206H/+ cohort and persist for much longer in the injury lesion. IL-1β inhibits satellite 
cell differentiation, IL-6 may precede myofiber rupture, and TNFα induced muscle wasting 
and prevented muscle regeneration in a chronic pulmonary inflammation mouse model 
[Allen et al. 1989, Tomiya et al. 2004, Langen et al. 2006]. These same cytokines also 
enhance proliferation of recruited fibroblasts [Mast et al. 1996] and macrophage secretion 
of matrix metalloproteinase (MMP) enzymes [Murray et al. 2011] that contribute to HO 
formation [Rodenberg et al. 2011, Davis et al. 2016]. TNFα has been shown to promote 
osteogenic differentiation of human mesenchymal stem cells via the NF-κB [Hess et al. 
2009]. Furthermore, fracture healing was significantly impaired in separate TNF receptor 
and IL-6 knock-out mice, demonstrating major roles for these cytokines in the bone 
formation process [Gerstenfeld et al. 2003, Yang et al. 2007]. Our data and supporting 
references suggest that prolonged expression of pro-inflammatory cytokines may actively 
suppress muscle repair and regeneration. 
I also identified an elevated pro-inflammatory response in Acvr1cR206H/+ mast cells 
(Figure 3.15), as mRNA expression of TNFα and IL-6 are significantly upregulated, with 
a trend toward increased IL-1β expression. Although mast cell density is significantly 
increased in Acvr1cR206H/+ lesions (Figure 3.8C), the massive increase in pro-inflammatory 
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cytokine levels observed in vivo is likely caused by multiple cell types secreting these 
factors. 
I examined Activin A expression in vivo and demonstrated increased levels in 
intermediate- and late-stage Acvr1cR206H/+ lesions (Figure 3.12A). Presence of Activin A in 
Acvr1cR206H/+ lesions, particularly within fibroproliferative cells and chondrocytes (Figure 
3.12B) is notable given the recent finding that Activin A can induce HO formation through 
a gain-of-function sensitivity conferred by the ACVR1 R206H mutation [Hatsell et al. 
2015, Hino et al. 2015]. Activin A skews macrophage polarization toward pro-
inflammatory M1 populations [Sierra-Filardi et al. 2011] and recruits mast cell progenitors 
to sites of inflammation [Funaba 2003], suggesting it may have broader pro-inflammatory 
functions in FOP beyond the specific Acvr1R206H receptor sensitivity.  
Although the pro-inflammatory response induced by Acvr1cR206H is comprehensive 
and robust, not all inflammatory factors are upregulated. MCP-1 and IL-13 expression was 
relatively mild and equivalent in Acvr1cR206H/+ and Acvr1+/+ lesions (Figure 3.11). IL-13 is 
expressed in many fibrosis pathologies [Kaviratne et al. 2004, Wynn 2008, Wynn et al. 
2012], suggesting that although there is a substantial fibroproliferative response in FOP, 
the disease should not be classified as fibrosis. 
Overall, a plentiful body of literature suggests that a prolonged pro-inflammatory 
response following tissue injury suppresses proper regeneration. In context with our results 
showing an amplified and prolonged inflammatory response in Acvr1cR206H/+ mice post-
injury, this strongly suggests that the ACVR1 R206H mutation induces a chronic 
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inflammatory state following injury that establishes a permissive microenvironment for the 
subsequent heterotopic endochondral ossification events. 
 
 
 
Figure 3.1: Cross-sectional injury study experimental design 
Acvr1cR206H/+ mice were placed on doxycycline chow (625 mg / kg) for five days prior to injury to induce 
expression of the conditional Acvr1cR206H allele. Hamstring muscles of Acvr1cR206H/+ and Acvr1+/+ mice were 
injected with cardiotoxin (50 μL of 20 μM concentration) and samples were collected at day 0 (uninjected 
controls); and days 1, 2, 3, 4, 5, 6, 7, 10 and 14 post-injury. n = 4 for each genotype, per day. 
 
Figure panel from Convente MR, Chakkalakal SA, Yang E, Caron RJ, Zhang D, Kambayashi T, Kaplan FS, 
Shore EM. (submitted). “Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an 
Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva” 
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Figure 3.2: The early response to injury in Acvr1cR206H/+ and Acvr1+/+ mice is indistinguishable 
Skeletal muscle tissue sections from Acvr1cR206H/+ and Acvr1+/+ mice from indicated days following 
cardiotoxin injury were detected for cartilage (Alcian Blue), bone (Orange G), cell nuclei/immune cells 
(Haematoxylin), and skeletal muscle (Eosin). (A) Skeletal muscle histology is similar in mutant and control 
mice before injury (day 0). (B, C) Skeletal muscle degradation and increasingly abundant immune cells are 
present by days 1-2 in both mutant and control mice. Scale bar = 100 μm for all images. Dotted lines indicate 
tissue areas as noted. n = 4 for each genotype, per day. Representative images are shown. Abbreviations: M 
= skeletal muscle, I = immune infiltration 
 
Figure panel modified from Convente MR, Chakkalakal SA, Yang E, Caron RJ, Zhang D, Kambayashi T, 
Kaplan FS, Shore EM. (submitted). “Depletion of Mast Cells and Macrophages Impairs Heterotopic 
Ossification in an Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva” 
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Figure 3.3: Extensive fibroproliferation and glycosaminoglycan accumulation in Acvr1cR206H/+ 
lesions 
Skeletal muscle tissue sections from Acvr1cR206H/+ and Acvr1+/+ mice from indicated days following 
cardiotoxin injury were detected for cartilage (Alcian Blue), bone (Orange G), cell nuclei/immune cells 
(Haematoxylin), and skeletal muscle (Eosin). (A) At day 3, immune cells increased further, but to a greater 
extent in Acvr1cR206H/+ tissue. (B, C, D) In control tissue, muscle repair progresses through the 
fibroproliferative stage and clearance of immune cells (days 4-6), however GAG proteins are detected (Alcian 
Blue) in Acvr1cR206H/+ tissue. Dotted lines indicate tissue areas as noted. n = 4 for each genotype, per day. 
Representative images are shown. Abbreviations: FP = fibroproliferation 
 
Figure panel modified from Convente MR, Chakkalakal SA, Yang E, Caron RJ, Zhang D, Kambayashi T, 
Kaplan FS, Shore EM. (submitted). “Depletion of Mast Cells and Macrophages Impairs Heterotopic 
Ossification in an Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva” JBMR. 
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Figure 3.4: Heterotopic endochondral ossification in Acvr1cR206H/+ lesions 
Skeletal muscle tissue sections from Acvr1cR206H/+ and Acvr1+/+ mice from indicated days following 
cardiotoxin injury were detected for cartilage (Alcian Blue), bone (Orange G), cell nuclei/immune cells 
(Haematoxylin), and skeletal muscle (Eosin). (A, B, C) In control tissue, skeletal muscle repair continues and 
is completed over days 7-14. (A, B) In Acvr1cR206H/+ lesions, endochondral ossification proceeds with 
maturation to hypertrophic chondrocytes and mineralized bone. (C) Ectopic bone with adjacent regions of 
mature cartilage and remaining fibroproliferation at day 14 is shown. n = 4 for each genotype, per day. 
Representative images are shown. Dotted lines indicate tissue areas as noted. Abbreviations: M = skeletal 
muscle, FP = fibroproliferation, C = chondrocytes, B = bone 
 
Figure panel modified from Convente MR, Chakkalakal SA, Yang E, Caron RJ, Zhang D, Kambayashi T, 
Kaplan FS, Shore EM. (submitted). “Depletion of Mast Cells and Macrophages Impairs Heterotopic 
Ossification in an Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva” 
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Figure 3.5: Presence of myocentric nuclei indicates ongoing muscle regeneration in Acvr1+/+ 
lesions 
Histological representative Acvr1+/+ skeletal muscle section at 200X magnification is shown, with dotted 
rectangle indicating further magnification at 400X. Myocentric nuclei, indicating ongoing muscle 
regeneration, is shown (white arrowhead). Note presence of uninjured tissue (freehand dotted region) and 
normal peripheral myonucleus location (black arrow). Scale bar = 100 μm for 200X, 50 μm for 400X 
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Figure 3.6: BMP signaling is upregulated in Acvr1cR206H/+ post-traumatic lesions 
Sections from early- (day 2), intermediate- (day 6), and late-stage (day 14) Acvr1cR206H/+ and Acvr1+/+ lesions 
were immunostained for expression of p-Smad 1/5/8 protein. No haematoxylin counterstain was performed 
in order to enhance contrast of nuclear p-Smad 1/5/8 stain. n = 3 for each genotype, per day. Representative 
images are shown  Scale bar = 100 μm for all images 
 
Figure panel from Convente MR, Chakkalakal SA, Yang E, Caron RJ, Zhang D, Kambayashi T, Kaplan FS, 
Shore EM. (submitted). “Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an 
Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva” 
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Figure 3.7: BMP signaling is upregulated in the Acvr1cR206H/+ endogenous knee joint growth 
plate and femoral bone marrow niche 
Sections from early- (day 2), intermediate- (day 6), and late-stage (day 14) Acvr1cR206H/+ and Acvr1+/+ (A) 
endogenous knee joint growth plates and (B) femoral bone marrow niches are shown. No haematoxylin 
counterstain was performed in order to enhance contrast of nuclear p-Smad 1/5/8 stain. n = 3 for each 
genotype, per day.  Representative images are shown. Scale bar = 100 μm for all images 
 
Figure panel from Convente MR, Chakkalakal SA, Yang E, Caron RJ, Zhang D, Kambayashi T, Kaplan FS, 
Shore EM. (submitted). “Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an 
Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva” 
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Figure 3.8: Immune cell density is elevated and prolonged in Acvr1cR206H/+ lesions. 
Specific immune cell populations were detected and quantified in injured Acvr1cR206H/+ and Acvr1+/+ skeletal 
muscle over time; early- (day 2), intermediate- (day 6), and late- (day 14) stages after injury are shown. (A) 
Neutrophils were detected by myeloperoxidase IHC. (B) Macrophages were detected with F4/80 IHC. (C) 
Mast cells were detected by C.E.M. stain kit, and indicated by black arrows. (D) T cells were detected with 
CD3 IHC. Cells were quantified from three fields of view per independent sample; n = 3 for neutrophils, 
macrophages, T cells; n = 4 for mast cells. Representative images are shown. Scale bar = 50 μm. Data shown 
are mean values ± SEM; two-way ANOVA with Sidak’s multiple comparisons test comparing Acvr1cR206H/+ 
versus Acvr1+/+ per day was performed; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 
 
Figure panel from Convente MR, Chakkalakal SA, Yang E, Caron RJ, Zhang D, Kambayashi T, Kaplan FS, 
Shore EM. (submitted). “Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an 
Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva” 
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Figure 3.9: TNFα and IL-6 expression is robustly elevated and prolonged in Acvr1cR206H/+ 
lesions 
Specific pro-inflammatory cytokines were detected by immunostaining of injured tissues from early- (day 
2), intermediate- (day 6), and late- (day 14) stage Acvr1cR206H/+ and Acvr1+/+ lesions: (A) TNFα, (B) IL-6.  
n = 3 for each genotype, per day. Representative images are shown. Scale bar = 100 μm for all images. 
 
Figure panel modified from Convente MR, Chakkalakal SA, Yang E, Caron RJ, Zhang D, Kambayashi T, 
Kaplan FS, Shore EM. (submitted). “Depletion of Mast Cells and Macrophages Impairs Heterotopic 
Ossification in an Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva” 
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Figure 3.10: IL-1β expression is moderately elevated and prolonged in Acvr1cR206H/+ lesions 
IL-1β was detected by immunostaining of injured tissues from early- (day 2), intermediate- (day 6), and late- 
(day 14) stage Acvr1cR206H/+ and Acvr1+/+ lesions. n = 3 for each genotype, per day. Representative images 
are shown. Scale bar = 100 μm for all images. 
 
Figure panel modified from Convente MR, Chakkalakal SA, Yang E, Caron RJ, Zhang D, Kambayashi T, 
Kaplan FS, Shore EM. (submitted). “Depletion of Mast Cells and Macrophages Impairs Heterotopic 
Ossification in an Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva” 
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Figure 3.11: Variable MCP-1 and IL-13 expression in Acvr1cR206H/+ and Acvr1+/+ lesions 
Sections from early- (day 2), intermediate- (day 6), and late-stage (day 14) Acvr1cR206H/+ and Acvr1+/+ lesions 
were immunostained for expression of: (A) MCP-1, (B) IL-13. n = 3 for each genotype, per day. 
Representative images are shown. Scale bar = 100 μm for all images 
 
Figure panel modified from Convente MR, Chakkalakal SA, Yang E, Caron RJ, Zhang D, Kambayashi T, 
Kaplan FS, Shore EM. (submitted). “Depletion of Mast Cells and Macrophages Impairs Heterotopic 
Ossification in an Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva” 
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Figure 3.12: Elevated Activin A protein in intermediate- and late-stage Acvr1cR206H/+ lesions 
Sections from early- (day 2), intermediate- (day 6), and late-stage (day 14) Acvr1cR206H/+ and Acvr1+/+ lesions 
were immunostained for expression of: (A) Activin A. (B) Higher magnification insets demonstrating 
fibroblast and chondrocyte Activin A expression in Acvr1cR206H/+ lesions are shown, indicated by dotted 
rectangles in (A). n = 3 for each genotype, per day. Representative images are shown. Scale bar = 100 μm 
for all images in (A); scale bar = 50 μm for all images in (B). 
 
Figure panel modified from Convente MR, Chakkalakal SA, Yang E, Caron RJ, Zhang D, Kambayashi T, 
Kaplan FS, Shore EM. (submitted). “Depletion of Mast Cells and Macrophages Impairs Heterotopic 
Ossification in an Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva” 
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Figure 3.13: Confirmation of primary mast cell purity by flow cytometry 
Whole bone marrow was collected from Acvr1cR206H/+ and Acvr1+/+ mice and grown in suspension in mast 
cell maturation medium for 6 weeks. Mast cells were stained with fluoro-tagged primary antibodies (or “no 
antibody control”) against c-Kit and FcεRIα, cell surface receptors that in combination identify mast cells. 
Mast cells were gated as double-positive cells (upper right quadrant). Numbers listed are cell percentages per 
gating. 
 
Figure panel from Convente MR, Chakkalakal SA, Yang E, Caron RJ, Zhang D, Kambayashi T, Kaplan FS, 
Shore EM. (submitted). “Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an 
Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva” 
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Figure 3.14: BMP signaling is increased in Acvr1cR206H/+ mast cells and macrophages 
(A) Quantification of BMP/TGF-β type I and II receptor mRNAs in Acvr1+/+ mast cells and macrophages. 
Note expression of Acvr1, the receptor mutated in FOP (rectangle). (B) Mast cells treated with BMP4 ligand 
show dose responsive increases in p-Smad1/5/8 protein levels with enhanced pSmad1/5/8 detected in mutant 
cells. Quantified p-Smad1/5/8 protein relative to untreated control cells is shown. Quantification of (C) mast 
cell and (D) macrophage p-Smad 1/5/8 levels. n = 4; data shown are mean values ± SEM in A. 
 
Figure panel modified from Convente MR, Chakkalakal SA, Yang E, Caron RJ, Zhang D, Kambayashi T, 
Kaplan FS, Shore EM. (submitted). “Depletion of Mast Cells and Macrophages Impairs Heterotopic 
Ossification in an Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva” 
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Figure 3.15: Enhanced pro-inflammatory activation in Acvr1cR206H/+ mast cells 
mRNA expression of specific pro-inflammatory cytokines in (A) mast cells and (B) macrophages was 
detected by qRT-PCR following mast cell treatment with 100 μM Substance P or macrophages treatment 
with 1 ng/mL lipopolysaccharides, then 15 ng/mL BMP4 for 1 hour. Data were normalized to Gapdh and are 
shown as mean values ± SEM; Student’s t-test compared expression in Acvr1cR206H/+ vs. Acvr1+/+; * p < 0.05; 
ns = not significant. n = 6 per gene, per genotype. (C) Mast cells were treated with 100 μM Substance P, plus 
15 ng/mL BMP4, for 1 hour. Cells were spun down and conditioned medium was collected and added to 
tryptase substrate for 2 hours. Free pNA, indicating degranulation activity, was quantified using a microplate 
reader at a wavelength of 405 nm. n = 5; data shown are mean values ± SEM; Student’s t-test comparing 
Acvr1cR206H/+ versus Acvr1+/+ was performed; **** p < 0.0001 
 
Figure panel modified from Convente MR, Chakkalakal SA, Yang E, Caron RJ, Zhang D, Kambayashi T, 
Kaplan FS, Shore EM. (submitted). “Depletion of Mast Cells and Macrophages Impairs Heterotopic 
Ossification in an Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva” 
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Chapter Four 
 
Modulation of the immune system to control heterotopic ossification 
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4.1 Summary 
 Current treatments for FOP are mostly ineffective at preventing disease progression 
to HO. Pre-clinical therapeutics targeting the endochondral ossification stage of FOP have 
shown promise in mouse models and are under clinical trial investigation; however, there 
still is an unmet need of effective therapies. The immune system is an appealing therapeutic 
target for FOP, as inflammation is the earliest stage of disease progression, therefore 
treating FOP at its earliest phase may provide optimal disease management. A precise 
understanding of the cellular and molecular inflammatory response, in context with the 
ACVR1 R206H mutation, is key to developing novel and effective methods of inhibiting 
HO formation. 
 I investigated whether expression of Acvr1cR206H restricted to immune cell lineages 
is sufficient to produce HO in Acvr1+/+ mice. I performed two experiments to address this 
question – a bone marrow transplant (BMT) of Acvr1cR206H/+ whole bone marrow into 
Acvr1+/+ recipients, and Cre-recombinase-mediated expression of the Acvr1cR206H allele in 
myeloid lineage cells via use of the Lysozyme M (LysM-Cre) promoter. I additionally 
investigated whether blocking the cellular and molecular inflammatory response could 
impair HO formation in Acvr1cR206H/+ mice; this was examined via two approaches: 
administration of two neutralizing agents against pro-inflammatory cytokines, and 
development of immunodeficient Acvr1cR206H/+ mice. Our results suggest that while 
immune cells expressing Acvr1cR206H are alone insufficient to induce HO formation, 
depleting mast cells and macrophages dramatically impaired HO development in 
Acvr1cR206H/+ mice, highlighting their necessity for HO formation in vivo. 
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4.2 Introduction 
 Modulation of the immune system to control disease progression in FOP has been 
an approach of significant interest. The most noteworthy attempt to treat FOP in this 
manner involved a single patient who, in addition to FOP, presented with aplastic anemia 
[Kaplan et al. 2007]. This patient underwent two allogeneic HLA-matched bone marrow 
transplants (BMT) from his sister, who did not have FOP, as treatment for aplastic anemia. 
Complete engraftment and reconstitution of donor bone marrow was confirmed by genetic 
analysis of short tandem repeats. Following successful BMT, the patient developed acute 
and chronic graft-versus-host disease and was treated with prednisone, cyclosporine, and 
methotrexate for fourteen years. During this time period, FOP disease progression was 
halted, with no advancement of HO observed. After discontinuation of the 
immunosuppressive regimen, the patient’s FOP symptoms rapidly rebounded, with new 
HO developing in previously unaffected areas [Kaplan et al. 2007]. This case report 
suggested two significant findings: a wild-type immune system in an ACVR1 R206H 
background is insufficient to prevent disease progression, and suppressing the immune 
system may be an effective method to halt FOP disease progression. 
 To further enhance our understanding of the cellular inflammatory contribution to 
HO, I investigated the converse question: are immune cells expressing the R206H mutation 
sufficient to develop HO in an Acvr1+/+ genetic background? Although previous studies 
have shown that cells of hematopoietic origin do not directly contribute to the 
fibroproliferative, chondrogenic, and osteogenic stages of heterotopic endochondral 
ossification [Kaplan et al. 2007, Kan et al. 2009], I hypothesized that the upregulated 
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inflammatory activation present in Acvr1cR206H/+ mast cells (Figure 3.15A, C) and possibly 
other immune cell lineages may suggest that hematopoietic lineages alone are sufficient to 
induce HO formation in FOP. Notably, cells that do not express Acvr1R206H are capable of 
contributing to the chondrogenic and osteogenic stages of lesion formation [Chakkalakal 
et al. 2012], suggesting that expression of Acvr1R206H restricted to hematopoietic cells may 
be able to induce an HO response with the participation of Acvr1+/+ fibro-progenitor cells. 
To investigate the above hypothesis, I performed two experiments: a BMT of Acvr1cR206H/+ 
whole bone marrow into Acvr1+/+ recipient mice, and a genetic approach of myeloid-
specific Acvr1cR206H expression via generation of LysM-Cre;Acvr1cR206H/+ mice. For both 
experiments, I challenged skeletal muscle with cardiotoxin injury and quantified HO 
development. These experiments would improve our understanding of the cell-autonomous 
effects of the ACVR1 R206H mutation in immune cells toward directing chondro-
/osteogenesis. 
 The observation that global immunosuppresive medicines can suppress HO 
formation suggests the immune system as an appealing therapeutic target [Kaplan et al. 
2007]. HO development in a ligand-independent, constitutively-active Acvr1Q207D mouse 
model of HO required an inflammatory millieu, and dexamethasone treatment impaired 
HO development [Yu et al. 2008], providing a proof-of-principle experiment that 
inflammatory inhibition may be an effective treatment approach in FOP. Despite the 
promise of global immunosuppressive therapies, these compounds must be used with 
caution and are generally not recommended for systemic use in pediatric FOP patients due 
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to adverse events, such as increased propensity for infection, myopathies, and other 
complications [Poetker et al. 2010]. 
 Targeted immunosuppression of specific immune cells and inflammatory mediators 
may impair HO formation while also maintaining substantial immune function. I designed 
two immunosuppressive experiments based on results detailed in Chapter 3, which 
demonstrated robust upregulation of TNFα and IL-6 in Acvr1cR206H/+ lesions and mast cells 
(Figures 3.9 and 3.15A) and significantly increased macrophage and mast cell density in 
Acvr1cR206H/+ lesions (Figure 3.8B, C). I hypothesized that systemic neutralization of TNFα 
and IL-6 would inhibit HO formation in Acvr1cR206H/+ mice. I also hypothesized that 
depletion of mast cells and macrophages in Acvr1cR206H/+ mice would inhibit HO formation. 
These in vivo experiments provide key insight into the direct immune cellular and 
molecular contributions to HO formation. 
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4.3 Results 
4.3.1 Reconstitution of an Acvr1cR206H/+ hematopoietic system in Acvr1+/+ recipient 
mice is insufficient to induce HO formation 
 An unresolved research question is whether expression of the ACVR1 R206H 
mutation restricted to hematopoietic lineages is sufficient to induce HO formation in an 
Acvr1+/+ genetic background. I first investigated this question by conducting a BMT of 
donor Acvr1cR206H/+ whole bone marrow into Acvr1+/+ recipient mice. For this experiment, 
I used tamoxifen-inducible ERT2-Cre;Acvr1cR206H/+ mice as donors. Because of unknown 
effects of Acvr1cR206H/+ increased BMP signaling on hematopoietic survival, engraftment 
potential, and reconstitution, I used two groups of donor ERT2-Cre;Acvr1cR206H/+ mice: a 
cohort in which I induced Acvr1cR206H allele expression by tamoxifen administration in 
donor cells prior to transplant, and a cohort in which I induced Acvr1cR206H in recipient 
mice post-transplant after engraftment and reconstitution. I also included two control 
Acvr1+/+ donor cell groups; cells that received tamoxifen injections prior to BMT, and cells 
that received tamoxifen injections post-transplant in recipients. Tamoxifen is not expected 
to affect Acvr1+/+ allele expression, nor are these control mice expected to develop HO 
(Table 4.1). To detect donor marrow engraftment and reconstitution in recipients, I took 
advantage of murine CD45 receptor biology in which two CD45 isoforms – CD45.1 and 
CD45.2 – can be used to lineage trace the sources of bone marrow cells [Spangrude et al. 
1988]. All donor ERT2-Cre;Acvr1cR206H/+ mice express the CD45.2 isoform, and all 
recipient B6.SJL mice express CD45.1 [Waterstrat et al. 2010], allowing for flow 
cytometry detection of donor cell engraftment and reconstitution efficiency post-BMT. 
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Expression of the Acvr1cR206H allele in donor cells prior to BMT was confirmed by PCR 
(Figure 4.1). 
 A catalog of all recipient mice, and source/genotype of donor bone marrow, can be 
found in Table 4.1. Six week old B6.SJL recipient mice were irradiated with 1000 rads and 
then injected with 5 X 106 whole bone marrow cells from donor mice via tail vein injection 
(tamoxifen-treated or non-tamoxifen-treated; see Table 4.1). Engraftment and 
reconstitution occurred over 8 weeks. Following this 8 week period, appropriate cohorts 
were adminsistered tamoxifen by intraperitoneal injection for four consecutive days. All 
recipient mice were injured by cardiotoxin injection (100 μL of 10 μM) into right hamstring 
muscles; contralateral hamstring muscles were injected with PBS. All mice were sacrificed 
at 21 days post-injury, after which mice were assessed for HO formation by X-ray and 
μCT. At sacrifice, bone marrow was collected to confirm donor CD45.1 cell reconstitution, 
as well as to confirm Acvr1cR206H allele recombination. 
 Data analysis suggested that the BMT experiment produced inconclusive results. 
Mouse #9 received Acvr1cR206H/+ donor bone marrow, but did not receive tamoxifen 
injections as a control against possible leaky Acvr1cR206H expression. Detection of the 
recombined Acvr1cR206H allele occurred only in three of seven recipients that received 
Acvr1cR206H/+ donor bone marrow and tamoxifen injections: mice #11, #12, and #305. 
Detection of the recombined Acvr1cR206H allele was also expected in mice numbers 6, 7, 8, 
and 10, however these amplicons were not detected (Figure 4.2). Of all Acvr1+/+ recipient 
mice that received Acvr1cR206H/+ donor bone marrow, only one developed any HO, and this 
amount was very small (Figure 4.3). Engraftment and reconstitution of donor CD45.1+ 
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bone marrow was variable across individual recipients, suggesting that irradiation may 
have been incomplete in some recipients; however, mature immune cells were detected in 
all mice analyzed (Table 4.2 and Figure 4.4). Importantly, as a positive control, I included 
an Acvr1cR206H/+ recipient mouse that received Acvr1cR206H/+ donor bone marrow (mouse 
#305). Although this mouse expressed Acvr1cR206H/+ globally, and mature mutant immune 
cells were detected (Table 4.2 and Figure 4.4), no HO was observed (Figure 4.3). These 
results suggest that Acvr1cR206H/+ hematopoietic cells are unable to induce HO formation in 
an Acvr1+/+ background, however possible experimental design limitations and technical 
issues may prevent conclusive data interpretation (see Chapter 4.4 Discussion). 
 
4.3.2 Myeloid-restricted Acvr1cR206H expression is insufficient to induce HO formation 
 Based on potential experimental design limitations and technical issues with our 
BMT experiment, I next used a genetic approach to address the same question: whether 
expression of the ACVR1 R206H mutation restricted to hematopoietic lineages is sufficient 
to induce HO formation in an Acvr1+/+ genetic background. 
Lysozyme M (encoded by the Lyz2 gene, also referred to as LysM) is a glycoside 
hydrolase enzyme that is expressed in almost all myelomonocytic lineages, including 
mature neutrophil granulocytes and macrophages [Cross et al. 1988, Faust et al. 2000]. I 
generated LysM-Cre;Acvr1cR206H/+ mice (Figure 2.5) in which recombination and 
expression of the Acvr1[R206H]FlEx allele occurs exclusively within myelomonocytic 
lineages. I injected cardiotoxin into the right hamstring muscles into LysM-
Cre;Acvr1cR206H/+ mice and grouped mice into two cohorts: 2 weeks post-injury and 4 
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weeks post-injury. Two global knock-in Acvr1cR206H/+ mice were injected using same 
protocol and served as positive controls. 
No HO was detected in any LysM-Cre;Acvr1cR206H/+ mice, either at 2 weeks or 4 
weeks post-injury. HO was detected in both globally-expressing Acvr1cR206H/+ positive-
control mice at 2 weeks post-injury (Figure 4.5 A, B). 
 
4.3.3 Systemic neutralization of TNFα and IL-6 reduces inflammation but is 
insufficient to prevent HO formation in Acvr1cR206H/+ mice 
 Immunosuppressive corticosteroid therapy has proven effective at halting disease 
progression in a single FOP patient and in a constitutively-active Acvr1Q207D FOP mouse 
model [Kaplan et al. 2007, Yu et al. 2008]. However, the former data represents only a 
single adult human patient and has not been extensively evaluated in other FOP patients. 
Global immunosuppresive regimens are risky for use in pediatric FOP patients due to 
infectious disease vulnerability, and long-term use of these therapeutics may increase the 
prevalence of adverse events, such as increased propensity for infection, myopathies, and 
other complications [Poetker et al. 2010]. 
Immunomodulary biologics are a class of extremely effective therapeutics used in 
the clinic for treatment of inflammatory disorders [Sathish et al. 2013]. Biologics are most 
commonly recombinant DNA-based monoclonal antibodies or decoy fusion receptors that 
bind and sequester soluble cytokines and chemokines. Due to their target specificity, 
biologics are remarkably effective and have limited off-target effects. 
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 Based on results from Chapter Three showing that Acvr1cR206H/+ mice express 
significantly higher and persistent levels TNFα and IL-6 following skeletal muscle injury 
(Figure 3.9A, B), I considered the use of biologics as an approach to reduce cytokine levels 
in Acvr1cR206H/+ mice. I hypothesized that systemic neutralization of TNFα and IL-6 would 
inhibit HO formation. 
 Acvr1cR206H/+ mice were injected with cardiotoxin (50 μL of 20 μM concentration) 
into the gastrocnemius muscle of both hind limbs, with mouse sacrifice and sample 
collection at 2 weeks post-injury. I neutralized TNF-α and IL-6 using specific neutralizing 
agents. I neutralized TNF-α via etanercept, a soluble fusion protein of the TNF-α receptor 
and the IgG1 constant region that binds TNF-α and confers long-term neutralization of 
TNF-α [Peppel et al. 1991, Kolls et al. 1994]. I neutralized IL-6 using a custom produced 
mouse-anti-IL-6-antibody. Our experimental design included four Acvr1cR206H/+ cohorts: 
PBS vehicle control, etanercept (4.0 mg/kg, 3X week), mouse-anti-IL-6 (150 mg per 
mouse, 3X week), or etanercept plus mouse-anti-IL-6-antibody (previous concentrations). 
Neutralizing agents were delivered via retro-orbital delivery into Acvr1cR206H/+ mice. To 
confirm efficacy of cytokine neutralization, I quantified serum levels of C-reactive protein 
(CRP), a pan-inflammatory marker [Pepys et al. 2003], from serum collected throughout 
the experiment. 
 Our results show that both etanercept and mouse-anti-IL-6 were effective at 
reducing systemic inflammation in Acvr1cR206H/+ mice post injury, with the greatest down-
regulation of serum CRP at the intermediate fibroproliferative cell stage (Figure 4.6A). In 
contrast, vehicle-treated Acvr1cR206H/+ mice exhibited a 40% increase in serum CRP levels 
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over baseline measurements. By day 14, CRP levels were equivalent among all groups. 
Intramuscular mineral content and HO volume were significantly reduced in the etanercept 
cohort, compared to the anti-IL-6 cohort (Figure 4.6B, C). HO volume was also 
significantly reduced in the combined etanercept plus anti-IL-6 cohort, compared to the 
anti-IL-6 cohort (Figure 4.6C). Despite the reduction in ectopic bone parameters in the 
etanercept cohorts, there was considerable variability in the vehicle positive control mice 
that prevented conclusive interpretation of results; however, I concluded that mouse-anti-
IL-6 is ineffective at preventing HO formation. 
Due to the promising etanercept results, I conducted a second experiment of 
etanercept experimental groups. The second experiment utilized the following dosing 
regimens: etanercept (4 mg/kg, 2X week; 2 mg/kg, 2X week; 4 mg/kg, 3X week). I 
quantified HO volume at 2 weeks post-injury and in contrast to the first experiment, HO 
volume was not reduced in any etanercept-treated Acvr1cR206H/+ cohort (Figure 4.6D). 
Based on the results of both neutralizing agent experiments, I concluded that systemic 
neutralization of TNF-α and IL-6, while efficiently reducing systemic cytokine levels, is 
insufficient to inhibit HO formation in Acvr1cR206H/+ mice. 
 
4.3.4 Depletion of mast cells and macrophages significantly impairs injury-induced 
heterotopic ossification development in Acvr1cR206H/+ mice 
Two immune cell populations previously implicated in HO development are mast 
cells and macrophages [Gannon et al. 2001, Kan et al. 2009, Kan et al. 2011, Salisbury et 
al. 2011]. Given the increased cell density and prolonged presence of mast cells and 
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macrophages in FOP lesions (Figure 3.8B, C), as well as their relevance in multiple HO 
disorders [Convente et al. 2015], I investigated the contribution of mast cells and 
macrophages to injury-induced HO by generating immunodeficient Acvr1cR206H/+ mice. 
The homozygous mutant White Sash c-KitW-sh/W-sh mouse fully lacks mast cells due 
to a 3 mb inversion in the upstream regulatory region of the c-Kit transcriptional start site 
[Nagle et al. 1995, Grimbaldeston et al. 2005]. The heterozygous mutant c-KitW-sh/+ mouse 
exhibits partial mast cell deficiency [Grimbaldeston et al. 2005]. Importantly, the c-KitW-
sh/W-sh mouse exhibits no other immune cell deficiencies [Grimbaldeston et al. 2005]. To 
deplete mast cells in the context of global expression of the R206H mutation, I generated 
Acvr1cR206H/+;c-KitW-sh/W-sh and Acvr1cR206H/+;c-KitW-sh/+ mice. To deplete macrophages, 
Acvr1cR206H/+ mice were injected with clodronate liposomes (Clo), which selectively induce 
apoptosis in mature macrophages [van Rooijen et al. 1984, Van Rooijen 1989] (Figure 4.7). 
This pharmacological approach allowed generation of combined mast cell- and 
macrophage-deficient mice by injecting Acvr1cR206H/+;c-KitW-sh/W-sh mice with clodronate 
liposomes. Macrophage depletion was confirmed via flow cytometry (Figure 4.8) and mast 
cell depletion was confirmed via histological detection (Figure 4.9). 
Compared to Acvr1cR206H/+ mice, heterozygous Acvr1cR206H/+;c-KitW-sh/+ mice 
consistently had a moderate, but statistically insignificant, decrease in HO volume (Figure 
4.10A, B). However, fully mast cell-deficient Acvr1cR206H/+;c-KitW-sh/W-sh mice exhibited a 
~50% decrease in HO volume relative to Acvr1cR206H/+ mice. Macrophage-deficient 
Acvr1cR206H/+;Clo-treated mice had a similar ~50% decrease in HO. Combined deficiency 
of mast cells and macrophages (Acvr1cR206H/+;c-KitW-sh/W-sh;Clo) resulted in a further 
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reduction in HO, with a ~75% decrease relative to Acvr1cR206H/+ mice (Figure 4.10A, B). 
These results show that both mast cells and macrophages contribute to HO initiation and 
development. 
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4.4 Discussion 
4.4.1 Acvr1R206H cells of hematopoietic origin are insufficient to induce heterotopic 
ossification 
 The origin of the progenitor cells that differentiate to form heterotopic 
endochondral ossification in FOP is a major ongoing question of investigation. In vitro 
studies using fibroblastic mesenchymal cells from both human sources and mouse models 
have demonstrated chondro-/osteogenic potential that is further accelerated with 
expression of Acvr1R206H, providing initial clues about the properties of cells directly 
contributing to HO [Billings et al. 2008, Culbert et al. 2014]. Additional in vivo studies 
have further expanded information about the identity of cells that directly participate in HO 
formation, including cells expressing Tie-2, PDGFRα, Mx1, and Scx [Lounev et al. 2009, 
Wosczyna et al. 2012, Agarwal et al. 2016, Dey et al. 2016]. Although previous work has 
shown that hematopoietic cells do not participate directly to form ectopic bone [Kaplan et 
al. 2007], an unresolved question was whether Acvr1R206H hematopoietic cells could induce 
HO formation in an otherwise Acvr1+/+ background via recruitment of chondro-/osteo-
progenitor cells to the site of tissue injury.  
I showed in Chapter Three that Acvr1cR206H/+ mast cells exhibit an upregulated 
inflammatory response (Figure 3.15A, C), and mast cells are known to recruit fibroblasts 
to sites of injury and biomaterial implants [Tang et al. 1998, Zhao et al. 2008, Levick et al. 
2009, Thevenot et al. 2011]. Additionally, Acvr1+/+ chondro-/osteo-progenitor cells 
participate in ectopic skeletogenesis in the presence of Acvr1R206H cells [Chakkalakal et al. 
2012]. Our results from Chapter 3 and supporting literature suggested a hypothesis that 
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enhanced inflammatory signaling present in Acvr1cR206H/+ immune cells may be sufficient 
to recruit Acvr1+/+ fibroblastic progenitor cells and induce HO formation. 
 The results from our Acvr1cR206H/+ BMT and LysM-Cre;Acvr1cR206H/+ experiments 
strongly oppose our hypothesis. HO formed in only one Acvr1+/+ recipient mouse (#12) 
that received Acvr1cR206H/+ donor bone marrow (in which Acvr1cR206H expression was 
confirmed; Figure 4.2). Experimental design and technical issues limit conclusive 
interpretation of the BMT experiment. I did not fractionate donor bone marrow into a 
hematopoietic-specific pool; whole bone marrow is a heterogeneous mixture that also 
contains mesenchymal stromal cells with chondro-/osteogenic potential [Reagan et al. 
2016]. Given that Acvr1cR206H/+ donor engraftment and reconstitution was reasonably high 
in mouse #12 (Figure 4.4), it is possible that some bystander Acvr1cR206H/+ stromal cells 
were also transplanted and contributed to the development of low HO volume in that 
mouse. Additionally, our experience with Acvr1cR206H/+ mice suggests that HO is unable to 
form if the ACVR1 R206H mutation is induced in mice older than ~7-8 weeks of age. 
Given the 8 week duration for engraftment and reconstitution of donor bone marrow, 
recipient mice were ~14 weeks of age at time of injury. This length of time (compared to 
the 4 week old mice used in our standard experimental protocal of HO induction) may 
explain why our positive-control Acvr1cR206H/+ mouse (#305) did not develop HO (Figure 
4.3), even though it received Acvr1cR206H/+ syngeneic CD45.2 donor bone marrow (Figures 
4.2 and 4.4). 
 To address the experimental design concerns of the BMT, I utilized an alternative, 
genetic approach to selectively express Acvr1cR206H in cells of hematopoietic lineage. I 
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induced Acvr1cR206H expression in myeloid lineage cells due to their significant presence 
and contribution to FOP and other HO disorders [Convente et al. 2015]. This genetic 
approach improves the BMT experimental design in two ways: Acvr1cR206H expression is 
restricted to myeloid lineages without bystander stromal cell expression, and this model 
removes potential mouse age restrictions that impede HO formation. However, I did not 
detect HO in any LysM-Cre;Acvr1cR206H/+ mice, even at 4 weeks post-injury (Figure 4.5), 
which is double the normal time needed for HO development. 
 Based on the results of the BMT and LysM-Cre;Acvr1cR206H/+ experiments, I 
conclude that Acvr1R206H cells of hematopoietic origin are insufficient to induce heterotopic 
ossification. These data are corroborated by a recent publication that reported no HO 
development in Vav1-Cre;Acvr1Q207D mice that express constitutively-active Acvr1Q207D in 
all hematopoietic lineage cells [de Boer et al. 2003, Dey et al. 2016]. 
 
4.4.2 Neutralization of TNFα and IL-6 is insufficient to inhibit heterotopic ossification 
 Targeting a subset of the immune system to treat HO is an appealing approach due 
to potentially reduced adverse events and off-target effects that often results with global 
immunosuppressive regimens such as corticosteroids. I specifically targeted TNFα and IL-
6 for neutralization due to their robust upregulation in Acvr1cR206H/+ lesions and mast cells 
(Figures 3.9A, B and 3.15A), as well as their role in chronic inflammatory myopathies 
[Karalaki et al. 2009, Philippou et al. 2012], a microenvironment mimicked in Acvr1cR206H/+ 
lesions (Figure 3.9). 
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 Systemic neutralization of TNFα and IL-6 was effective at reducing inflammation 
in Acvr1cR206H/+ mice post-injury (Figure 4.6A), but over the course of two independent 
experiments, was ineffective to reduce HO. Results from the first experiment were 
promising; however, HO volume was far lower than normally seen in positive-control 
Acvr1cR206H/+ (Figure 4.6C). On our second attempt, HO volume returned to consistent 
amounts and all regimens of etanercept showed no efficacy at reducing HO (Figure 4.6D). 
 It is possible that neutralization of TNFα and/or IL-6 is insufficient to reduce HO 
formation due to compensating effects from other cytokines and enzymes, such as IL-1β, 
IFN-γ, MCP-1, MMP-9, and chymase, among numerous other candidates. Pro-
inflammatory cytokines induce substantial concentrations of chemokines and growth 
factors that support tissue remodeling and restoration [Karalaki et al. 2009, Philippou et al. 
2012], suggesting a more comprehensive anti-inflammatory therapeutic regimen may be 
necessary to inhibit HO formation. 
 
4.4.3 Depletion of immune cells dramatically impairs heterotopic ossification 
development 
 Immune cells are sources of numerous inflammatory mediators that direct a potent 
inflammatory response to tissue injury. Myeloid-lineage cells including neutrophils, 
macrophages, and mast cells are known to express and secrete dozens of cytokines, 
chemokines, enzymes, and other inflammatory small molecules that amplify and sustain 
an inflammatory response and participate in tissue regeneration [Mosser et al. 2008, 
Murray et al. 2011, Kolaczkowska et al. 2013, Wynn et al. 2013, Moon et al. 2014, de 
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Oliveira et al. 2016, Vukman et al. 2017]. Given that immune cells are the primary source 
of inflammatory factors, depleting immune cells is a proof-of-principle approach that may 
reduce overall inflammation and impair HO development. 
 Several previous studies have demonstrated that immuno-ablating select immune 
cells impairs HO development [Kan et al. 2009, Kan et al. 2011]. Our study is the first to 
investigate the requirement of mast cells and macrophages for HO formation in the 
Acvr1cR206H/+ mouse model. Our in vivo results suggest that mast cells and macrophages 
are key cells for HO progression in FOP (Figure 4.10). I found that ablation of only mast 
cells or only macrophages reduced HO formation significantly but not completely, while 
ablating both resulted in enhanced inhibition, indicating that a single target may be 
insufficient to completely prevent HO. These data, in combination with our neutralization 
data, suggest that the inflammatory HO initiation mechanism by mast cells and 
macrophages may be due to factors not investigated in this project, such as the 
aforementioned chemokines and growth factors. 
Importantly in the context of developing therapeutics to inhibit HO formation in 
FOP, multiple methods that block mast cell inflammatory signaling, including targeting the 
Substance P neuroinflammatory pathway, all inhibited HO formation in a BMP2-implant 
model of HO [Kan et al. 2011, Salisbury et al. 2011]. Macrophages have been shown to 
produce osteoinductive signals [Champagne et al. 2002], promote osteogenic 
differentiation of mesenchymal stem cells [Tu et al. 2015], inhibit osteoclastogenesis 
[Jacquin et al. 2009], and promote fracture repair [Alexander et al. 2011], highlighting their 
potential relevance to HO development. Our data and these supporting literature suggest 
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that depleting mast cells and macrophages may severely limit their comprehensive 
inflammatory, pro-fibrotic, and pro-osteogenic functions, ultimately restricting the cascade 
of events that result in heterotopic endochondral ossification. 
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Donor 
Marrow 
Source 
Tamoxifen 
in donor or 
recipient 
Recipient 
Mice 
Genotype 
Recipient 
Mouse 
Number 
HO 
Response 
Acvr1+/+ Donor Acvr1+/+ 1 - 
Acvr1+/+ Donor Acvr1+/+ 2 - 
Acvr1+/+ Recipient Acvr1+/+ 3 - 
Acvr1+/+ Donor Acvr1+/+ 4 - 
Acvr1+/+ Donor Acvr1+/+ 5 - 
Acvr1cR206H/+ Recipient Acvr1+/+ 6 - 
Acvr1cR206H/+ Recipient Acvr1+/+ 7 - 
Acvr1cR206H/+ Donor Acvr1+/+ 8 - 
Acvr1cR206H/+ None Acvr1+/+ 9 - 
Acvr1cR206H/+ Donor Acvr1+/+ 10 - 
Acvr1cR206H/+ Donor Acvr1+/+ 11 - 
Acvr1cR206H/+ Donor Acvr1+/+ 12 + 
Acvr1cR206H/+ Recipient Acvr1cR206H/+ 305 - 
 
Table 4.1: Bone marrow donors and recipients table 
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Figure 4.1: Detection of recombined and expressed Acvr1cR206H allele in donor bone marrow 
pre-BMT 
DNA isolated from donor bone marrow or tail snip was amplified with primers specific to recombination of 
Acvr1[R206H]FlEx amplicon (and Acvr1+/+ control amplicon), indicating active Acvr1cR206H allele expression; 
Lane A was bone marrow sample from ERT2-Cre; Acvr1[R206H]FlEx + Tam.; Lane B was bone marrow sample 
from ERT2-Cre;Acvr1+/+ mouse + Tam; Lane C was bone marrow sample from ERT2-Cre;Acvr1[R206H]FlEx 
mouse without Tam; Lane D was tail snip from same mouse as in A; Lane E was tail snip from same mouse 
as in B. H2O indicates “water, no DNA control” lane. Abbreviation: Tam. = Tamoxifen-treated. 
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Figure 4.2: Detection of recombined and expressed Acvr1cR206H reconstituted bone marrow in 
Acvr1+/+ post-BMT recipients 
DNA isolated from reconstituted recipient bone marrow was amplified with primers specific to 
recombination of Acvr1[R206H]FlEx amplicon (and Acvr1+/+ control amplicon), indicating active Acvr1cR206H 
allele expression. Lane numbers correspond to mice indicated in Table 4.1. H2O indicates “water, no DNA 
control” lane. 
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Figure 4.3: Acvr1cR206H/+ whole bone marrow is insufficient to generate HO in Acvr1+/+ 
recipients 
Six week old Acvr1+/+ recipient mice (and a positive-control Acvr1cR206H/+ mouse #305) were irradiated with 
1000 rads and injected with 5 X 106 Acvr1cR206H/+ whole bone marrow cells by tail vein injection. Donor 
marrow engraftment and reconstitution time was 8 weeks. Recipient mouse hamstring muscles were injected 
with cardiotoxin (100 μL of 10 μM) and sacrificed at 3 weeks post-injury. Hind limbs were analyzed by μCT 
for visualization of HO. Only recipient #12 developed a small volume of HO (red arrow). The global knock-
in Acvr1cR206H/+ recipient mouse #305 (positive control) did not develop HO. 
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 B cells  CD4 
T cells 
 CD8  
T cells 
 
Mouse 
Number 
CD45.1 
% 
CD45.2 
% 
CD45.1 
% 
CD45.2 
% 
CD45.1 
% 
CD45.2 
% 
1 0.4 95 7.5 92 8.2 92 
2 0.99 96 7.3 92 6.9 93 
3 2.0 94 13 85 10.1 90 
4 91 0.54 95 0.051 99 0.019 
5 5.8 91 37 60 36 64 
6 31 63 71 27 45 54 
7 91 0.35 97 0.016 99.2 0 
8 90 0.39 89 1.2 96 0.23 
9 85 0.71 87 1.1 94 0.43 
10 66 28 64 33 70 30 
11 2.2 95 10 89 13 87 
12 65 4.2 35 7 46 51 
305 0 92 0.35 99 0.23 99.7 
 
 
 
 
 
 
 
 
Table 4.2: Donor CD45.2 bone marrow engraftment and reconstitution table 
Mice numbers 1-5 received Acvr1+/+ donor bone marrow. Mice numbers 6-12 and 305 received Acvr1cR206H/+ 
donor bone marrow. 
 
 
 
 
 
 
 
 NK 
cells 
 Neutrophils  
Mouse 
Number 
CD45.1 
% 
CD45.2 
% 
CD45.1 
% 
CD45.2 
% 
1 0.16 99.7 4.7 92 
2 0.69 99 0 95 
3 0.73 99.1 0 98 
4 100 0 96 0.22 
5 5.1 95 0.22 93 
6 90 9.7 46 48 
7 99 0 95 0.24 
8 89 2.0 94 0.35 
9 92 1.6 90 1.7 
10 56 41 57 34 
11 5.3 95 2.6 91 
12 52.4 43.3 96 0.48 
305 0.94 99 0 94 
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Figure 4.4: Variable efficiency of CD45.2 donor bone marrow engraftment and 
reconstitution in recipients 
Bone marrow was collected from recipient mice at sacrifice for quantification of donor bone marrow 
engraftment and reconstitution. Bone marrow was incubated with primary antibodies against CD45.1, 
CD45.2, and a panel of fluoro-tagged antibodies to detect specific immune cell populations (see Chapter 
2.8.3). Percentages of donor reconstituted immune cells (CD45.2) and host residual immune cells (CD45.1) 
are listed for each recipient mouse. Mice numbers 1-5 received Acvr1+/+ donor bone marrow. Mice numbers 
6-12 and 305 received Acvr1cR206H/+ donor bone marrow. 
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Figure 4.5: Myeloid-restricted Acvr1cR206H expression is insufficient to induce HO formation 
following skeletal muscle injury 
Four week old LysM-Cre;Acvr1cR206H/+ mice (and Acvr1cR206H/+ positive controls) were injected with 
cardiotoxin (60 μL; 8 μg total peptide) into right hamstring muscles. (A) Hind limbs were analyzed by μCT 
for visualization of HO. No HO was detected in any LysM-Cre;Acvr1cR206H/+ mouse; HO was detected in both 
Acvr1cR206H/+ mice (red arrow). Representative μCT 3D volume renderings per cohort are shown. (B) 
Quantification of HO for each cohort. n = 4 for each LysM-Cre;Acvr1cR206H/+ cohort, n = 2 for Acvr1cR206H/+ 
cohort. Data shown are mean values ± SEM; one-way ANOVA with Tukey’s multiple comparisons test 
compared Acvr1cR206H/+ vs. other cohorts; * p < 0.05 
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Figure 4.6: TNFα and IL-6 neutralization is insufficient to inhibit HO formation 
Four week old Acvr1cR206H/+ mice were injected with cardiotoxin (50 μL of 20 μM) into the gastrocnemius 
muscle of both hind limbs. Four experimental groups: PBS vehicle, mouse-anti-IL-6, etanercept, mouse-anti-
IL-6 + etanercept. Mice were sacrificed at 2 weeks post-injury. Hind limbs were scanned by μCT for HO 
quantification. (A) CRP levels were quantified at the beginning, middle, and end of 2-week experiment. n = 
8 for all cohorts except etanercept (n = 6). Data shown are mean values ± SEM; two-way repeated measures 
ANOVA with Holm-Sidak’s multiple comparisons test compared values to baseline measurements; * p < 
0.01 versus Day 1 within treatment. (B) Intramuscular mineral content was quantified. (C) HO volume was 
quantified. n = 8 for all cohorts except etanercept (n = 6). Data shown are mean values ± SEM; one-way 
ANOVA with Tukey’s multiple comparisons test was performed. (D) HO volume was quantified. n = 10 for 
all groups, except etanercept, 4mg/kg; 3X (n = 2). Data shown are mean values ± SEM; one-way ANOVA 
with Tukey’s multiple comparisons test was performed. Abbreviation: CRP = C-reactive protein 
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Figure 4.7 Clodronate-liposome-mediated macrophage depletion experimental design 
Acvr1cR206H/+ mice were placed on doxycycline chow (625 mg / kg) for five days prior to injury to induce 
expression of the conditional Acvr1cR206H allele. Clodronate-liposomes (100 μL / 10 g bodyweight) were 
injected intraperitoneally into appropriate mouse cohorts at days indicated; an injection was performed 3 
days prior to cardiotoxin injection in order to deplete macrophages at the time of injury. Clodronate-
liposomes were injected every 3 days following this first injection to maintain macrophage depletion 
throughout study. Hamstring muscles were injected with cardiotoxin (50 μL of 20 μM) and samples were 
collected at Day 17 post-injury. Abbreviation: Clo. = clodronate-liposomes 
 
Figure panel from Convente MR, Chakkalakal SA, Yang E, Caron RJ, Zhang D, Kambayashi T, Kaplan FS, 
Shore EM. (submitted). “Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an 
Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva” 
 
 
 
 
 
 
 
 
 
 127 
 
 
Figure 4.8: Confirmation of macrophage depletion in clodronate-liposome mice 
(A) Whole bone marrow was collected from Acvr1cR206H/+ mice injected with Clo. or PBS and stained with 
fluoro-tagged primary antibodies against F4/80, CD11b, and MHC Class II, cell surface receptors that in 
combination identify macrophages. Cells were first gated for F4/80 and CD11b expression, and then double-
positive cells were gated for MHC Class II expression. Numbers listed are cell percentages per gating. (B) 
Bone marrow macrophage percentages in PBS versus Clodronate-liposome-injected mice. n = 18 for PBS, n 
= 16 for Clo.; data shown are mean values ± SEM. Abbreviation: Clo. = clodronate-liposomes 
 
Figure panel from Convente MR, Chakkalakal SA, Yang E, Caron RJ, Zhang D, Kambayashi T, Kaplan FS, 
Shore EM. (submitted). “Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an 
Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva” 
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Figure 4.9: Confirmation of mast cell deficiency in c-KitW-Sh/W-sh mice 
Mast cells were quantified by C.E.M. stain kit in sections obtained at sacrifice from all cohorts analyzed in 
Figure 4.10. Representative images at 200X magnification of each cohort are shown, with dotted rectangles 
indicating further magnification at 400X. Mast cells are indicated by black arrows. Note absence of mast 
cells in Acvr1cR206H/+;c-KitW-Sh/W-sh and Acvr1cR206H/+;c-KitW-Sh/W-sh;Clo. mouse cohorts. Scale bar = 100 μm for 
200X, 50 μm for 400X. Abbreviation: Clo. = clodronate-liposomes 
 
Figure panel from Convente MR, Chakkalakal SA, Yang E, Caron RJ, Zhang D, Kambayashi T, Kaplan FS, 
Shore EM. (submitted). “Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an 
Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva” 
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Figure 4.10: Mast cell and macrophage depletion impairs formation of heterotopic 
ossification in Acvr1cR206H/+ mice. 
Cardiotoxin-injured skeletal muscles of Acvr1cR206H/+ mice with intact or depleted mast cells and/or 
macrophages were examined by μCT to detect heterotopic ossification after 17 days. Mast cells were 
genetically ablated in Acvr1cR206H/+;c-KitW-sh/W-sh mice or partially ablated in Acvr1cR206H/+;c-KitW-sh/+ mice. 
Macrophages were chemically depleted Clo. Data are compared to Acvr1cR206H/+ (positive HO control) and 
Acvr1+/+ (negative control). (A) Representative μCT 3D volume renderings showing mean HO volume per 
hind limb are shown. (B) Quantification of HO for each cohort (n = 5-20); HO per hind limb was added for 
total HO per mouse. Data shown are mean values ± SEM; one-way ANOVA with Tukey’s multiple 
comparisons test compared Acvr1cR206H/+ vs. other cohorts; * p < 0.05, ** p < 0.01, ns = not significant. 
Abbreviation: Clo = Clodronate-liposomes. 
 
Figure panel from Convente MR, Chakkalakal SA, Yang E, Caron RJ, Zhang D, Kambayashi T, Kaplan FS, 
Shore EM. (submitted). “Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an 
Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva” 
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5.1 Summary 
 Inflammation is the earliest recognized event of HO formation. Long before the 
publication reporting the identification of the FOP gene in spring 2006 [Shore et al. 2006], 
the presence of an inflammatory component was thought to be an essential feature of 
disease etiology. Identification of the mutation that causes FOP rapidly expanded the 
knowledge and research tools that enabled investigation of how HO forms in FOP. Studies 
using the in vitro and in vivo FOP model systems that followed discovered that the ACVR1 
R206H mutation confers increased BMP pathway signaling and accelerates 
chondrogenesis of fibroblastic progenitor cells. However, similar substantial advances in 
knowledge regarding the inflammatory role in HO formation remained limited. 
 In this thesis research, I have conducted the first in-depth investigation on the 
effects of Acvr1R206H on the inflammatory response in FOP. I focused specifically on the 
impact of Acvr1R206H on the cellular and molecular inflammatory response to skeletal 
muscle injury, including the tissue regeneration program. I also investigated whether 
Acvr1R206H hematopoietic cells are sufficient to induce HO formation in genetically normal 
backgrounds. Lastly, I examined whether immune cells play a significant role in inducing 
HO formation via mast cell- and macrophage-depleted Acvr1cR206H/+ mouse experiments. 
Given the shared immunological features of ectopic bone formation in FOP and non-
genetic HO disorders, our studies bring new insight into the immunological contributions 
to HO disorders. These data also support consideration of novel treatment approaches for 
both FOP and more common non-hereditary forms of HO, potentially benefiting a wide 
range of patients. 
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5.2 Discussion 
5.2.1 The effect of Acvr1R206H on the inflammatory response to tissue injury 
 An inflammatory milieu is the earliest recognized phase of lesion formation in FOP, 
as discussed in Chapter One (Figure 1.4). The response of immune cell influx and cytokine 
upregulation is qualitatively mirrored in the normal response to tissue injury, however, as 
discussed in Chapter One (Figure 1.4) and shown in Chapter Three (Figures 3.2, 3.3, 3.4), 
Acvr1cR206H mutant tissue does not appropriately repair and regenerate skeletal muscle to 
its pre-injury state, but instead progresses toward heterotopic endochondral ossification. 
Previous clinical reports and mouse model studies have demonstrated the importance of 
active inflammation for HO disease progression [Kaplan et al. 2007, Yu et al. 2008], yet 
no group conclusively demonstrated that the immune response is amplified in FOP. Given 
the established participation of BMP signaling in activating an inflammatory state [Mohler 
et al. 2001, Kwon et al. 2009, Lee et al. 2011, Lee et al. 2012, Martinez et al. 2015, 
Villavicencio et al. 2016], I hypothesized that the enhanced BMP pathway activation by 
Acvr1cR206H amplifies the inflammatory response to tissue injury beyond the normal cellular 
and molecular response. To address this hypothesis, I performed a cross-sectional injury 
experiment (Chapter Three), comparing the inflammatory response and tissue repair 
programs between Acvr1cR206H/+ and Acvr1+/+ mice. I observed that mutant tissue and 
normal tissue are indistinguishable up to 2-3 days post-injury; however, Acvr1cR206H/+ 
lesions progressively diverged toward terminal heterotopic endochondral ossification 
instead of appropriately regenerating skeletal muscle, as occurred in Acvr1+/+ controls. I 
showed that the cellular and molecular inflammatory response is robustly amplified in 
 133 
 
Acvr1cR206H/+ mice and persists into the late-stage lesion phase, as opposed to returning to 
pre-injury levels. Furthermore, I showed that Acvr1cR206H exhibits cell-autonomous pro-
inflammatory effects in mast cells, as Acvr1cR206H/+ mast cells exhibited increased pro-
inflammatory mRNA expression and degranulation. 
During the normal skeletal muscle repair program, the early pro-inflammatory 
response dampens and transitions into an anti-inflammatory response, mediated primarily 
by M2 macrophages, that facilitates wound repair and tissue regeneration via secretion of 
IL-4, IL-10, and growth factors [Tidball 2005, Karalaki et al. 2009, Murray et al. 2011, 
Philippou et al. 2012]. Disruption of this pro-inflammatory to anti-inflammatory transition 
leads to chronic inflammation and deficient tissue regeneration. Our in vivo and in vitro 
data reflect a chronic inflammatory scenario in the presence of the ACVR1 R206H 
mutation. 
The overall amplified and prolonged immune response in FOP could be, at least in 
part, the result of deficient MSC immunomodulatory function. Upon inflammatory 
stimulation by lymphocytes and secreted factors such as IFN-γ, IL-1β, and TNFα, MSCs 
subsequently suppress prolonged inflammation through production of indolamine 2,3-
dioxygenase (IDO) and Treg induction in humans, and nitric oxide (NO) via expression of 
inducible nitric oxide synthase (iNOS) in mice [Shi et al. 2010]. MSCs are able to suppress 
T and B cell proliferation via cell-cell contact through the programmed death-1 (PD-1) 
signaling pathway [Augello et al. 2005], NK cell proliferation [Sotiropoulou et al. 2006], 
and dendritic cell maturation [Zhang et al. 2004]. MSCs are also capable of reduction T 
cell and monocyte production of  IFN-γ and TNFα [Ben-Ami et al. 2011]. Notably, IL-6 
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produced by MSCs protects lymphocytes and neutrophils from apoptosis [Xu et al. 2007, 
Raffaghello et al. 2008]. IL-6 is robustly expressed in Acvr1cR206H/+ lesions (Figure 3.9), 
which may contribute to significantly elevated neutrophil and lymphocyte density (Figure 
3.8A, C). Investigation of MSC immunomodulary function in FOP could be accomplished 
via co-culture experiments combining MSCs and immune cell populations, with immune 
cell proliferation and activation as the primary data point. Assessing MSC 
immunomodulary function in FOP is a novel area for future investigation. 
Our findings show for the first time that the ACVR1 R206H mutation amplifies and 
prolongs the usual inflammatory response present in tissue injury, mimicking a chronic 
inflammatory state. 
 
5.2.2 The role of immune cells and inflammatory activation in heterotopic ossification 
formation 
 The origin of the progenitor cells that directly differentiate to ectopic bone is a 
major ongoing research question. Much progress has been made, as several chondro-
/osteogenic populations have been suggested to directly contribute to HO in vivo. [Lounev 
et al. 2009, Wosczyna et al. 2012, Agarwal et al. 2016, Dey et al. 2016]. Other work has 
also conclusively eliminated the hematopoietic cell lineage as contributing cells to 
fibroproliferative, chondrogenic, and osteogenic stages of HO [Kaplan et al. 2007]. Given 
this supporting literature, an unresolved question is what is the role of immune cells in the 
etiology of HO development, particularly within the context of FOP. 
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 Lesion development in FOP occurs through a series of progressive inflammatory, 
fibroproliferative, and chondro-/osteogenic cellular and tissue events that results in mature 
HO. One possibility is that Acvr1R206H/+ immune cells are sufficient to initiate and support 
all stages of lesion formation, from immune cell influx to mature HO. This is an appealing 
mechanism given that immune cells secrete numerous chemokines and growth factors that 
support recruitment and proliferation of muscle tissue fibroblasts [Karalaki et al. 2009, 
Philippou et al. 2012], as well as previous work showing that Acvr1+/+ cells can participate 
in heterotopic endochondral ossification in a mouse model that contains both Acvr1+/+ and 
Acvr1R206H cells [Chakkalakal et al. 2012]. One specific cytokine secreted by activated 
macrophages is PDGF [Karalaki et al. 2009, Philippou et al. 2012], which is notable given 
that PDGFRα receptor and cells within muscle tissue exhibit robust BMP-induced 
osteogenic capacity and participated in HO formation following intramuscular transplant, 
even in the absence of the ACVR1 R206H mutation [Wosczyna et al. 2012]. Increased 
activation of PDGFRα disrupts connective tissue development and drives systemic fibrosis 
[Olson et al. 2009], and a recent publication reported that expression of an endogenous 
kinase-inactivated decoy PDGFRα receptor during tissue repair attenuates muscle fibrosis 
[Mueller et al. 2016]. Given previous data and supporting literature, I hypothesized that an 
Acvr1R206H/+ hematopoietic system is sufficient to induce HO formation in an Acvr1+/+ 
background. 
 Our results from Chapter Four oppose the hypothesis that Acvr1R206H hematopoietic 
cells alone are sufficient to induce HO formation in a normal background. My bone marrow 
transplant (BMT) experiment was the most direct approach to address this question, 
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however this experiment was inconclusive due to experimental design limitations (as 
discussed in Chapter 4). Bone marrow is a hetergeneous mixture comprised of HSCs, 
various precursor and mature immune cells, stromal cells, and fat cells [Reagan et al. 2016]. 
The donor bone marrow sample used for the BMT experiment was not fractionated into an 
HSC-pure CD34-positive population [Challen et al. 2009] prior to injection. This allows 
for the possibility of bystander stromal and/or fat cells with chondro-/osteogenic potential 
being transplanted simultaneously as HSCs, which may contribute to HO formation when 
expressing Acvr1R206H [Augello et al. 2005]. 
Therefore, I conducted an alternate genetic approach to address the sufficiency of 
hematopoietic cells for Acvr1R206H/+-mediated HO, generating LysM-Cre;Acvr1cR206H/+ 
mice that express Acvr1cR206H exclusively within myeloid lineages. The results are 
corroborated by an independent group that recently reported no HO formation in mice 
expressing the constitutively-active Acvr1Q207D receptor in all hematopoietic lineages (as 
well as endothelial cells) driven by the Vav1-Cre promoter [Dey et al. 2016]. 
 Our finding that HO formation was dramatically reduced in mast cell-deficient and 
macrophage-depleted Acvr1cR206H/+ mice (Chapter Four) suggests that immune cells are 
necessary participants for HO formation, even if they are alone insufficient to induce HO. 
Previous studies have reported similar results in non-FOP mouse models of HO [Kan et al. 
2009, Salisbury et al. 2010, Kan et al. 2011, Salisbury et al. 2011], bolstering the 
importance of mast cells and macrophages in HO pathology. 
 In the context of FOP and HO formation, what are the functions of mast cells and 
macrophages? During the normal skeletal muscle regeneration program, these cells 
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potentiate an inflammatory microenvironment, produce enzymes that digest damaged 
tissue, and recruit fibroproliferative cells that act as intermediaries during normal tissue 
regeneration [Tidball 2005, Karalaki et al. 2009, Galli et al. 2011, Murray et al. 2011, 
Philippou et al. 2012, Wynn et al. 2013]. During chronic inflammatory myopathies, the 
resident inflammatory response is exaggerated, leading to disrupted tissue regeneration and 
macrophage- and mast cell-mediated fibrosis [Gallant-Behm et al. 2008, Zhao et al. 2008, 
Levick et al. 2009, Wynn et al. 2010, Philippou et al. 2012, Hugle 2014]. In a non-FOP 
context, the terminal result of chronic inflammatory myopathy is fibrosis [Wynn 2008, 
Wynn et al. 2012], however in the context of FOP, the enhanced BMP pathway signaling 
conferred by Acvr1R206H re-directs the tissue response toward ectopic cartilage and bone 
[Shen et al. 2009, Culbert et al. 2014]. Our findings from Chapter Three suggest that the 
amplified and prolonged inflammatory response in an Acvr1cR206H/+ background mimics 
chronic inflammatory myopathy and establishes a conducive microenvironment for the 
pro-chrondrogenic and pro-osteogenic effects of Acvr1R206H to manifest. Depleting mast 
cells and macrophages from Acvr1cR206H/+ mice may simultaneously reduce levels of 
multiple inflammatory cytokines, chemokines, and fibroblast growth factors that in unison 
arrest HO formation (discussed further in Future Directions). 
 The data presented in this thesis and supporting literature allow consideration of 
the inflammatory role in FOP disease pathology. The LysM-Cre;Acvr1cR206H/+ data showing 
no HO response, in combination with the report that no HO was detected in Vav1-
Cre;Acvr1Q207D mice, and additional studies that investigated lesion development at 
different stages, can help direct several remaining questions for FOP etiology, including: 
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what cell types have the potential to contribute to ectopic cartilage and bone, what cell 
types require the ACVR1 R206H mutation for participation in lesion development, what 
are the contributions of tissue-resident vs. migratory progenitor cells, and what is the 
overall immune system role in disease progression. 
 Several cell populations with the capacity to contribute to ectopic cartilage and 
bone have been identified. Our group identified Tie-2+ cells within the fibroproliferative, 
cartilage, and bone stages of lesion progression in vivo [Lounev et al. 2009]. Double-
positive Tie-2+/PDGFRα+ cells were shown to contribute to HO in response to BMP2 
stimulation [Wosczyna et al. 2012]. Two additional cell populations that can contribute to 
HO formation have also been identified: Mx1+ muscle-resident interstitial cells, and Scx+  
tendon-derived progenitor cells [Agarwal et al. 2016, Dey et al. 2016]. Both Mx1+ and Scx+ 
cells that participated in HO expressed an Acvr1 mutation, R206H or Q207D; however, 
Tie-2+ and Tie-2+/PDGFRα+ cell participation in HO was in a BMP2 stimulation model, 
and these cells did not express an Acvr1 mutation, but showed enhanced osteogenesis in 
response to BMPs [Lounev et al. 2009, Wosczyna et al. 2012]. 
 Fibro/adipogenic progenitors (FAPs) are muscle-resident cells that support proper 
skeletal muscle regeneration following damage [Joe et al. 2010]. FAPs are defined by a 
Lin-/Sca-1+/α7 integrin-/CD34+ expression profile, with over 85% of cells in undamaged 
muscle and up to 98% of cells in damaged muscle also expressing PDGFRα [Joe et al. 
2010]. In response to muscle damage, FAPs expand and provide important pro-
differentiation signals for proliferating myogenic precursors. Although initially recognized 
for their ability to differentiate toward fibrogenic and adipogenic lineages, in addition to 
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their primary supportive role for myogenic differentiation, FAPs have recently been 
appreciated for their role in ectopic bone formation. FAPs express alkaline phosphatase, a 
key enzyme for mineral deposition during osteogenesis, following stimulation with BMP7 
[Uezumi et al. 2010]. Additionally, the muscle-resident Tie-2+/PDGFRα+ cells that can 
contribute to HO formation in response to BMP2 stimulation, described above [Wosczyna 
et al. 2012], may be classified as FAPs. The R206H mutation has been shown to accelerate 
chondrogenic differentiation in MEF cells [Culbert et al. 2014], and it is possible that the 
mutation may also alter the cell fate of FAPs toward a fibrogenic and heterotopic 
endochondral ossification differentiation program [A. Bonomi, personal communication]. 
 The above data suggest that while certain cell populations are able to contribute to 
HO when expressing Acvr1R206H, and that the R206H mutation is required for initiation of 
HO in FOP [Chakkalakal et al. 2012], the R206H mutation may not be required in all cell 
types that particpate in lesion development, including immune cells and fibroblast-like 
cells that form ectopic cartilage and bone. This was also demonstrated in a chimeric 
Acvr1R206H/+ mouse model where ~50% of cells in endochondral bone lesions expressed 
Acvr1+/+ [Chakkalakal et al. 2012]. This surprising result suggests that there may be a 
threshold percentage and/or lineage subset requirement of cells expressing Acvr1R206H in 
order to support HO formation. Mice expressing Acvr1R206H in mesodermal lineage cells 
using a Prrx1-Cre driving system developed robust HO in limbs [Chakkalakal et al. 2016], 
supporting the possibility of a threshold percentage and lineage restriction of cells with the 
capacity to form ectopic cartilage and bone. 
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 An ongoing question is the location origin of cells that participate in ectopic 
cartilage and bone formation. Tissue-resident cells, such as FAPs and other fibroblast-like 
cells that have been shown to have chondrogenic and osteogenic potential, are prime 
candidates for cells that form HO. However, there also have been migratory cell 
populations shown to participate in HO formation. Cells from the endoneurium, which line 
the myelin sheath of nerves, were observed migrating toward an implanted matrigel BMP2 
source and forming HO at their new location in a mouse model of HO formation [Olmsted-
Davis et al. 2017]. These cells expressed osterix, a transcription factor that functions as a 
master regulator of osteoblast differentiation. Additionally, osterix+ cells were observed in 
proximity to ectopic bone in human patients with HO [Olmsted-Davis et al. 2017]. Immune 
cells, through chemokine ligand and receptor signaling pathways, have significant roles in 
recruiting cells to participate in wound healing and immunoprotection of multiple tissues, 
including skin [Ishida et al. 2007], skeletal muscle [Warren et al. 2005], and lung [Mikhak 
et al. 2013]. Mast cells contribute to activation of the sympathetic nervous system via 
degranulation [Salisbury et al. 2011], and mast cells and macrophages control early 
neutrophil recruitment via the chemokines CXCL1 and CXCL2  [De Filippo et al. 2013]. 
Given the increased and prolonged immune cell density and activation observed in 
Acvr1cR206H/+ samples, it is possible that the amplified immune response may induce 
fibroblast-like cell migration, or amplify the migration rate over the normal repair program. 
Although Acvr1R206H expression restricted to hematopoietic lineages is insufficient 
to cause HO, soft connective tissue repair programs may still be disrupted in this setting. 
Elevated inflammatory factor expression caused by the R206H mutation in the above 
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setting may still disrupt the normal skeletal muscle regeneration program, but instead of 
progressing to mature HO, the tissue morphology only advances to a fibrotic stage, 
mimicking events that occur in chronic inflammatory myopathies [Mann et al. 2011]. 
Consideration of the data presented in this thesis, in combination with supporting literature, 
may explain how the response to skeletal muscle injury may differ depending on the 
inflammatory reaction and whether the R206H mutation is present. 
During the normal skeletal muscle regeneration program, pro-inflammatory 
activation induces a cellular and molecular response that results in immune cell recruitment 
and macrophage phagocytosis of damaged tissue and transient accumulation of collagen 
fibers [Mann et al. 2011]. An anti-inflammatory response, mediated primarily by the class-
switching from M1 to M2 macrophages, dampens the pro-inflammatory response and 
supports myogenic differentiation to restore muscle function. In individuals with chronic 
inflammatory myopathies, excessive pro-inflammtory activation and elevated numbers of 
M1 macrophages cause an overabundance of collagen accumulation and impede myogenic 
differentiation, resulting in fibrosis [Wynn et al. 2010, Mann et al. 2011]. However, since 
these individuals do not possess the R206H mutation, fibrotic tissue does not progress to 
ectopic cartilage and bone. In patients with FOP, the R206H mutation amplifies and 
prolongs the pro-inflammatory response to muscle injury, mimicking chronic 
inflammation. This overactive immune response may stimulate tissue-resident progenitor 
cell proliferation, and may recruit additional fibroproliferative cells to the site of injury. 
These fibroproliferative cells, also expressing Acvr1R206H, have the capacity to aberrantly 
differentiate into ectopic cartilage and bone, resulting in mature HO [Culbert et al. 2014]. 
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Mast cells expressing Acvr1R206H exhibit an increased pro-inflammatory response, 
and other immune cells may have a similar inflammatory response. Immune cells 
expressing Acvr1R206H can further amplify the immune response to injury, but cell(s) with 
chondro-/osteogenic potential must also express the R206H mutation in order for 
chondrogenesis and osteogenesis to form, as Acvr1R206H expression restricted to 
hematopoietic lineages is insufficient for HO formation (Figure 4.5; [Dey et al. 2016]). 
Additionally, Acvr1R206H expression in immune cells is not required for HO to develop, as 
has been observed in a Prrx1-Cre;Acvr1cR206H/+ mouse model and a human patient who 
received an BMT of Acvr1+/+ donor marrow for treatment of aplastic anemia [Kaplan et al. 
2007]. The above literature and data from this thesis suggest that while an immune system 
expressing Acvr1R206H may support a more robust HO response in a global R206H 
background, a wild-type immune system is also sufficient for HO formation in the same 
genetic background. Based on this paradigm, the importance of the immune response in 
FOP may reside in secreted inflammatory factors from immune cells, more so than whether 
immune cells express the R206H mutation. This is further supported given that non-
hereditary HO can form in absence of any causative ACVR1 mutation, but is often 
associated with a robust inflammatory phase. 
 
5.2.3 The shared inflammatory features of FOP and non-hereditary heterotopic 
ossification disorders 
An inflammatory component is associated with almost all forms of HO [Convente 
et al. 2015], including non-hereditary HO disorders associated with severe trauma such as 
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invasive arthroplasties [Pignolo et al. 2005, Cohn et al. 2011, Bedi et al. 2012], combat 
blast injuries, and other traumatic wounds [Potter et al. 2010, Alfieri et al. 2012]. Although 
FOP is an extremely rare genetic disorder, the prevalence of HO in the above scenarios is 
common, approaching 30% following hip replacement surgery and 65% following combat 
blast injuries [Neal et al. 2002, Potter et al. 2010]. Strikingly, non-hereditary HO disorders 
and FOP share immunological mediators. Serum levels of IL-6 were significantly elevated 
in combat blast injury patients who developed HO [Evans et al. 2012, Forsberg et al. 2014], 
which is notable given the robust increase in IL-6 in Acvr1cR206H/+ lesions and Acvr1cR206H/+ 
mast cells (Chapter Three). MCP-1 was identified as a biomarker that predicted HO 
development in combat blast injury patients [Evans et al. 2012]. Although MCP-1 
expression was equivalent between Acvr1cR206H/+ and Acvr1+/+ lesions (Chapter Three), its 
presence in the FOP setting could contribute to the chronic inflammatory response. 
An influx of immune cells is also observed in non-hereditary HO disorders. A 
robust T- and B-cell influx to sites of injury was shown in a burn injury HO mouse model. 
In this same study, ablation of mature lymphocytes using Rag1 knock-out mice caused a 
60% decrease in bone compared to immunocompetent controls, demonstrating a prominent 
role for the adaptive immune system in burn injury HO formation [Ranganathan et al. 
2016]. Additionally mast cells have been observed in cardiac valve bone formation as well 
as in BMP ligand-induced HO episodes [Mohler et al. 2001, Kan et al. 2011, Salisbury et 
al. 2011]. 
While there may be unique inflammatory contributions to FOP, such as a gain-of-
function Acvr1R206H sensitivity to Activin A [Hatsell et al. 2015], common inflammatory 
 144 
 
mediators across HO disorders establish the immune system as an appealing treatment 
target that may benefit large numbers of patients (to be discussed in Future Directions). 
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5.3 Future Directions 
5.3.1 Identifying additional immune cells and inflammatory factors involved in 
heterotopic ossification etiology 
 The immune system is an incredibly rich and complex network of cells and factors 
that act in concert to direct inflammatory responses. There exists dozens of hematopoietic 
subtypes, interleukins, chemokines, and other mediators that function in response to 
pathogen invasion and tissue damage [Charo et al. 2006, Akdis et al. 2011, Turner et al. 
2014, de Graaf et al. 2016, Vukman et al. 2017]. Our data show upregulation of major pro-
inflammatory cytokines in Acvr1cR206H/+ mice following injury, including TNFα, IL-1β, IL-
6, and Activin A. I also show increased neutrophil, macrophage, mast cell, and T cell 
density in Acvr1cR206H/+ lesions (Chapter Three). However, there are additional immune 
cells yet to be investigated that may contribute to HO formation, such as T cell subsets (T 
helper 1 cells, T helper 2 cells, T helper 17 cells, and others), B cells, dendritic cells, and 
NK cells. I showed that mast cell and macrophage depletion reduced HO by ~75% in 
Acvr1cR206H/+ mice (Chapter Four), suggesting that other inflammatory cells and mediators 
may have a role in HO development. T cells and B cells have been observed in FOP patient 
biopsies and in cardiac valve HO [Mohler et al. 2001, Kaplan et al. 2005], and our results 
have demonstrated a significant role for myeloid lineage cells in HO formation (Chapters 
Three and Four). These data and supporting literature suggest that dendritic cells and NK 
cells, which function as intermediaries between the innate and adaptive immune system, 
may be an appealing area of future investigation. 
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I focused on investigating the well-defined major pro-inflammatory cytokines 
TNFα, IL-1β, IL-6, given their significant roles in mediating positive-feedback 
inflammatory responses [Akdis et al. 2011, Turner et al. 2014] and known involvement in 
tissue injury response [Gallucci et al. 1998, Luo et al. 2003, Karalaki et al. 2009, Philippou 
et al. 2012]. Appealing future experiments could investigate a broader profile of 
inflammatory mediators, including interferons, chemokines, and mast cell-released 
compounds such as histamine and chymase, that may be involved as part of the total 
inflammatory contribution to HO formation. The chemokine CX3CR1 is involved in skin 
wound repair via recruitment of fibroblasts [Ishida et al. 2007], and CXCR6 recruits bone 
marrow-derived fibroblast precursors that increase susceptibility to renal fibrosis [Xia et 
al. 2014], highlighting the role of chemokines as potent chemotactic factors for fibro-
progenitor cells in injury settings. CX3CR1 is produced by macrophages and CXCR6 is 
produced by CD4+ and CD8+ T cells [Charo et al. 2006], two immune cell lineages present 
in FOP lesions. 
 
5.3.2 Investigating the role of Acvr1R206H on anti-inflammatory responses during 
tissue injury 
 The normal inflammatory response to tissue injury involves an early phagocytic 
pro-inflammatory phase that eventually transitions into a subsequent regenerative anti-
inflammatory phase. Our results from Chapter Three demonstrate that the cellular and 
molecular pro-inflammatory response in FOP is amplified and prolonged, mimicking 
chronic inflammatory myopathies. 
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 A major event that directs the transition of pro-inflammation to anti-inflammation 
is the class-switching of M1 macrophages to M2 macrophages [Italiani et al. 2014]. M2 
macrophages appear subsequent to early-responding M1 macrophages during the normal 
tissue repair program. M2 macrophages secrete anti-inflammatory factors, including IL-4, 
IL-10, TGF-β1, and tissue inhibitors of metalloproteinases (TIMPs), as well as growth 
factors that suppress fibrosis and mediate tissue regeneration [Mosser et al. 2008, Wynn et 
al. 2012]. In chronic inflammatory myopathies, the transition of M1 to M2 macrophages is 
disrupted, maintaining the pro-inflammatory microenvironment that promotes fibrosis at 
the expense of appropriate tissue regeneration [Wynn et al. 2012]. 
 Our macrophage depletion experiment via clodronate-liposomes depleted 
macrophages prior to injury and throughout the response and repair program (Chapter 
Four). An appealing future experiment would be to adjust the timing of macrophage 
depletion so as to specifically target early M1 or late M2 macrophages for depletion, and 
examine how that impacts HO formation. Previous work in the musculoskeletal field 
showed that pro-inflammatory M1 macrophages are essential for skeletal muscle 
regeneration [Arnold et al. 2007]. However, this study also showed that selectively 
depleting M2 macrophages after the M1 response resulted in diminished muscle fiber 
diameter, suggesting that both populations are essential for proper skeletal muscle 
regeneration [Arnold et al. 2007]. A preliminary experiment quantifying specific M1 and 
M2 macrophage populations in Acvr1cR206H/+ and Acvr1+/+ lesions using well-defined 
markers [Jablonski et al. 2015] would provide initial insight about a more detailed 
macrophage phenotype in FOP. 
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 A key lymphoid cell involved in dampening inflammation is the regulatory T cell 
(Treg). Tregs are derived from CD4
+ T cells and depend on the forkhead transcription factor 
FoxP3 for specification and function [Josefowicz et al. 2012]. Tregs are major sources of 
IL-10 and IL-2R that function to suppress T cell activation and maintain immune 
homeostasis in part by inducing CD4+ T cell apoptosis [Pandiyan et al. 2007, Josefowicz 
et al. 2012]. In the context of muscular disorders, Tregs suppress muscle inflammation and 
injury in the mdx mouse model of Duchenne Muscular Dystrophy [Villalta et al. 2014], 
highlighting a potential role for Tregs reducing inflammation in other muscular injury 
settings, such as occurs in HO disorders. 
 Future work could also quantify levels of anti-inflammatory cytokines, such as IL-
4, IL-10, and TGF-β1. This could be done in primary mast cell and macrophage cultures, 
as well as serum enzyme-linked immunosorbent assay (ELISA) quantification from new 
in vivo samples. IHC using sections from the cross-sectional injury study. I quantified 
TGF-β1 mRNA expression in Acvr1cR206H/+ and Acvr1+/+ mast cells and macrophages, but 
found no differences in expression (Figure 3.15A, B). These preliminary data suggest that 
the anti-inflammatory response may be unaffected by the ACVR1 R206H mutation, but 
much additional work must be done for conclusive interpretation. 
 
5.3.3 Targeting the immune system as a novel approach to inhibit heterotopic 
ossification 
There is a pressing need for therapeutics that prevent HO formation in FOP and 
non-hereditary HO disorders, as current treatments are palliative [Pignolo et al. 2016]. 
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Palovarotene, a retinoic acid receptor-gamma (RARγ) agonist that potently inhibits HO 
formation in Acvr1cR206H/+ mice by disrupting chondrogenesis [Chakkalakal et al. 2016], is 
currently being investigated in a clinical trial for FOP patients. This represents a major 
milestone in the search for an effective treatment or cure for FOP. Efforts to find additional 
treatments for HO are ongoing, and targeting the immune system is an appealing approach 
given that it is the earliest phase of lesion formation. 
Blocking mast cell and macrophage signaling may be an effect method to inhibit 
HO formation, both in FOP and non-hereditary HO disorders. Multiple methods that block 
mast cell inflammatory signaling, including targeting the Substance P neuroinflammatory 
pathway, all inhibited HO formation in a BMP2-implant model of HO [Kan et al. 2011, 
Salisbury et al. 2011]. An additional option targeting mast cells is the use of imatinib, a c-
Kit tyrosine kinase inhibitor that induces mast cell apoptosis. Imatinib has been shown to 
reduce rheumatoid arthritis inflammation [Juurikivi et al. 2005] and decreased HO in an 
Achilles tendon injury model of HO [Werner et al. 2013]. Our group showed that imatinib 
reduced hypoxia-induced HO formation, further bolstering the use of imatinib as an 
effective HO therapeutic, as well as highlighting the role of hypoxia in HO pathology 
[Wang et al. 2016]. Notably, imatinib robustly decreases PDGFR phosphorylation and 
PDGF effector signaling [van Steensel et al. 2009], suggesting its inhibitory effect may be 
through downregulating the PDGF signaling pathway, and also highlighting PDGF as a 
potential key factor in HO development. 
An additional approach to inhibit mast cell activation is via administration of mast 
cell stabilizers that block degranulation and release of inflammatory factors. Cromolyn, 
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quercetin, and other small molecules that block degranulation may be effective and 
inhibiting HO by preventing the release of cytokines, chemokines, and enzymes that 
participate in fibrosis during chronic inflammatory myopathies [Galli et al. 2008, Weng et 
al. 2012, Vukman et al. 2017]. 
Macrophages have been shown to produce osteoinductive signals [Champagne et 
al. 2002], promote osteogenic differentiation of mesenchymal stem cells [Tu et al. 2015], 
inhibit osteoclastogenesis [Jacquin et al. 2009], and promote fracture repair [Alexander et 
al. 2011], highlighting their potential relevance to HO development. I utilized clodronate-
liposomes to transiently deplete macrophages in our immunodeficient Acvr1cR206H/+ mouse 
studies. Although this approach is normally used only for proof-of-principle animal 
experiments, at least one attempt in humans has been reported [Barrera et al. 2000]. Patients 
scheduled for knee joint replacement received a single intra-articular injection of 
clodronate-liposomes into the knee synovium. Biopsy analysis post-surgery showed 
significantly decreased numbers of CD68+ macrophages, demonstrating drug efficacy. 
However, this study has significant limitations, as it included only 10 patients receiving a 
single clodronate-liposome injection. Due to hematopoietic replenishment of depleted 
macrophages, clodronate-liposomes would have to be administered regularly to maintain 
cell depletion if used as treatment for HO. Therapeutics that target macrophage activation 
and inflammatory signaling are a much preferred approach. 
Overall, targeting the immune system for treatment of HO in an appealing approach 
due to early intervention in disease, offering the possibility of halting lesion progression 
long before maturation into chondro-osseous tissue. Additionally, considering the shared 
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immunological contributions among FOP and many HO disorders, advancements in this 
area may provide benefits for FOP and more common non-hereditary forms of HO, which 
could significantly benefit a wide range of patients. 
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5.4 Concluding Remarks 
 In this thesis, I elucidated the pro-inflammatory role of Acvr1R206H in response to 
skeletal muscle injury and demonstrated via in vivo and in vitro experiments an amplified 
and prolonged cellular and molecular inflammatory response that mimics chronic 
inflammation. I also demonstrated that Acvr1cR206H/+ hematopoietic cells, via BMT and 
myeloid-specific Acvr1cR206H/+ expression experiments, are insufficient to induce HO 
formation in an Acvr1+/+ background. Finally, I showed that mast cell and macrophage 
depletion significantly reduces HO development in Acvr1cR206H/+ mice. In total, these data 
suggest a role for Acvr1R206H in upregulating the inflammatory response in damaged tissue 
and recruited immune cells, which supports a comprehensive and chronic inflammatory 
microenvironment conducive to subsequent fibroproliferative, chondrogenic, and 
osteogenic events. 
 Although FOP is a rare disease, non-hereditary HO is fairly common [Neal et al. 
2002, Potter et al. 2010]. One of the most remarkable findings of this thesis work is the 
discovery of shared inflammatory mediators among FOP and many other HO disorders. 
The work detailed in this dissertation will serve as a foundation for future studies 
investigating the immunological contributions to HO disorders, which will hopefully 
uncover new advances in knowledge that facilitate drug discovery efforts to treat HO in 
FOP and related HO disorders. 
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